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Brief Introduction  
Immunity to pathogens involves innate responses driven by pattern recognition 
receptors able to respond to microbial determinants without the need of prior 
exposure. Thereafter, adaptive responses based on the stimulation of T and B cells 
able to specifically recognize unique molecular characteristics of the offending agent 
give rise to individualized responses and immune memory.  
NF-κB is a conserved transcription factor that regulates expression of genes 
critical to both adaptive and innate immunity. As such, NF-κB plays a central role in 
the response to microbial infection, while its inappropriate activation is important in 
the pathogenesis of multiple diseases, including immune disorders and cancer.  
Thus, the pathophysiologic consequences of NF-κB activation in human disease are 
vast, and this remains an area of intense study. NF-κB activity is primarily controlled 
by IκB proteins, which prevent nuclear accumulation of NF-κB dimers. IkB 
degradation leads to activation of this pathway, and occurs through a 
phosphorylation-dependent ubiquitination event. The kinase responsible, known as 
the IκB kinase (IKK), is a trimeric complex containing IKKα, IKKβ, and the scaffold 
protein NEMO. Upon IκB degradation, NF-κB dimers accumulate in the nucleus 
where they bind to promoter sites, activating transcription of gene targets.   
Comparatively, less is known about the mechanisms that subsequently terminate 
NF-kB initiated transcription.  It is known that NF-κB binding to chromatin occurs 
within a physiologic time window.  The NF-κB mediated resynthesis of IκB is thought 
to mediate export of nuclear NF-κB dimers into the cytosol, and by inference, the 
release of chromatin bound NF-κB. In addition, NF-κB also promotes the expression 
of the IKK inhibitory factors CYLD and A20, which serve to attenuate IKK activity and 
IκB degradation. Altogether, these mechanisms promote the resynthesis of IκB and 
the cytosolic export of NF-κB, and are regarded as the main homeostatic 
mechanisms.   
In addition to IκB dependent termination mechanism, it has been demonstrated 
that the ubiquitin dependent degradation of DNA-bound RelA is also critical to the 
termination of NF-κB activity.  Moreover, a role for NF-κB phosphorylation mediated 
by IKKα in these termination events has also been demonstrated.  Nevertheless, the 
identity of the ubiquitin ligase responsible for NF-κB termination, its regulation, and 
the biologic significance of this pathway in immunity were not previously known.   
Scope of this Thesis  
My work has focused on understanding the termination of NF-κB activity through the 
ubiquitination of RelA.  We have demonstrated that RelA ubiquitination, degradation 
and transcriptional termination are mediated by a ligase complex containing the co-
factor COMMD1.  This ubiquitously expressed protein is the prototype member of the 
COMMD protein family, a group of highly conserved and still poorly understood 
factors that we also identified.  This thesis will present the cumulative evidence 
that demonstrates that COMMD1 plays a critical role in the termination of NF-
κB activity and the control of inflammation, acting through the ubiquitination 
pathway.  In Chapter 1, the main events that mediate the inhibitory activity of 
COMMD1 in the NF-κB pathway are discussed.  The discovery of COMMD1 as an 
inhibitor of NF-κB was made from an initial observation in a Yeast-2-hybrid screen 
with the anti-apoptotic protein XIAP.  In Chapter 2 these initial studies are presented, 
9
which led to the appreciation of the broad role of COMMD1 (known at the time as 
MURR1) as an NF-κB inhibitor.  Moreover, these studies demonstrated that 
COMMD1 affects HIV-1 replication, a viral pathogen that requires NF-κB to complete 
its life cycle.  Subsequent to the discovery of COMMD1 as an NF-κB inhibitor, I 
identified that this factor is the prototype member of a conserved family of 
homologous factors termed COMMD proteins.  This discovery is presented in 
Chapter 3.  Although initially thought to act at the level of IκB degradation, 
subsequent studies revealed that COMMD1 does not substantially affect nuclear 
translocation of NF-κB, indicating that a nuclear mechanism must be at play.  Studies 
in my laboratory demonstrated that COMMD1 promotes the ubiquitination and 
degradation of NF-κB subunits through a Cullin-containing ligase, and these are 
displayed in Chapter 4.  Chapter 5 describes recent studies that delineate the 
molecular mechanism by which COMMD1 activates ubiquitin ligases of this class, 
primarily through the displacement of a ligase inhibitor.  Chapter 6 describes the 
identification that phosphorylation of the NF-κB subunit RelA is required for its 
degradation and that this is mediated by the same COMMD1 complex acting in 
concert with the transcriptional regulator, GCN5.  More recently, a collaborative study 
with Dr. Van de Sluisʼ group (UMCG, Groningen, The Netherlands) identified that 
Commd1 plays a critical role in inflammatory responses in vivo and that this gene is 
frequently repressed in the setting of human inflammatory bowel disease.  This is 
presented in Chapter 7.  Finally, in Chapter 8 all these results and the role of 
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COMMD Proteins and the Control of the NFkB Pathway
ABstrAct
The COMM domain containing (COMMD) family of proteins represents a recently 
discovered set of evolutionarily conserved factors characterized by the presence of a 
defining carboxy‑terminal motif. In vertebrates, there are ten members of the family, and 
among their emerging functions the control of the transcription factor NFkB has been most 
extensively studied. NFkB plays a critical role in a number of homeostatic processes in 
multicellular organisms, including the regulation of immunity and cell survival. COMMD 
proteins inhibit NFkB mediated gene expression, and recent mechanistic studies have 
revealed that COMMD1 controls the ubiquitination of NFkB subunits, an event linked to 
transcriptional termination. COMMD1 binds to a multimeric ubiquitin ligase containing 
Elongins B/C, Cul2 and SOCS1 (ECSSOCS1). In this complex, COMMD1 facilitates the 
binding of NFkB subunits to the ligase, thereby promoting their ubiquitination and degra‑
dation. Additional insights gained from these studies indicate that COMMD proteins 
likely play a broader role in cellular homeostasis through their participation in the ubiqui‑
tination pathway.
NFkB: currENt PArAdiGM
NFkB	 is	 a	 dimeric	 transcription	 factor	 formed	 by	 members	 of	 a	 highly	 conserved	
family	 of	 proteins	 that	 share	 a	 ∼300	 amino	 acid	 sequence	 termed	 the	 Rel	 Homology	
Domain	(RHD).	In	mammals,	there	are	five	genes	that	encode	members	of	this	family:	
RELA, RELB, REL, NFKB1	 and	NFKB2.	Through	 transcriptional	 regulation	 of	many	
gene	products,	NFkB	participates	in	a	number	of	biologic	processes	including	innate	and	
adaptive	 immune	 responses,	 programmed	 cell	 death,	 transcriptional	 regulation	 of	 viral	
replication,	cell	cycle	progression,	and	oncogenesis.1-5
NFkB	mediated	gene	expression	is	regulated	to	a	large	extent	by	cytoplasmic	seques-
tration	 of	 the	 NFkB	 complex.	 In	 the	 canonical	 NFkB	 pathway,	 this	 is	 the	 result	 of	
interactions	 between	 the	 inhibitory	 IkB	 proteins	 and	 NFkB	 complexes	 (Fig.	 1).6,7	
Activation	 of	 a	multimeric	 kinase	 known	 as	 the	 IkB	Kinase	 (IKK)	 complex,	 results	 in	
phosphorylation	 of	 IkB.	 Once	 phosphorylated,	 IkB	 is	 ubiquitinated	 by	 a	 multimeric	
ubiquitin	 ligase	 containing	 Cul1	 (known	 as	 SCFb-TrCP),	 targeting	 it	 for	 proteasomal	
degradation.8,9	 IkB	 degradation	 enables	 the	 translocation	 of	 NFkB	 complexes	 to	 the	
nucleus	where	 they	bind	 to	 cognate	DNA	 sequences	present	 in	 an	 array	of	promoters,	
ultimately	resulting	in	induction	of	gene	expression.	This	is	mediated	through	a	series	of	
complex	events	 at	 the	chromatin	 level	 that	 involve	 the	 removal	of	 repressive	 complexes	
containing	 histone	 deacetylases	 (HDACs)	 and	 their	 replacement	 with	 NFkB	 in	 asso-
ciation	with	 various	 transcriptional	 co-activators.10-13	Once	 transcription	 has	 occurred,	
termination	of	NFkB	activity	is	also	an	important	regulatory	step.	This	is	largely	mediated	
by	re-synthesis	of	IkB	proteins,	which	facilitate	nuclear	export	of	NFkB.14	In	addition,	
ubiquitination	 of	 chromatin-bound	 NFkB	 is	 also	 required	 for	 termination	 of	 NFkB	
dependent	gene	expression,	and	the	mechanism	responsible	for	this	ubiquitination	event	
has	begun	to	be	elucidated.15,16
coMMd1 As AN iNhiBitor oF NFkB
In	a	search	for	regulators	of	the	anti-apoptotic	factor	XIAP,	we	identified	an	interac-
tion	 between	XIAP	 and	 the	MURR1	 gene	 product	 (now	 referred	 to	 as	COMMD1).17	









NFkB	 activation.20	 As	 an	 extension	 of	 those	 observations,	 it	 was	
appreciated	that	COMMD1	functions	as	a	more	global	inhibitor	of	
NFkB	 activation	mediated	 by	 a	 variety	 of	 stimuli	 including	TNF,	
IL1b,	 phorbol	 esters,	 and	 ectopic	 expression	 of	 IKK	 subunits.21	
Interestingly,	COMMD1	binds	to	the	NFkB	complex,	a	fact	that	is	
likely	linked	to	its	global	effect	on	NFkB	mediated	transcription.20
More	 recently,	we	 have	 demonstrated	 that	COMMD1	 controls	
the	 expression	 of	 a	 number	 of	 endogenous	 NFkB	 inducible	 gene	




isolated	 peripheral	 blood	 mononuclear	 cells	 across	 a	 membrane	
barrier.	This	 increase	 in	chemotaxis	rate	correlated	with	heightened	
secretion	of	NFkB	inducible	chemokines	such	as	CCL2.
In	 addition	 to	 these	 effects	 of	 COMMD1	 on	NFkB	mediated	
events,	a	 role	 for	 this	 factor	 in	controlling	the	HIV-1	 life	cycle	has	
been	 previously	 demonstrated.21	 Expression	 levels	 of	 COMMD1	
in	 freshly	 isolated	 naïve	CD4+	 lymphocytes	modulated	 the	 rate	 of	
HIV-1	 replication.	 Cells	 overexpressing	 COMMD1	 demonstrated	
blunted	HIV-1	replication,	while	decreased	expression	of	COMMD1	
following	 RNA	 interference	 (RNAi)	 resulted	 in	 greater	 rates	 of	
replication.	This	finding	is	consistent	with	the	known	role	of	NFkB	
in	 the	 life	 cycle	 of	HIV-1,	 as	well	 as	with	 gene	 expression	 data	 in	
animal	models	 of	 SIV	disease	 progression.23	 Specifically,	macaques	
that	experienced	slow	disease	progression	after	SIV	infection	had	the	
highest	levels	of	COMMD1	expression	before	infection	and	during	
the	 seven	 weeks	 of	 disease	 progression,	 compared	 to	 animals	 with	
typical	 or	 accelerated	 rates	 of	 disease	 progression	 (GEO	 database,	
record	 GDS172).	 Altogether,	 these	 findings	 establish	 a	 role	 for	
COMMD1	in	the	control	of	NFkB	mediated	transcription,	which	
in	 turn	 regulates	 events	 such	 as	 pro-inflammatory	 gene	 expression	
and	 the	 rate	of	HIV-1	 replication,	 and	possibly	others	 that	 remain	
to	be	elucidated.
discovEry oF thE coMMd ProtEiN FAMily
A	biochemical	 screen	 for	COMMD1	associated	 factors	 revealed	
the	presence	of	three	COMMD1-associated	proteins,	which	notably	
had	 sequence	 homology	 to	 COMMD1.20	 Additional	 efforts	 to	
search	 for	 COMMD1	 homologous	 proteins	 in	 public	 databases	
identified	a	total	of	ten	factors	in	vertebrates,	which	were	subsequently	
designated	 as	 COMMD	 proteins	 (COpper	 Metabolism	 MURR1	
Domain	 containing).	The	 defining	 characteristic	 of	 all	COMMDs	
is	 the	 presence	 of	 a	 ∼70	 amino	 acid	 region	 of	 high	 homology	 in	
their	 extreme	 carboxy-termini,	 designated	 as	 the	 COMM	 domain	
(Fig.	 2).	This	 motif	 serves	 as	 an	 interface	 for	 COMMD	 proteins	






of	 all	 COMMDs	 suggests	 the	 presence	 of	 tandem	a-helices.	This	
is	 consistent	 with	 the	 recently	 reported	 solution	 structure	 of	 the	
amino-terminus	 of	 COMMD1.24	 However,	 the	 structure	 of	 the	
COMM	domain	itself	remains	to	be	elucidated.
Figure 1. Schematic representation of the canonical NFkB pathway. In rest‑
ing cells, NFkB exists as dimers associated with IkB proteins. Cell stimulation 
by a broad range of factors promotes the activation of the IKK complex. IkB 
proteins become phosphorylated by IKK, resulting in their ubiquitination and 
proteasomal degradation. This enables NFkB to translocate to the nucleus 
and induce expression of pro‑inflammatory genes.
Figure 2. Schematic representation of the COMMD family of proteins. The 
conserved COMM domain is shown in red, along with the respective amino 
















coMMd ProtEiNs suPPrEss NFkB iN A MANNEr distiNct 
FroM ikB ProtEiNs
Stimulation-dependent	 degradation	 of	 the	 IkB	 proteins	 allows	
translocation	 of	 NFkB	 dimers	 to	 the	 nuclear	 compartment	 of	
cells,	 a	 critical	 step	 for	 the	 initiation	 of	kB-mediated	 gene	 expres-
sion.	Turnover	 of	 IkB	 proteins	 is	 mediated	 by	 a	 Cul1-containing	
multimeric	 ubiquitin	 ligase	 called	 SCFb-TrCP,	 which	 promotes	
poly-ubiquitination	 of	 the	 phosphorylated	 form	 of	 IkB,	 targeting	
it	 for	 proteasomal	 degradation.6,26	While	COMMD1	 can	 stabilize	
phosphorylated	 IkBa	 presumably	 through	 an	 interaction	 with	
Cul1,21	 this	 event	 does	 not	 seem	 to	 be	 physiologically	 dominant	
since	 nuclear	 translocation	 of	 RelA	 is	 unaffected	 by	 COMMD1	
expression.20	 Interestingly,	 an	additional	 indication	 that	COMMD	
proteins	 operate	 in	 a	 different	 manner	 than	 IkB	 is	 the	 fact	 that	





matin	 bound	 NFkB	 subunits	 through	 various	 pathways.13,15,27,28	
Evidence	indicates	that	COMMD1	regulates	NFkB	after	its	nuclear	
entry.20	The	interaction	of	RelA	(the	most	abundant	NFkB	subunit)	
with	 chromatin	 is	 regulated	 by	 COMMD1.	 Increased	 expression	
of	 COMMD1	 decreased	 the	 binding	 of	 RelA	 to	 chromatin	 and	
conversely,	 decreased	 endogenous	 expression	 of	 COMMD1	 after	
RNAi	 intensified	 the	 association	 of	 RelA	 to	 the	 promoter	 site.	 In	
addition	 to	 these	 findings,	 COMMD1	was	 found	 to	 be	 recruited	
to	 the	 promoter	 itself	 in	 a	 stimulus-dependent	 manner.	 However,	
the	 mechanism	 responsible	 for	 the	 effects	 of	 COMMD1	 on	
RelA-chromatin	interactions	remained	elusive	until	recently.
coMMd1 iNhiBits NFkB throuGh A uBiquitiNAtioN 
PAthwAy
Ubiquitination	 and	 proteasomal	 degradation	 of	 DNA-bound	




effect	 of	 COMMD1	 on	 kB-mediated	 transcription	 was	 recently	
examined.22	 Indeed,	 multiple	 data	 demonstrated	 that	 COMMD1	






ubiquitination	 reaction	 itself	 or	 an	 indirect	 effect	 that	 ultimately	
facilitates	 this	 step.	 In	 support	 of	 the	 first	 possibility,	 endogenous	
COMMD1	 immunoprecipitates	 can	 catalyze	 the	 formation	 of	
polyubiquitin	 chains	 in	 an	 in	 vitro	 ubiquitination	 reaction	 when	
provided	 with	 the	 necessary	 co-factors	 (E1	 and	 E2	 enzymes,	
ubiquitin,	 and	 ATP),	 indicating	 that	 COMMD1	 associates	 with	
a	 complex	 that	 has	 E3	 ubiquitin	 ligase	 activity.	 The	 identity	 of	
this	 complex(es)	would	 likely	 explain	 the	 ability	 of	COMMD1	 to	
promote	RelA	ubiquitination.
coMMd1 ProMotEs NFkB uBiquitiNAtioN throuGh  
A distiNct MultiMEric uBiquitiN liGAsE
It	has	been	demonstrated	that	a	protein	called	SOCS1	promotes	







Given	 that	 COMMD1	 promotes	 RelA	 ubiquitination	 and	 its	
immunoprecipitates	contain	ubiquitin	ligase	activity,	the	notion	that	
COMMD1	may	associate	with	the	ECSSOCS1	complex	was	examined.	
Indeed,	 endogenous	 COMMD1	 co-precipitated	 with	 endogenous	
SOCS1	 and	 Cul2,	 with	 the	 latter	 interaction	 being	 an	 inducible	
event	critical	to	the	assembly	of	the	mature	ECSSOCS1	complex.	In	
addition,	COMMD1	was	shown	to	interact	with	core	components	
of	 the	ECSSOCS1	complex	 in	 cotransfection	experiments,	 including	
Elongin	C,	Cul2,	SOCS1,	and	Rbx1.	Furthermore,	the	data	indicate	
that	 COMMD1	 requires	 the	 ECSSOCS1	 complex	 to	 promote	 the	
ubiquitination	of	RelA.	Suppression	of	Cul2	or	SOCS1	expression	
after	 RNA	 interference	 abrogated	 the	 COMMD1-mediated	 accu-





tion	 of	NFkB	 subunits.	 Additional	 studies	 also	 demonstrated	 that	





tion	 of	 gene	 expression.5,31	 These	 include	 pathways	 that	 regulate	
the	translocation	of	NFkB	from	the	cytosol	to	the	nucleus	and	the	
assembly	 of	 complexes	 on	 chromatin	 that	 promote	 transcription.	
Once	 NFkB	 activation	 has	 taken	 place	 the	 termination	 of	 tran-
scription	 is	 an	 equally	 important	 regulatory	 step,	 which	 is	 partly	
mediated	by	re-synthesis	of	IkB	proteins	and	export	of	nuclear	NFkB	
complexes.	 However,	 other	 mechanisms	 that	 are	 critical	 for	 the	
termination	of	the	NFkB-response	are	beginning	to	be	uncovered.
It	 has	 been	 demonstrated	 that	 ubiquitination	 and	 proteasomal	









to	 be	 recruited	 to	 the	 promoter	 itself.16	 However,	 the	 identity	 of	
the	 ubiquitin	 ligase	 responsible	 for	 this	 event	 was	 not	 elucidated	




containing	 complex	 (known	 as	 ECSSOCS1)	 that	 targets	 RelA	 for	




of	 this	 complex	 is	 recruited	 to	 chromatin	 in	 a	 stimulus	dependent	
fashion,	 and	 that	 levels	 of	 COMMD1	 control	 the	 duration	 of	
RelA-chromatin	association.
A	 model	 that	 would	 bridge	 the	 findings	 of	 Saccani,	 Ryo	 and	
our	 own	 work	 suggests	 that	 in	 response	 to	 NFkB	 recruitment	
to	 promoter	 sites,	 a	 ubiquitin	 ligase	 containing	 COMMD1	 is	




peaks	 at	 about	 two	 hours	 after	 NFkB	 activation,	 suggesting	 that	
COMMD1-directed	 ubiquitination	 of	 NFkB	 may	 be	 critical	 for	
late	transcriptional	termination,	after	IkB-mediated	export	has	been	






The	 COMMD1-ECSSOCS1	 complex	 represents	 the	 second	
Cullin-containing	ubiquitin	ligase	that	regulates	the	NFkB	pathway.	
The	Cul1-containing	SCFb-TrCP	complex	plays	a	critical	role	in	the	
ubiquitination	 of	 IkB	 proteins	 and	 the	NFkB	 precursor	 subunits,	
p100	and	p105.6,7,32	 Interestingly,	COMMD1	binds	 to	 additional	
Cullins,	 including	 Cul1,	 Cul2,	 Cul3	 and	 Cul5,	 a	 fact	 that	 is	 not	
entirely	 surprising	 since	 the	 Cul2-COMMD1	 interaction	 was	
mapped	 to	 the	 conserved	 Cullin-homology	 domain.	 Given	 the	
multitude	 of	 targets	 that	 these	 ubiquitin	 ligases	 have,	 it	 can	 be	
speculated	that	COMMD1	likely	plays	a	role	outside	of	regulating	
NFkB,	and	this	may	underlie	other	reported	activities	of	this	protein	
such	 as	 its	 involvement	 in	 copper	metabolism	or	 the	 regulation	of	
ENaC.17,33	 Similarly,	 the	 COMMD	 family	 contains	 9	 additional	
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Although human immunodeficiency virus-1 (HIV-1) infects
quiescent and proliferating CD41 lymphocytes, the virus repli-
cates poorly in resting T cells1–6. Factors that block viral replica-
tion in these cells might help to prolong the asymptomatic phase
of HIV infection7; however, the molecular mechanisms that
control this process are not fully understood. Here we show
that Murr1, a gene product known previously for its involvement
in copper regulation8,9, inhibits HIV-1 growth in unstimulated
CD41 T cells. This inhibition was mediated in part through its
ability to inhibit basal and cytokine-stimulated nuclear factor
(NF)-kB activity. Knockdown of Murr1 increased NF-kB activity
and decreased IkB-a concentrations by facilitating phospho-IkB-
a degradation by the proteasome. Murr1 was detected in CD41
T cells, and RNA-mediated interference of Murr1 in primary
resting CD41 lymphocytes increased HIV-1 replication. Through
its effects on the proteasome, Murr1 acts as a genetic restriction
factor that inhibits HIV-1 replication in lymphocytes, which
could contribute to the regulation of asymptomatic HIV infec-
tion and the progression of AIDS.
Murr1 is a highly conserved 190-amino-acid protein that does
not have any identifiable motifs, and a homozygous deletion in the
gene encoding canine Murr1 leads to copper toxicosis in Bedlington
terriers8. In this study, Murr1 was initially identified in a two-hybrid
screen by binding the X-linked inhibitor of apoptosis, a known
activator of NF-kB (refs 10, 11, and E.B., unpublished observations).
To study its effect on NF-kB, HIV-1 reporter plasmids with wild-
type or mutant (DkB) sites2 were co-transfected with control or
Murr1 expression plasmids in the different cell lines. Murr1 inhib-
ited both basal and tumour necrosis factor (TNF)-a-dependent
HIV-1 transcription from the wild-type but not the kB-mutant
reporter in Jurkat T-leukaemia and 293T renal epithelial cell lines
(Fig. 1a, left and middle panels). In contrast, Murr1 did not
substantially inhibit tumour growth factor-b-dependent transcrip-
tion in HepG2 cells, confirming its specificity (Fig. 1a, right panel).
The kB effect was dose-dependent and observed with other inducers
of NF-kB, including interleukin-1 (IL-1) and 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) (Fig. 1b). Murr1 modulated the
expression of endogenous kB-regulated genes: transfection into
293T cells decreased the endogenous cell-surface expression of
major histocompatibility complex (MHC) class I, in contrast to
CD9, which is independent of NF-kB (Fig. 1c).
Its site of action in the NF-kB signalling pathway was further
defined by co-transfection of different regulators with an NF-kB
reporter in Jurkat T cells. Whereas Murr1 inhibited both IKK-1- and
IKK-2-induced NF-kB activity (Fig. 1d, middle and right panels), it
failed to block RelA-mediated transcription (Fig. 1d, left panel),
indicating that Murr1 might interact downstream of the IkB
kinase signalosome. As determined by immunoprecipitation, co-
transfected haemagglutinin (HA)-tagged Murr1 and Myc-tagged
IKK-2 did not associate in vivo (Fig. 2a, lane 2, left panel). Although
IKK-1 also did not associate with Murr1 (data not shown), an
interaction between transfected HA-tagged Murr1 and endogenous
IkB-a was readily detected (Fig. 2a, lane 6). The ankyrin domain of
IkB-a was required for association with Murr1, as were amino acids
1–160 of Murr1 (Supplementary Fig. 1a).
A polyclonal antibody against Murr1 demonstrated the associ-
ation between endogenous Murr1 and IkB-a in vivo. RelA antibody
immunoprecipitated IkB-a, IkB-b and Murr1 (Fig. 2b, lane 10).
IkB-a antibody also pulled down RelA and Murr1 (Fig. 2b, lane 12),
but the IkB-b antibody did not precipitate Murr1 (Fig. 2b, lane 14),
suggesting that Murr1 interacted preferentially with the NF-kB–
IkB-a complex. This association was confirmed in vivo by confocal
microscopy with fluorescent fusion proteins (Supplementary
Fig. 1b), similarly to the pattern of RelA association with IkB-a12–14.
The physiological consequences of these interactions were deter-
mined by knockdown of endogenous Murr1 in 293T cells using
control and Murr1-specific short interfering RNA (siRNA)
duplexes. The specificity of two such siRNAs, Murr1-1 and
Murr1-2, directed to different Murr1 sequences, was first confirmed
by transfecting 293T cells with wild-type or mutant siRNAs along
with wild-type or mutant Murr1 complementary DNAs modified at
the siRNA target site (Supplementary Fig. 2). Transient transfection
of Murr1-specific siRNA duplexes downregulated endogenous Murr1
and IkB-a, had little effect on IkB-b, p65 or IKK-2 (Fig. 3a, left panel),
and increased kB-dependent reporter activity (Fig. 3a, right panel).
To investigate the mechanism of Murr1 action, 293T cells were
transfected with a control or Murr1 siRNA. Four days after
transfection, cells were treated with the proteasome inhibitor
MG132 for 2 h or with vehicle alone and stimulated with TNF-a.
Cells depleted of Murr1 showed a decrease in basal IkB-a (Fig. 3a)
and an increase and persistence of phospho-IkB-a in response to
stimulation with TNF-a (Fig. 3b, left panel). This effect was
observed in the absence of a proteasome inhibitor, MG132, but
not in its presence (Fig. 3b, right panel), indicating that Murr1
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Figure 1 Murr1 suppresses NF-kB-dependent activity from independent stimuli by acting
downstream of IkB kinase. a, Murr1 inhibits kB-dependent gene expression in Jurkat
T-leukaemia cells (left) or 293T human embryonic kidney cells (middle) transfected with
HIV (WT) or DkB-luciferase reporter (DkB) and Murr1 (solid bars) or vector plasmid (open
bars). HepG-2 cells (right) were transfected with p3TP-Lux reporter. Cells were treated
with the indicated cytokines after 24 h, and luciferase activity was measured at 36 h.
b, Murr1 inhibits NF-kB induced by IL-1 and TPA in 293 cells. c, Murr1 decreases the
expression of NF-kB-dependent endogenous class I MHC in 293T cells transfected with
HA–LacZ (left) or HA–Murr1 (middle) by flow cytometry for class I and CD9 in HA-positive
cells. The decrease in MHC class I expression is summarized (right). d, Murr1 blocks the
activation by IKK-1 and IKK-2 but does not inhibit RelA transactivation. Fold stimulation
(left) and expression (right) are shown. An average of three independent experiments in
triplicate, standardized for transfection efficiency, are shown (a, b, d).
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might act similarly to a proteasome inhibitor to enhance and sustain
phospho-IkB. Phospho-IkB-a is degraded by ubiquitin–protein
conjugates that require three enzymes, which participate in a
cascade of ubiquitin transfer reactions: a ubiquitin-activating
enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin
ligase (E3). The specificity of protein ubiquitination and 26S
proteasome degradation is determined by the E3 enzymes15.
Skp1/Cul1/b-TrCP1 (F-Box) complexes constitute a class of E3
enzymes that are required for the degradation of phospho-IkB-
a16. The possible association of endogenous Murr1 with Skp1/Cul1/
b-TrCP1 (F-box) complexes was examined. As determined by
immunoprecipitation followed by western blotting, Murr1 inter-
acted biochemically with the Cul1 and not the Skp1 component of
the E3 ligase complex, in contrast to a denatured negative control
(Fig. 3c). Although Murr1 binds to common constituents of E3
ligase, it nevertheless showed specificity because knockdown did not
alter steady-state concentrations of b-catenin, the target of protea-
somal degradation of the Wnt signalling pathway (Fig. 3d). Taken
together, these results suggest that Murr1 blocked NF-kB activation
through its ability to interact with E3 ligase and inhibit the
proteasomal degradation of IkB.
To determine whether Murr1 was detectable in T cells, lympho-
cytes from normal healthy individuals were examined. Both CD4þ
and CD8þ cells expressed Murr1, with higher concentrations in
CD4þ cells (Fig. 4a), raising the possibility that Murr1 might affect
HIV-1 replication in these cells. This possibility was examined first
by transfection of Murr1 in primary T cells and compared with
another inhibitor of NF-kB activation, the IkB super-repressor
(IkB-SR). Expression of recombinant Murr1 or IkB-SR inhibited
HIV-1 replication in activated T cells similarly relative to controls
(Fig. 4b; P ¼ 0.02; paired t-test), indicating that Murr1 might
inhibit HIV-1 replication comparably to NF-kB inhibitors in
primary activated T cells. To determine its effect on HIV-1 replica-
tion in resting primary T cells, CD4þ cells from HIV-1-negative
donors were transfected with an siRNA for Murr1 (Murr1-1) or a
negative control. To identify transfected cells, siRNAs were mixed
with an unrelated fluorescent Cy3-labelled luciferase siRNA at a
ratio of 2:1, and more than 30% of cells displayed fluorescence. In
Murr1 siRNA-transfected cells, a maximum decrease in Murr1
protein concentration was achieved between 48 and 72 h after
electroporation, and these cells did not display T-cell activation
markers—CD69, CD25 and HLA-DR—at the time of HIV-1 infec-
tion (data not shown). Murr1 siRNA increased dose-dependent
HIV-1 replication in primary resting CD4þ T cells from three
separate cell donors (Fig. 4c; P ¼ 0.0007, 0.0024 and 0.0014,
respectively; paired t-test), implicating Murr1 in the regulation of
HIV infection in these cells.
Whereas HIV-1 entry into activated CD4þ lymphocytes leads to a
productive infection1, the virus remains latent in resting CD4þ
lymphocytes17, existing as a preintegration complex awaiting cell
stimulation, which facilitates the transition to productive replica-
tion3,4,6,7,18. The molecular mechanisms responsible for HIV-1
Figure 2 Murr1 associates with the NF-kB–IkB-a complex. a, Murr1 does not associate
with IKK-2 but interacts with endogenous IkB-a. Lysates from transfected 293T cells,
treated with lactacystin (10 mM) 16 h before harvesting, were immunoprecipitated (IP) as
indicated and immunoblotted with antibody against IKK-2 (left) or IkB-a (right).
b, Immunoprecipitation of Murr1–NF-kB–IkB-a in 293T cells with antibodies against
indicated proteins. IgH, immunoglobulin heavy chain.
Figure 3 Murr1 regulates IkB-a turnover through effects on proteasomal degradation.
a, Knockdown of Murr1 decreases cellular IkB-a and increases basal NF-kB activity in
293T cells transfected with control or Murr1 siRNAs, analysed by immunoblotting to the
indicated proteins at 48 h (left). Fold stimulation of the indicated co-transfected plasmids
is shown (right). b, Murr1 alters IkB-a phosphorylation in 293T cells transfected with
control or Murr1 siRNAs. At 90 h after transfection, cells were treated with vehicle (left) or
MG132 (right) for 2 h, followed by stimulation with TNF-a and immunoblotting for Murr1
and phospho-IkB-a (top) and quantification (bottom). c, Immunoprecipitation (IP) of
Skp1–Cul1–b-TrCP1 complexes in 293T cell extracts with antibodies against Murr1 or
Skp1, immunoblotted for Cul1, Skp1 or Murr1. d, Knockdown of Murr1 by Murr1-2 siRNA
compared with a negative control (GFP) does not alter b-catenin concentrations.
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latency are not well understood. Among the factors that can activate
HIV-1 replication are host transcription factors such as NF-kB
(ref. 2), epigenetic modifications at the site of integration19, prema-
ture termination of transcription due to the absence of sufficient
concentrations of Tat and NF-kB (refs 20, 21), and inefficient export
of RNAs for structural proteins5. The roles of these factors in resting
CD4þ T cells are inferred from cell culture experiments and affect
viral transcription, translation or RNA transport. Here we show
that Murr1 regulates IkB-a turnover, which inhibits the productive
HIV-1 infection of resting T lymphocytes. Expression of Murr1 in
activated HIV-infected T cells also inhibited virus replication,
indicating that it might also have a function in limiting the extent
of viral replication, or burst size. NF-kB is sequestered in the
cytoplasm by a 450-kDa IkB complex12,22–25 and, after activation
of T cells, phosphorylation of IkB-a (ref. 26) in this complex by two
inducible kinases, IKK-1 and IKK-2, leads to the subsequent
ubiquitination and degradation of IkB-a by the 26S proteasome27.
Degradation of IkB-a by the proteasome releases NF-kB, which then
translocates to the nucleus to stimulate the synthesis of genes
involved in immune activation. NF-kB enhances transcription
and subsequently recruits several transcriptional activators, includ-
ing positive transcription elongation factor b, which is ubiquiti-
nated and degraded by the proteasome28. Inhibition of proteasomal
activity by Murr1, after it rebounds from its initial degradation and
after this processive transcription complex has formed, could
subsequently stabilize it and enhance transcription. The protea-
some, through the ubiquitin E3 ligase complex, is also involved in
viral processing and the maturation of Gag29. Because Murr1
inhibits proteasomal degradation, it could further block HIV-1
infection by decreasing the proteasome-dependent degradation and
maturation of Gag-associated factors required for viral replication,
and although Murr1 acts selectively on the NF-kB and not the Wnt
signalling pathway (Fig. 3), it remains possible that it might yet
affect other such proteins degraded by the proteasome. Such an
example is APOBEC3G, shown recently to associate with a Cul5 E3
ligase31. Blocks to viral replication in resting lymphocytes, as well as
in cells containing latent provirus, might affect disease progression
and viral rebound after the discontinuation of anti-retroviral
therapy (reviewed in ref. 7). A more precise understanding of the
molecular regulation of these events might identify novel genetic
restriction factors, like Murr1, through which anti-viral drugs might
delay the progression of HIV-1 infection to AIDS. A
Methods
Plasmids, siRNA and cell transfections
The gene encoding chloramphenicol acetyltransferase (CAT) in HIV-LTR–CAT and
HIV-LTR-DkB–CAT2 was replaced with the luciferase gene from pGL3 basic (Promega) to
construct HIV-LTR–Luc and HIV-LTR-DkB–Luc. The HA-IkB-a SR, p3TP-Lux reporter,
green fluorescent protein (GFP)–RelA, pRK-Myc-IKK-1, pRK-Myc-IKK-2, p65 and IkB-a
cDNAs are described in Supplementary Methods, as are siRNA sequences and the cell
transfection techniques.
T-cell purification and transfection
To purify resting T cells, CD4þ T lymphocytes were isolated from Ficoll-purified
peripheral blood mononuclear cells (PBMCs) by negative selection with a CD4þ T-cell
isolation kit containing CD8, CD11b, CD16, CD19, CD36 and CD56 antibodies (Miltenyi
Biotech). CD25þ and HLA-DRþ cells were then removed from this population by using
CD69, CD25 and HLA-DR antibodies (Miltenyi Biotech) by negative selection. The purity
of the isolated resting T cells was assessed by fluorescence-activated cell sorting (FACS)
analysis for CD4, CD69, CD25 and HLA-DR (BD-Pharmingen); 95% of the cells were
CD4þ and there were less than 0.1% of activated T cells as defined by the presence of CD69,
CD25 or HLA-DR. Resting CD4þ T cells (107) were transfected with control or Murr1
siRNA (Dharmacon). For each transfection, 1.2 mM siRNA (800 nM unlabelled siRNA and
400 nM Cy3-labelled siRNA) was used. Transfections were performed with a 2:1 mixture of
unlabelled siRNA and Cy3 luciferase. To transfect the resting CD4þ T cells with siRNA, 107
cells were resuspended in 100 ml T-cell Nucleofector reagent and immediately
electroporated with the recommended protocol U-14 on the Nucleofector instrument
(Amaxa Biosystems). The electroporated cells were washed 4 h after transfection and
incubated in 1.5 ml RPMI and infected with HIV-1 48 h after electroporation. FACS
analysis was performed with CD69, CD25 and HLA-DR antibodies (BD Pharmingen) to
check the activation status of the cells at the time of infection. For plasmid transfections,
CD4þ T lymphocytes isolated from Ficoll-purified PBMCs by negative selection were
stimulated with phytohaemagglutinin (10 mg ml21) (Calbiochem) and 40 U ml21 IL-2
(Peprotech) for 24 h and maintained in 40 U ml21 IL-2 for 4 days. Cells were then washed
to remove IL-2, and 107 cells were resuspended in 100 ml T-cell Nucleofector reagent
containing 0.5 mg of the respective plasmids and immediately electroporated with
recommended protocol T-20 on the Nucleofector instrument. The electroporated cells
were washed 12 h after transfection and incubated in 1.5 ml of RPMI supplemented with
40 U ml21 IL-2 and infected with HIV-1 24 h after electroporation.
HIV-1 infection and flow cytometric analysis for expression of p24-Gag
At 48 h after siRNA transfection or 24 h after plasmid transfection, HIV-1 infection of
CD4þ T lymphocytes was performed in 96-well round-bottomed culture plates by
combining 40 ml virus stock with 20 ml CD4þ T lymphocytes (1.5 £ 105 cells). The
multiplicity of infection of undiluted virus was,1.0. After incubation for 2 h at 37 8C, cells
were washed twice and continued in culture with indinavir at 1 mM. CD4þ T lymphocytes
were harvested for intracellular p24-Gag staining 48 h after exposure to virus. In brief, cells
were stained with anti-CD4-PE and ethidium bromide monoazide (EMA) for 10 min.
EMA was cross-linked to the cells by exposure to a bright light source for 15 min. Cells were
washed once, fixed and permeabilized with Cytoperm/Cytofix (BD Pharmingen) for
Figure 4 Murr1 inhibits productive HIV-1 infection in CD4þ lymphocytes. a, Murr1
concentrations in CD4þ and CD8þ T cells shown by immunoblotting with Murr1 antisera
and reprobing with b-actin antibody. b, Murr1 inhibits HIV-1 replication in
phytohaemagglutinin/IL-2-stimulated human CD4þ cells transfected with plasmids
encoding HA–LacZ (control), HA–Murr1 or HA–IkB-SR, infected with HIV-1BaL
(p24 ¼ 75 ng ml21) 36 h later. HIV-1 replication was analysed 48 h after infection by
staining for intracellular p24. A representative of three independent HIV-1-negative
donors is shown (P ¼ 0.02, control versus Murr1). c, Murr1 siRNA-transfected resting
CD4þ T lymphocytes from three healthy donors show increased susceptibility to HIV-1
infection after transfection with siRNA for Murr1 (Murr1-1) compared with GFP (control).
Cy3 luciferase siRNA was mixed with siRNAs (2:1) to label transfected cells. Single-round
HIV-1 replication was measured in labelled cells at 48 h. The multiplicity of infection of
undiluted virus was ,1.0.
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20 min. Cells were then stained for p24 Gag (KC-57 fluorescein isothiocyanate (FITC);
Coulter) for 20 min and washed once in 1 £ Perm/wash buffer (BD Pharmingen). Cells in
each group were analysed by flow cytometry for intracellular HIV-1 p24 and CD4 after the
exclusion of dead cells by their affinity for EMA. For a detailed description of HIV-1
production, infection and flow cytometric analysis see ref. 30.
Antibodies, western blots and immunoprecipitations
Cell lysis for western blots and immunoprecipitations were performed in cell lysis buffer
(Cell Signal). Antibodies against b-actin (Sigma), His (Invitrogen), HA, HA-PE, p65,
IkB-a, IkB-b, Cul1, Skp1 (Santa Cruz), IKK1, IKK2, Ser-32-phospho IkB-a, b-catenin
(Cell Signal) and HLA Class1 FITC (Biosource) were used in flow cytometry,
immunoblotting and immunoprecipitations in accordance with the manufacturer’s
instructions. Polyclonal Murr1 antibody has been described previously9.
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In mammals, dosage compensation ensures equal X-chromo-
some expression between males (XY) and females (XX) by
transcriptionally silencing one X chromosome in XX embryos1.
In the prevailing view, the XX zygote inherits two active X
chromosomes, one each from the mother and father, and X
inactivation does not occur until after implantation2–6. Here,
we report evidence to the contrary in mice. We find that one X
chromosome is already silent at zygotic gene activation (2-cell
stage). This X chromosome is paternal in origin and exhibits a
gradient of silencing. Genes close to the X-inactivation centre
show the greatest degree of inactivation, whereas more distal
genes show variable inactivation and can partially escape silenc-
ing. After implantation, imprinted silencing in extraembryonic
tissues becomes globalized and more complete on a gene-by-gene
basis. These results argue that the XX embryo is in fact dosage
compensated at conception along much of the X chromosome.
We propose that imprinted X inactivation results from inheri-
tance of a pre-inactivated X chromosome from the paternal germ
line.
In mice, X-chromosome inactivation (XCI) takes on two lineage-
specific forms. Random XCI1, in which both X chromosomes have
an equal chance of being inactivated, occurs in the epiblast (embryo
proper). In contrast, imprinted XCI7 leads to paternal X-chromo-
some (XP) silencing in the extraembryonic tissues (placenta).
Although the imprint is set in gametes, classical studies support a
view in which both XP and XM (maternal X chromosome) are
transmitted to the zygote in an active form: the absence of a late-
replicating X chromosome in pre-implantation embryos2 suggests
equal X-transcriptional status, and bimodal distributions of enzy-
matic activities for two X-linked genes (Hprt3,4, Gla5) suggest twice
as much expression in XX as compared with XYembryos. Thus, the
prevailing view postulates that XX and XY embryos have a twofold
imbalance of X dosage until implantation, when XCI takes place for
the first time in the extraembryonic and embryonic lineages6,8–10.
However, some recent observations have not been explained easily11.
Studies of the X-linked Pgk1 (refs 12, 13) revealed that, whereas the
maternal allele is expressed during pre-implantation development,
the paternal allele is silent. Furthermore, one Xist allele is expressed
at high levels in pre-implantation embryos9, leading to the idea that
the X chromosomes may be transcriptionally distinct6,11. Indeed, the
maternal and paternal haplogenomes can behave differently in early
letters to nature
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MURR1 is a multifunctional protein that inhibits nu-
clear factor B (NF-B), a transcription factor with
pleiotropic functions affecting innate and adaptive im-
munity, apoptosis, cell cycle regulation, and oncogene-
sis. Here we report the discovery of a new family of
proteins with homology to MURR1. These proteins form
multimeric complexes and were identified in a biochem-
ical screen for MURR1-associated factors. The family is
defined by the presence of a conserved and unique motif
termed the COMM (copper metabolism gene MURR1)
domain, which functions as an interface for protein-
protein interactions. Like MURR1, several of these fac-
tors also associate with and inhibit NF-B. The proteins
designated as COMMD or COMM domain containing
1–10 are extensively conserved in multicellular eukary-
otic organisms and define a novel family of structural
and functional homologs of MURR1. The prototype of
this family, MURR1/COMMD1, suppresses NF-B not by
affecting nuclear translocation or binding of NF-B to
cognate motifs; rather, it functions in the nucleus by
affecting the association of NF-B with chromatin.
NF-B is a dimeric complex formed by members of a highly
conserved family of proteins that share a defining motif desig-
nated the Rel homology domain (RHD).1 Through transcrip-
tional regulation of many gene products, NF-B participates in
a number of biological processes including innate and adaptive
immune responses, programmed cell death, cell cycle progres-
sion, and oncogenesis (1–6). Additionally, by its ability to reg-
ulate transcription of various viral genomes including human
immunodeficiency virus-1 (HIV-1) (7–10), NF-B also partici-
pates in viral cycle progression.
Studies into the regulation of NF-B activation have largely
focused on the role of cytoplasmic sequestration of the NF-B
complex as a mainstay level of control. In most cells NF-B is
localized in the cytoplasm through the interaction of the com-
plex with members of the IB family (11). These proteins con-
tain ankyrin repeats that allow their interaction with NF-B
and mask the nuclear localization signal present in the RHD.
Phosphorylation of IB by a multimeric kinase known as the
IB kinase complex targets these proteins for ubiquitination
and proteasomal degradation (3, 12). This allows the translo-
cation of NF-B to the nucleus where it binds to cognate DNA
sequences present in an array of gene promoters.
MURR1 is a recently identified factor that has been shown to
participate in two apparently distinct activities, regulation of
the transcription factor NF-B and control of copper metabo-
lism (13). Mutations in MURR1 are responsible for copper
toxicosis in an inbred canine strain (Bedlington terriers) (14),
and an interaction betweenMURR1 and the copper transporter
ATP7B (15) has been recently reported.
In addition to its role in copper metabolism in mammals, more
recent studies implicate MURR1 in the regulation of the tran-
scription factor NF-B (13, 16). MURR1 was found to be a broad
inhibitor of NF-B, affecting B-responsive transcription from
endogenous and viral promoters including the HIV-1 enhancer
(16). Through this effect, MURR1 can function as a factor that
limits HIV-1 replication in resting CD4 lymphocytes.
Here we report the discovery of a family of proteins structur-
ally and functionally related to MURR1. These factors contain a
unique and defining domain termed the COMM (copper metab-
olism gene MURR1) domain, and thus, these proteins have been
named COMM domain-containing or COMMD proteins. Similar
to MURR1/COMMD1, several of these factors associate with
NF-B and inhibit its transcriptional activity. In addition, we
find that COMMD proteins form heteromeric complexes that are
mediated by the COMM domain. The prototype of the family,
MURR1/COMMD1, exerts its ability to inhibit B-mediated
transcription without affecting nuclear translocation but through
nuclear regulation of NF-B. We show here that MURR1/
COMMD1 is recruited to chromatin of a B-responsive promoter
upon NF-B activation and negatively regulates the association
of RelA to chromatin. Therefore, this work identifies a novel
family of factors that regulate NF-B-mediated transcription by
controlling the occupancy of NF-B on chromatin.
* This work was supported in part by the University of Michigan
Biological Scholars Program, Department of Defense Idea Award
PC040215 and National Institutes of Health Grant GM067827 (to
C. S. D.), by an American Gastroenterological Association Research
Scholar Award, a Merit Review Entry Program Award, and a Veterans
Education and Research Association of Michigan Award (to E. B.), by
NCI, National Institutes of Health Grants K01CA78595, R01CA104397,
and R01CA095644 (to M. W. M.), and by T32 CA09676 (to J. C. W.). The
costs of publication of this article were defrayed in part by the payment of
page charges. This article must therefore be hereby marked “advertise-
ment” in accordance with 18 U.S.C. Section 1734 solely to indicate this
fact.
□S The on-line version of this article (available at http://www.jbc.org)
contains a supplemental figure and table.
** To whom correspondence should be addressed: Med. Sci. I, Rm.
5315, 1301 Catherine, Ann Arbor, MI 48109-0602. Tel.: 734-615-6414;
Fax: 734-615-7012; E-mail: colind@umich.edu.
1 The abbreviations used are: RHD, Rel homology domain; EGFP,
enhanced green fluorescence protein (GFP); TAP, tandem affinity pu-
rification; GST, glutathione S-transferase; TNF, tumor necrosis factor;
MS, mass spectroscopy; RT, reverse transcription; EMSA, electro-
phoretic mobility shift assay; ChIP, chromatin immunoprecipitation;
RNAi, RNA interference; siRNA, small interfering RNA; HIV-1, human
immunodeficiency virus-1.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 280, No. 23, Issue of June 10, pp. 22222–22232, 2005
Printed in U.S.A.
This paper is available on line at http://www.jbc.org22222
 at University of G










Supplemental Material can be found at: 
31
EXPERIMENTAL PROCEDURES
Plasmids—The plasmids pEBB, pEBG, pEBB-MURR1-Flag and
pEBB-MURR1-GST, pEBB-T7-IB-S.D., 2B-luc, and EGFP-p65
(kindly provided by Dr. Rainer de Martin) have been described previously
(17–22). pEBB-COMMD1-GST vectors expressing exon 1, exon 2-3, and
exon 1-3 were generated by PCR amplification using pEBB-MURR1-Flag
as template with the boundaries outlined in Fig. 3C. pEBB-MURR1-TAP
was constructed by subcloning MURR1 into pEBB-TAP, which was gen-
erated by PCR amplification of the coding sequence for the tandem affin-
ity purification (TAP) tag using pBS1539 as template (23). Expression
vectors for COMMD proteins in fusion with Flag and glutathione S-
transferase (GST) (pEBB-COMMD-Flag or pEBB-COMMD-GST) were
generated by PCR amplification of the coding sequences for each of these
proteins. To that effect the following full-length IMAGE clones were used
as templates to amplify COMMD2 through COMMD10, respectively:
4443942, 3531636, 5743903, 6644608, 1692591, 5275167, 4051246,
4333615, and 3683093. pEBG-RelA-(1–305), pEBG-RelA-(306–551),
and pEBG-RelA-(1–180), pEBG-c-Rel-(1–180), pEBG-RelB-(97–267), and
pEBG-p50-(1–233) and pEBG-p52-(1–212) were generated by PCR using
the vectors RSV-RelA, RSV-c-Rel, RSV-RelB, RSV-p50, and RSV-p52 as
templates, respectively (kindly provided by Dr. Neil Perkins) (24).
Cell Culture, Transfection, and Luciferase Assays—Human embry-
onic kidney 293 cells and prostate cancer and DU145 cells were ob-
tained from ATCC. 293 cells were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum and L-
glutamine, and DU145 cells were cultured in minimum Eagle’s medium
supplemented with 10% fetal bovine serum, L-glutamine, sodium bicar-
bonate, and pyruvate. A standard calcium phosphate transfection pro-
tocol (20) was used to transfect plasmids and siRNA oligonucleotides
into 293 cells. Delivery of siRNA oligonucleotides into DU145 cells was
performed using Oligofectamine (Invitrogen) as specified by the manu-
facturer. For luciferase reporter experiments, cells were seeded in
6-well plates and transfected with 4 g of pEBB plasmid, and 25 ng of
the reporter plasmid 2B-luciferase. Luciferase assays were performed
as described previously (25). TNF (Roche Applied Science) treatments
consisted of 1000 units/ml for 12 h. For immunoprecipitation experi-
ments cells were seeded in 10-cm plates and transfected with a total of
12 g of plasmid. Finally, suppression of endogenous COMMD expres-
sion was achieved by transfection of 293 cells seeded in 6-well plates
with 2 g of the corresponding siRNA oligonucleotides (Qiagen).
TAP Screening—293 cells seeded in 15-cm plates were transiently
transfected with pEBB-MURR1-TAP (15 g of plasmid/plate) and 2
days later were lysed in Triton lysis buffer (25 mM HEPES, 100 mM
NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100, protease inhibitors).
The lysate was supplemented with NaCl and Nonidet P-40 and ap-
plied to a chromatography column containing IgG-Sepharose beads
(Amersham Biosciences). After 2 h of incubation at 4 °C the column
was drained and washed with IPP150 buffer (10 mM Tris-HCl, pH
8.0, 150 mM NaCl, 0.1% Nonidet P-40, protease inhibitors) and TEV
cleavage buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Non-
idet P-40, 0.5 mM EDTA, 1 mM dithiothreitol, protease inhibitors).
After incubation for 2 h at 16 °C in TEV cleavage buffer supple-
mented with TEV enzyme (Invitrogen), the eluate was collected and
supplemented with CaCl2 and IPP150 calmodulin binding buffer (10
mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Nonidet P-40, 1 mM
magnesium acetate, 1 mM imidazole, 2 mM CaCl2, 10 mM -mercap-
toethanol). This was then applied to a chromatography column con-
taining calmodulin 4B beads (Amersham Biosciences) and incubated
at 4 °C for 1 h. The column was then drained and washed with IPP150
calmodulin binding buffer. After incubation at 4 °C with IPP150
calmodulin elution buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl,
0.1% Nonidet P-40, 1 mM magnesium acetate, 1 mM imidazole, 2 mM
EGTA, 10 mM -mercaptoethanol), a final eluate was collected. Pro-
teins were precipitated by adding cold 10% trichloroacetic acid in
acetone; after overnight incubation at 20 °C, the precipitate was
collected by centrifugation at 4 °C (10,000  g for 30 min), rinsed in
100% acetone, and allowed to air dry. These samples were then
submitted to the Proteomics Centre at the University of Victoria for
further processing, including tryptic digestion, high performance liq-
uid chromatography separation, and tandem mass spectrometry (MS/
MS) to determine peptide sequences.
RT-PCR and Expression Data—Total RNA was extracted from 293
cells using RNeasy (Qiagen) according to the manufacturer’s instruc-
tions. Yield and purity was determined by measuring A260/280 of RNA
diluted in water. Oligonucleotides and internal probes for RT-PCR
and quantitative RT-PCR of COMMD transcripts were designed
with the use of the automated primer design tool, AutoPrime
(www.autoprime.de). Detailed information about sequences and cy-
cling parameters are available upon request. For non-quantitative
RT-PCR, Titan One-Tube RT-PCR (Roche Applied Science) was used
according to the manufacturer’s instructions. For quantitative RT-
PCR reactions, an RT reaction with 500 ng of total RNA in 25 l was
performed using random hexamers and Taqman reverse transcrip-
tion reagents (Applied Biosystems). This was followed by quantitative
PCR performed in the 7500 real time PCR system (Applied Biosys-
tems). In all reactions, Taqman PCR Master Mix with the appropriate
primers and probes was used. Primers and probe sets for c-IAP2
(BIRC3) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
as an internal control were obtained from Applied Biosystems. Ex-
pression data in normal tissues were obtained from the Genomics
Institute of the Novartis Research Foundation (26), downloaded, and
further analyzed.
Immunoblotting and Immunoprecipitation—Cell lysates were pre-
pared by adding Triton lysis buffer; immunoblotting and GSH precipi-
tations were performed as previously described (19). A polyclonal
COMMD1 antiserum was raised by immunizing New Zealand White
rabbits. Recombinant protein, which was used as immunogen, was
produced in Escherichia coli by expressing GST-COMMD1 using the
pGEX-4T1 bacterial expression vector (Amersham Biosciences). GST-
COMMD1 was purified over a glutathione-Sepharose chromatography
column (Amersham Biosciences), and COMMD1 was generated by
thrombin cleavage of the GST affinity tag according to the manufactur-
er’s instructions. Antibodies against Flag (Sigma, A8592), RelA (BD
Transduction Laboratories, 610868), c-Rel (Santa Cruz, sc-6955), RelB
(Santa Cruz, sc-226), p50 (Upstate Biotechnology, 06–886), p52 (Up-
state Biotechnology, 05–361), IB- (Upstate Biotechnology, 06–494),
GST (Santa Cruz, sc-459), -tubulin (Molecular Probes, A11126), and
GCN5 (Santa Cruz, sc-20698) were used as indicated.
Confocal and Fluorescence Microscopy—293 cells were plated in
chambered cover glass plates or 6-well plates and transfected with
EGFP-p65 (25 or 50 ng/well, respectively). Morphological assays for
nuclear translocation of EGFP-p65 were performed by observing cells
with a Zeiss Axiovert 100 M confocal microscope before and after treat-
ment with TNF. Representative images were obtained, and 250–400
cells were observed and scored accordingly.
Electrophoretic Mobility Shift Assay (EMSA)—293 cells were seeded
in 10-cm dishes and transfected as indicated. TNF stimulation, when
performed, consisted of treating cells with 1000 units/ml for 30 min before
lysis. The preparation of nuclear extracts and EMSA have been described
previously (24). For our studies, a double-stranded oligonucleotide en-
compassing a canonical B sequence was used as probe (forward se-
quence, AGCTTACAAGGGACTTTCCGCTGGGGACTTTCCAGGG).
Cellular Fractionation—293 cells were plated in 10-cm plates 48 h
before the procedure. Medium was aspirated, and the cells were
rinsed in phosphate-buffered saline, scraped, and collected in a mi-
crocentrifuge tube. The cells were resuspended in 200 l of buffer 1
(25 mM HEPES, 5 mM KCl, 0.5 mM MgCl2, 1 mM phenylmethylsulfonyl
fluoride, 1 mM dithiothreitol, and protease inhibitors). After that, 200
l of buffer 2 were added (Buffer 1 with 1% Nonidet P-40), and the
cells were incubated with constant rotation at 4 °C for 15 min. The
samples were centrifuged for 1 min at 600  g, and the supernatant,
corresponding to the cytoplasmic fraction, was collected. The precip-
itated material was gently rinsed in 100 l of buffer 3 (1:1 mixture of
buffers 1 and 2). After centrifuging the samples again as before, the
supernatant was collected as part of the cytoplasmic fraction. The
remaining precipitated material was then treated by the addition of
500 l of buffer 5 (25 mM HEPES, 10% sucrose, 350 mM NaCl, 1 mM
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 0.01% Nonidet
P-40, protease inhibitors) and incubated with constant rotation at
4 °C for 60 min. After this, the samples were centrifuged for 10 min
at 16,100  g. The supernatant, corresponding to the nuclear frac-
tion, was collected separately.
Chromatin Immunoprecipitation—Subconfluent DU145 cells were
treated with TNF (1000 units/ml) before cross-linking for chromatin
immunoprecipitation (ChIP) analysis. For attachment assays, 293 cells
were re-plated in serum-free media on laminin-coated plates (Discovery
Labware) as previously described (27). ChIP protocol and primers se-
quences have been previously described (28). Antibodies used in the
ChIP studies include COMMD1 (described above), M2 Flag (Sigma,
F3165), RNA polymerase II (Santa Cruz, SC-9001), and RelA (Upstate,
06-418).
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FIG. 1. A, identification of the COMMD protein family. Fractions obtained during TAP purification were separated by SDS-PAGE, and the gel
was silver-stained. The lysate was subjected first to an immunoglobulin column, and the flow-through (Ig FT) and eluate (TEV) were collected. This
eluate was further purified over a calmodulin column, and the eluates were collected in four fractions (Elution fractions). COMMD3, -4, and -6 were
identified in the final eluate by liquid chromatography-MS/MS. B, human COMMD proteins. Analysis of the human protein databases using
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Biochemical Screen for MURR1-associated Factors—To fur-
ther understand the cellular activities of MURR1, a biochemi-
cal screen for associated proteins was performed based on the
TAP scheme that has been previously described (23). Briefly,
MURR1 in fusion with the TAP affinity tag was transiently
expressed in 293 cells, and MURR1-TAP was subsequently
purified from cells lysates using two sequential chromatogra-
phy columns containing IgG and calmodulin beads, respec-
tively (Fig. 1A). The material obtained was subjected to tryptic
digestion, and the peptides generated were then identified by
tandem mass spectrometry (MS/MS) after initial separation
using liquid chromatography. A number of associated factors
were identified, including three proteins that upon close in-
spection demonstrated the presence of a region with close ho-
mology to MURR1 in their carboxyl termini (Fig. 1, A and B).
These factors were later designated as COMMD3, -4, and -6
(see below).
Identification of the COMMD Protein Family—After the
identification of three MURR1 homologous factors in our bio-
chemical screen, we performed an extensive search of the se-
quence databases for additional homologs. Through this ap-
proach we were able to identify 10 proteins in humans,
including MURR1, that contain highly conserved carboxyl-ter-
minal sequences (Fig. 1B). The majority of these genes were
only known as open reading frames and had not been previ-
ously characterized.
Further analysis of orthologs present across multiple species
demonstrated that the area of close homology in the carboxyl
termini of these proteins represents a previously unrecognized,
unique, and highly conserved motif (Fig. 1C). This leucine-rich,
70–85 amino acid long sequence is predicted to form a -sheet.
We have termed this region the copper metabolism gene
MURR1 (COMM) domain.
The designation of homologs of MURR1 identified here re-
quired the generation of a new nomenclature. Murr1 derived
its name from its proximity to the U2af1-rs1 locus in mice
(mouse U2af1-rs1 region 1); however, this genomic organiza-
tion is not observed in other organisms including humans. In
addition, an unrelated gene that also lies in close proximity to
U2af1-rs1 has been designated Murr2, precluding the use of
this name for MURR1 homologs (29). In consultation with the
HUGO gene nomenclature committee, the term COMMD
(COMM Domain containing) is proposed to designate these
factors based on the shared structural domain that defines this
family of proteins and has been adopted in NCBI public data-
bases. The name COMMD1 is suggested for MURR1 as a
means to standardize the nomenclature to designate this pro-
tein family and will be used hereafter.
With the exception of COMMD1, no other COMMDs have
been previously described in any detail. COMMD5 was identi-
fied as an open reading frame that is overexpressed in natu-
rally hypertensive rats and suppressed in a number of primary
tumors and cancer cell lines (30). The expressed protein local-
izes to the nucleus, although a direct role in transcription had
not been previously demonstrated. COMMD6 is orthologous to
a mouse gene located in a region that is necessary for normal
embryonic development, although it is unclear whether
COMMD6 itself is required for normal embryogenesis (31).
Similarly, COMMD3 was previously identified as a locus with
close proximity to the Polycomb-group gene Bmi-1 (32). Finally,
an expressed sequence tag corresponding to COMMD7 was
found to be consistently repressed in an experimental system
designed to screen for factors involved in leukemogenesis (33).
COMMD Genes Are Highly Conserved—We found that all 10
genes have been conserved throughout vertebrate evolution, as
can be gleaned from orthologs found in Silurana tropicalis,
Xenopus laevis, Danio rerio,Oncorhynchus mykiss, andOryzias
latipes (see the supplemental table). In general, mammalian
sequences are about 90% conserved when compared with their
human orthologs. Furthermore, lower metazoans, including
insects, worms, and molds, also possess COMMD genes; how-
ever, none of these genes were identified in unicellular eukary-
otic organisms or bacteria. Five of these genes were found in
Drosophila melanogaster (COMMD2, -3, -4, -5, and -10) and
Dictyostelium discoideum (COMMD4, -5, -7, -8, and -10). Over-
all, eight of the COMMD genes can be found in lower metazo-
ans, with COMMD1 and COMMD9 orthologs being restricted
to vertebrate species (see the supplemental figure).
Despite the presence of a conserved and defining motif in all
these proteins, a significant proportion of the sequence of each
COMMD protein is composed of unique regions that are diver-
gent across members of the family. For example, human and
zebrafish COMMD1 are 72% conserved, whereas human
COMMD1 and COMMD10 are only 34% conserved when re-
gions outside the COMM domain are included in the compari-
son (data not shown).
COMMD Genes Are Widely Expressed—Given that COMMD
proteins were initially identified as COMMD1-associated fac-
tors in 293 cells, we first investigated the pattern of expression
of human COMMD genes in this cell line. To this end, we
designed primers for RT-PCR of each one of these genes includ-
ing in each case one primer that was selected at an exon-exon
junction. This strategy minimizes the possibility of spurious
amplification from contaminating genomic DNA because such
junctions are generated only after splicing. In addition, the
potential for mispriming against the intronic boundary was
taken into account in the design. With this algorithm we iden-
tified primers for all 10 human COMMD genes, with the am-
plicon size and position of exon-exon primers indicated in Fig.
2A. Using these primers and total RNA extracted from 293 cells
we were able to amplify the appropriate size products for each
of the COMMD genes (Fig. 2B). Template-lacking negative
controls did not amplify these products (data not shown). This
indicated that 293 cells express all COMMD genes, a fact that
was also confirmed by publicly available expression data (not
shown here).
Next, the level of COMMD expression in multiple tissues
was analyzed using data available from the Genomics Institute
of the Novartis Research Foundation. Utilizing oligonucleotide
arrays, expression levels for more than 44,000 mRNA tran-
scripts across 79 human tissues were determined (26). This raw
data were downloaded, and the corresponding probes for most
COMMD genes (with the exception of COMMD6) were identi-
fied. Expression levels in 13 selected tissues were further an-
alyzed and are presented in Fig. 2C. As shown, COMMDs are
BLAST allowed for the identification of six additional proteins with sequence homology to MURR1. A partial alignment of all 10 human COMMD
proteins is shown, demonstrating a region of higher conservation (COMM domain). The accession numbers for the 10 human mRNA sequences are
NM_152516, AY542158, AY542159, AY542160, NM_014066, AY542161, AY542162, AY542163, AY542164, and AY542165, corresponding to
COMMD1–10, respectively. The degree of conservation of each amino acid residue among these sequences is indicated based on Dayhoff PAM 250
scoring matrices (red, 90% conserved; blue, 70% conserved; yellow, 50% conserved). C, alignment of 91 COMMD proteins from multiple species
across the COMM domain. All protein sequences spanning through the COMM domain were aligned using the ClustalV algorithm, and this
alignment was then refined using the SAM program. The resulting alignment was then annotated using the GeneDoc program. The degree of
conservation of each amino acid residue among these sequences is indicated based on Dayhoff PAM 250 scoring matrices as before.
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widely expressed in human tissues, but the relative abundance
of any given COMMD mRNA is different across the samples.
For example, whereas COMMD1 expression is highest in the
testis, COMMD3 is the highest expressed in the thymus,
COMMD7 in the lung, and COMMD8 in the thyroid. Con-
versely, any given tissue has a complement of COMMD genes
that demonstrate highest expression, and these subsets are not
identical in each case (data not shown).
COMMD1 Can Associate with Other COMMD Proteins—
COMMD3, -4, and -6 were initially identified biochemically by
their ability to interact with COMMD1. Therefore, the ability of
all the members of the family to interact with COMMD1 was
evaluated. Each of the 10 COMMD proteins was fused to GST
and expressed in 293 cells. COMMD-GST fusion proteins were
then precipitated from cell lysates with glutathione-Sepharose
beads, and the recovered material was immunoblotted for en-
dogenous COMMD1 (Fig. 3A). COMMD1–8 and COMMD10
could readily precipitate endogenous COMMD1; COMMD9
also co-associates with COMMD1 but to a lesser extent (not
shown here). These experiments demonstrated that COMMD1
can interact with itself and with all other COMMD proteins,
consistent with the interactions detected in the initial
TAP screen.
COMMD-COMMD Protein Interactions Are Mediated by the
COMM Domain—To define the domain(s) required for
COMMD multimer formation, a variety of deletion constructs
of COMMD1 were tested for their ability to bind COMMD1 and
COMMD3. The coding regions corresponding to each exon of
COMMD1 were used as boundaries in constructs expressing
fusion proteins with GST (Fig. 3B). The hereditary canine
copper toxicosis mutation described previously consists of a
genomic deletion encompassing exon 2 of COMMD1 such that
the expressed open reading frame lacks 94 amino acid residues
(14). This protein product was also expressed in fusion with
GST and similarly tested for its ability to bind COMMD1
and COMMD3.
FIG. 2. A, amplicon size and position of mRNA-specific primers utilized for RT-PCR. B, COMMD genes are expressed in 293 cells. Using the
primer sets described, RT-PCR was performed with total RNA extracted from 293 cells serving as template. The presence of amplified products of
the proper sizes was determined by agarose gel electrophoresis as shown here. C, expression of COMMD genes in 13 normal tissues. Levels of
mRNA expression were determined using oligonucleotide microarrays.
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These fusion proteins were expressed in 293 cells and pre-
cipitated with glutathione-Sepharose beads. The ability of
these fragments to support an interaction was determined by
the presence of COMMD1 or COMMD3 in the precipitate (Fig.
3, C and D). The carboxyl terminus of COMMD1 (exon 2-3),
which contains the COMM domain, was found to be sufficient
for interactions with COMMD1 and COMMD3. The lack of the
COMM domain in the exon 1-GST fusion protein abrogated
binding in both cases. Furthermore, the exon 1-3 product, rep-
licating the protein product in dogs with copper toxicosis and
lacking part of the COMM domain, had a significant impair-
ment in binding. These data demonstrated that the COMM
domain that defines this protein family serves as an interface
for COMMD-COMMD interactions.
Several COMMD Proteins Suppress B-mediated Transcrip-
tion—MURR1/COMMD1, the prototype member of the family,
was recently reported to inhibit B-mediated transcription
from endogenous and viral promoters (16). Therefore, the abil-
ity of other COMMD proteins to inhibit NF-B was investi-
gated. Cells were transfected with a B-responsive reporter
plasmid (2B-luc) along with each of the COMMD proteins, and
the response to TNF stimulation was subsequently evaluated.
As shown in Fig. 4A, COMMD1, -2, -4, -7, -9, and -10 were
capable of strongly inhibiting TNF-mediated NF-B activation,
whereas COMMD3 and -8 inhibited NF-B weakly in this
assay. Similarly, most COMMD proteins also inhibited basal
levels of B-mediated transcription.
Next, the ability of these proteins to control transcription of
an endogenous B-responsive gene was evaluated. Expression
levels of endogenous COMMD1, -4, and -6 were decreased by
the use of RNA interference (RNAi), and the induction of c-
IAP2mRNA levels in response to TNF was evaluated (Fig. 4, B
and C). The effectiveness of RNAi against COMMD1, -4, and -6
was confirmed by quantitative RT-PCR (Fig. 4C). When com-
pared with mRNA levels present in control samples, transfec-
tion with siRNA oligonucleotides against COMMD1, -4, and -6
resulted in a 75–95% suppression of mRNA expression, consist-
ent with efficient RNAi of these transcripts. Next, the effect of
reduced COMMD expression on cIAP-2 transcription was eval-
uated (Fig. 4B). In cells transfected with oligonucleotides
against an irrelevant target (GFP), treatment with TNF re-
sulted in a 9-fold increase in c-IAP2mRNA levels, as measured
by quantitative RT-PCR, a fold increase that is identical to that
observed in untransfected cells (data not shown). Decreased
COMMD levels resulted in heightened expression of c-IAP2
after TNF treatment, with this effect being most notable after
COMMD6 RNAi. Therefore, these factors not only share a
common domain but have similar functional properties in the
regulation of NF-B transcriptional activity.
COMMD Proteins Associate with the NF-B Complex—The
ability of COMMD1 to inhibit B-mediated transcription was
previously found to depend on its association with the NF-B
complex (16). Indeed, precipitation of endogenous COMMD1
with the use of rabbit polyclonal sera against COMMD1 re-
sulted in the co-precipitation of endogenous RelA and c-Rel
(Fig. 5A).
The possibility that other COMMD proteins can interact
with the NF-B complex was evaluated using fusion proteins
with GST expressed in 293 cells. Precipitations with gluta-
thione-Sepharose beads were performed followed by immu-
noblotting for detection of endogenous NF-B subunits RelA,
c-Rel, RelB, NF-B1/p105, and NF-B2/p100. As was the case
for COMMD1, most COMMD proteins were also capable of
precipitating NF-B complexes (Fig. 5B). Although the inten-
sity of recovery of NF-B subunits correlated with the level of
expression of the COMMD-GST proteins themselves (data
not shown), the pattern of association with NF-B subunits
was different between the various COMMDs. Some COMMD
proteins favor complexes containing RelB and NF-B1/p105
(as in the case of COMMD3 and 9), whereas others seem to
interact preferentially with RelA-containing complexes (as in
the case of COMMD6 and -7). COMMD1, -2, -4, -5, -8, and -10
could associate more broadly with NF-B subunits, although
pattern differences were still evident. COMMD1 could asso-
FIG. 3. A, COMMD-COMMD interactions. Each of the 10 COMMD
proteins was expressed in 293 cells in fusion with GST and precipitated
(IP) from cell lysates by glutathione-Sepharose beads. The presence of
endogenous COMMD1 in the precipitates was determined by immuno-
blotting. B, schematic representation of COMMD1 and the amino acid
residues that are the boundaries for interaction mapping experiments.
C and D, the COMM domain is required for the association of COMMD
proteins. COMMD1-Flag (C) or COMMD3-FLAG (D) were expressed in
293 cells along with various regions of COMMD1 in fusion with GST as
indicated. COMMD1-GST was precipitated from cell lysates by gluta-
thione-Sepharose beads and the presence of COMMD1 or -3 in the
precipitates was determined by immunoblotting (WB) with a Flag
antibody.
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ciate with all five subunits and was the only COMMD able to
precipitate c-Rel, whereasCOMMD2 also associated broadly
with NF-B subunits but interacted more strongly with RelB-
containing complexes.
COMMD1-NF-B Interactions Can Be Mapped to Distinct
Domains—The ability of various regions of COMMD1 to sus-
tain an interaction with endogenous RelA was evaluated next.
In these experiments GST fusions of various domains of
COMMD1, as depicted in Fig. 3B, were used for co-precipita-
tion experiments. Unlike COMMD1-COMMD interactions that
seem to require only the COMM domain (Fig. 3, C and D),
COMMD1-RelA interactions are only detectable with full-
length COMMD1 (Fig. 6A). Therefore, the interaction between
COMMD1 and RelA relies on the presence of elements other
than the COMM domain.
Next, the interaction between COMMD1 and RelA was eval-
uated further by determining the domains in RelA that are
required for this interaction (Fig. 6B). Different domains of
RelA in fusion with GST were expressed in 293 cells and
COMMD1, -4, and -6 were determined by quantitative RT-PCR and
compared with the corresponding control samples transfected with the
GFP siRNA oligonucleotide. The data are presented as a percentage of
the control samples, which was standardized to 100%.
FIG. 4. A, COMMD proteins suppress B-mediated transcription.
Cells were transfected with the 2B-luciferase reporter and COMMD
proteins and were treated with TNF (1000 units/ml) for 12 h. Transcrip-
tional activation of NF-B was determined by luciferase assay (top
panel), and expression of COMMD proteins in these lysates was deter-
mined by Flag immunoblotting (bottom panel). RLU, relative lumines-
cence units. B, effect of COMMDs on c-IAP2 expression. Endogenous
levels of COMMD1, -4, and -6 were decreased with the use of siRNA
oligonucleotides. The effects of TNF treatment on the expression levels
of c-IAP2, a known NF-B responsive gene, were evaluated by quanti-
tative RT-PCR. C, efficiency of COMMD RNAi. Levels of expression of
FIG. 5. A, COMMD1 associates with endogenous NF-B subunits.
Endogenous COMMD1 was immunoprecipitated (IP) from cell lysates
prepared from 293 cells. This material was immunoblotted for endoge-
nous RelA (top panel) and c-Rel (bottom panel). B, other COMMDs also
associate with NF-B. GST fusions with all COMMD proteins were
expressed in 293 cells and precipitated from cell lysates by glutathione-
Sepharose beads, and the presence in the precipitates of endogenous
RelA, c-Rel, RelB, NF-B1/p105, and NF-B/p100 was determined by
immunoblotting.
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precipitated with glutathione-Sepharose beads; the presence of
COMMD1, p50 or its precursor p105, and IB- in the precip-
itates was determined by immunoblotting. As shown in Fig. 6C,
the RHD of RelA was sufficient for binding to COMMD1, p50 or
p105, and IB-. The carboxyl-terminal 246 amino acids of
RelA (306–551), which correspond to the transactivation do-
main of the molecule (TAD), did not bind any of these mole-
cules. Within the RHD, the first 180 amino acids comprise the
DNA binding domain, whereas the remainder of the RHD (181–
305) contains residues involved in IB binding and dimeriza-
tion with other subunits and the nuclear localization signal.
Interestingly, the first 180 amino acids of RelA were capable of
binding COMMD1 but not p50/p105 or IB-, probably because
of the absence of the dimerization sequences. Reciprocal exper-
iments, in which precipitation of COMMD1-GST was per-
formed to determine its ability to bind to different domains of
RelA, also supported these results (data not shown).
The RHD is highly conserved in all five NF-B subunits (34).
Therefore, the possibility that COMMD1 could also bind to
similar sequences present in the RHD of other NF-B subunits
was similarly evaluated. Sequences contained in c-Rel-(1–180),
RelB-(97–267), p50-(1–233), and p52-(1–212) were found to be
homologous to RelA-(1–180) by aligning all five subunits using
the ClustalV algorithm (data not shown). Each one of these
regions in fusion with GST was expressed in 293 cells and
precipitated from cell lysates with glutathione-Sepharose
beads, and the presence of COMMD1 was determined by im-
munoblotting. As shown in Fig. 6D, these homologous regions,
present in the RHD of all five NF-B subunits, were capable of
binding to COMMD1.
COMMD1 Does Not Affect Nuclear Translocation of NF-B—
In most cells NF-B is ordinarily localized in the cytoplasm
through interactions with members of the IB family, which
results in masking of the nuclear localization signal and cyto-
plasmic sequestration of the complex (11). Because the trans-
location of NF-B from the cytosol to the nucleus is a well
characterized regulatory step in the activation of B-dependent
transcription, the ability of COMMD1 to affect this process
was investigated.
First, cellular localization of a fusion protein between RelA
and EGFP was assessed by fluorescence microscopy before and
after TNF treatment. TNF stimulation resulted in nuclear
translocation of EGFP-RelA, a process that was inhibited in
cells cotransfected with a superdominant form of IB- (Fig. 7,
A and B). In contrast, the distribution of EGFP-RelA was
unchanged by COMMD1 transfection, suggesting that unlike
IB-, COMMD1 does not suppress the nuclear translocation of
the NF-B complex.
The translocation of NF-B complexes into the nucleus and
their DNA binding capacity was also evaluated by EMSA. Cells
transfected with a control vector and subsequently treated with
TNF demonstrated increased B binding activity in nuclear
extracts (Fig. 7C). As a control, this induction was blocked by
tation experiments. The presence of endogenous RelA in the precipitate
was determined by immunoblotting. B, shown is a schematic depicting
the boundaries of the RHD and transactivation domain (TAD) of RelA.
C, the ability of COMMD1 to bind to different regions of RelA was
evaluated. Different domains of RelA were expressed in fusion with
GST in 293 cells. These fusion proteins were precipitated from cell
lysates by glutathione-Sepharose beads, and the presence of COMMD1,
p50/p105, and IB- was determined by immunoblotting. Input levels
for COMMD1, p50, p105, and IB- were identical in all samples (data
not shown). D, regions derived from other NF-B subunits that are
homologous to RelA-(1–180) were expressed in fusion with GST and
precipitated from cell lysates with glutathione-Sepharose beads. The
presence of COMMD1 in the precipitate was determined by immuno-
blotting. Input levels for COMMD1 were identical in all samples (data
not shown). IP, immunopreipitate.
FIG. 6. A, domains involved in the interaction between COMMD1 and
RelA. Deletion constructs of COMMD1 in fusion with GST correspond-
ing to the boundaries described in Fig. 3B were utilized for co-precipi-
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transfection of superdominant IB-. However, COMMD1
transfection had no appreciable effects on the induction of B
binding activity in nuclear extracts after TNF treatment. In
addition, whereas RNAi of COMMD1 led to transcriptional
activation of NF-B, this did not lead to induction of B binding
by EMSA (data not shown).
COMMD1 Binds to B-responsive Promoter Regions and Af-
fects NF-B Binding to Chromatin—Although COMMD pro-
teins can interact with the NF-B complex, the ability of
COMMD1 to inhibit transcriptional activation is independent of
the nuclear translocation of NF-B. This suggested that the ac-
tivity of NF-B complexes in the nucleus was compromised by
COMMD1. To investigate this possibility, the presence of nuclear
COMMD1 was first established. Subcellular fractions were pre-
pared from 293 cells during timed stimulation with TNF (includ-
ing an early and late time point). As shown in Fig. 8A, COMMD1
was present in both nuclear and cytosolic fractions, and its quan-
tity seemed slightly increased in the late time point (180 min). As
expected, TNF stimulation also resulted in nuclear translocation
of RelA and early degradation of IB- with late accumulation of
this protein in the nuclear fraction. The purity of the fractions
was determined by immunoblotting for tubulin (cytosolic
marker) and GCN5 (nuclear marker).
Based on the above findings, the effects of COMMD1 on
NF-B nuclear function were investigated by examining the
recruitment of RelA to chromatin. Utilizing ChIP, the effects of
COMMD1 levels on the recruitment of RelA to the B-respon-
sive c-IAP2 promoter were determined. The effects of stimula-
tion with TNF were compared after transfection of control and
COMMD1 siRNA oligonucleotides (Fig. 8B). Decreases in en-
dogenous COMMD1 levels resulted in prolongation of the oc-
cupancy time of RelA on the c-IAP2 promoter. In addition,
COMMD1 itself was found to be recruited to this B-responsive
site after TNF stimulation. A complementary set of experi-
ments was also performed to determine if increases in
FIG. 7. A, COMMD1 does not prevent nuclear translocation of NF-B.
293 cells were plated in cover glass-chambered slides and transfected
with a vector encoding for RelA in fusion with EGFP and with
COMMD1, IB-S.D. or a vector control (pEBB). Twenty-four hours
after transfection cells were treated with TNF for 1 h. Representative
images are shown (magnification bar corresponds to 18 m). B, quan-
tification of nuclear translocation. 293 cells were plated 6-well dishes,
transfected as described in A and treated with TNF for 1 h. Before and
after treatment, 250–400 cells in each group were counted under the
microscope and rated for the presence or absence of appreciable nuclear
signal from RelA, the absence of which was recorded as nuclear exclu-
sion. The data are presented as a percentage of the total number of cells
counted in each group. C, nuclear translocation was also evaluated by
EMSA. 293 cells plated in 10-cm plates were transfected with the
constructs indicated in the figure. TNF stimulation was performed 30
min before extraction of nuclear proteins, which were used for EMSA.
FIG. 8. A, presence of a nuclear pool of COMMD1. Cell lysates were
fractionated to obtain nuclear and cytosolic fractions during timed
stimulation with TNF. These fractions were used for immunoblotting to
determine the cellular localization of endogenous COMMD1. As a con-
trol for the of TNF stimulation, the effects on RelA and IB- levels
were also determined by immunoblotting. Tubulin and GCN5 served as
cytosolic and nuclear markers, respectively. B and C, COMMD1 inhib-
its chromatin occupancy by NF-B. ChIP analysis on the cIAP-2 pro-
moter after TNF stimulation was performed on DU145 cells transfected
with siRNA oligonucleotides to COMMD1 or GFP (control). (B). ChIP
analysis was performed on the cIAP-2 gene using 293 cells expressing
either Flag-tagged COMMD1 or empty vector control. Cell adhesion to
a laminin-coated plate was used as the NF-B activating stimulus. Pol,
polymerase.
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COMMD1 protein levels would have the converse effect on
RelA recruitment to chromatin. In this case, cell adhesion to
laminin was used as the stimulus for NF-B activation, as this
results in robust and sustained recruitment of RelA to the
c-IAP2 promoter site. As shown in Fig. 8C, overexpression of
COMMD1 resulted in a marked decrease in the duration of
RelA association with chromatin after NF-B activation; again,
COMMD1 recruitment to chromatin in response to stimulation
was also detected.
Taken together, these data indicate that COMMD1 affects
the half-life of the RelA-chromatin complex that is recruited in
response to NF-B-activating stimuli. Because COMMD1 itself
is recruited to chromatin and remains associated even after
NF-B has been displaced, this suggests that COMMD1 either
alone or through the recruitment of other factors can affect the
affinity of NF-B for chromatin.
DISCUSSION
In this report we describe the identification of a novel and
conserved family of homologs of MURR1. These factors are
defined by the presence of a unique carboxyl-terminal motif
termed the COMM domain. The existence of this protein family
and any insights into the cellular functions of these factors
were largely unknown up to this point.
We show here that all COMMD proteins can interact with
MURR1/COMMD1. Interestingly, whereas all 10 factors are
expressed in 293 cells, only COMMD3, -4, and -6 were identi-
fied as COMMD1-associated factors in our TAP screen, sug-
gesting that certain associations might be preferentially pres-
ent in cells. In addition, other COMMD-COMMD complexes
that do not include COMMD1 are likely to occur, and indeed,
our search of the Drosophila protein interaction map recently
published (35) predicts an interaction between Drosophila
COMMD2 and COMMD3. Therefore, once antibodies to all 10
proteins are available, the composition of physiologic COMMD-
COMMD complexes would be able to be identified. We also
show that interactions between COMMD proteins are medi-
ated by the COMM domain.
Several COMMD proteins are functionally similar to the
prototype member of the family, MURR1/COMMD1, and bind
to and suppress NF-B. We studied in further detail the bind-
ing mechanism by which COMMD1 interacts with RelA and
demonstrate that this is distinct from dimerization to other
NF-B subunits or binding to IB- (Fig. 6C), indicating that
these two events are not required for the interaction of
COMMD1 with NF-B. This is similarly supported by the ob-
servation that COMMDs can also associate with RelB (Fig. 5B),
an NF-B subunit that does not associate with IB- (36).
These findings suggest that the prior identification of an asso-
ciation between IB- and COMMD1 that requires the ankyrin
repeats of IB- could be potentially explained as a tertiary
complex, since the ankyrin repeats are required for IB- bind-
ing to the NF-B subunits (16).
Unlike the association between COMMD1 and itself or
COMMD3, COMMD1-RelA interactions are not supported by
the COMM domain alone (Figs. 3, C and D, and 6A), indicating
that the association of COMMDs to NF-B complexes is likely
mediated by a mechanism distinct from COMMD-COMMD
interaction. Similarly, the pattern of COMMD association to
NF-B could not be simply explained by COMMD multimer
formation. Despite the demonstrated interaction between
COMMD1 and COMMD3, only COMMD1 could precipitate
RelA. In addition, COMMD9 could readily precipitate RelB,
whereas COMMD6 did not despite the stronger COMMD6-
COMMD1 interaction (Figs. 3A and 5B).
NF-B-mediated transcription is largely controlled by the
cytoplasmic sequestration of NF-B complexes through the
binding to ankyrin repeat-containing inhibitory molecules such
as the IBs (11, 37). Activation of the IB kinase complex in
response to a variety of extracellular signals initiates a cascade
of events leading to IB degradation and nuclear translocation
on NF-B. Whereas a role for MURR1/COMMD1 in the regu-
lation of IB- degradation has been demonstrated (16), our
findings here suggest that this effect is not sufficient to explain
its ability to inhibit NF-B-mediated transcription, since nu-
clear translocation of NF-B subunits is unaffected by
COMMD1. Rather, we find that COMMD1 can regulate the
nuclear function of NF-B through its recruitment to B-re-
sponsive promoters where it affects the duration of RelA bind-
ing to chromatin.
Once activated, NF-B can mediate expression of multiple
gene targets. However, the observed responses are often spe-
cific to the cell type and stimulus in question. For example,
NF-B has been reported to be able to activate transcription of
both pro- and anti-apoptotic factors in various settings (5, 6).
The regulation of NF-B solely by IB-mediated sequestration
of the complex is unlikely to account for these differences in
gene expression. In this regard, post-translational modifica-
tions of NF-B (38) and preferential promoter binding by dif-
ferent subunits have been shown to participate in the regula-
tion of certain promoters in response to specific stimuli (36, 39).
However, additional layers of regulation that could account for
the tissue- and promoter-specific nature of the response are
likely at play. The identification here of the COMMD family
reveals an additional regulatory level that might be important
in this regard. The conservation of all 10 COMMD genes
through vertebrate evolution and the differential pattern of
association to NF-B complexes suggest that despite their sim-
ilarities, COMMD proteins probably serve unique and non-
redundant functions. A thorough understanding of the mode of
action of these factors in different cell types may help to ac-
count for the precision and selectivity by which expression of
the multitude of NF-B-responsive genes can be orchestrated
in response to a diverse range of stimuli.
Unlike other nuclear regulators of NF-B such as histone
acetylases and deacetylases, the COMMDs themselves possess
no apparent intrinsic enzymatic activity. The transcriptional
inhibitory functions of the COMMDs must in turn be regulated
in response to certain stimuli, possibly by post-translational
modifications. XIAP, a stress responsive pro-survival factor
(40), can ubiquitinate COMMD1, resulting in its degradation
(19), suggesting that the regulation of COMMD proteins might
be integrated into cellular stress responses that are known to
activate NF-B.
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Supplemental Table: All ten human COMMD loci are presented, along with orthologs to these 
genes identified in other species.  Altogether, 94 COMMD genes were identified, including 84 
genes in non-human species.  The proteins encoded by these orthologous genes were compared to 
the human proteins using the "BLAST 2 sequences" program available at NCBI.  The degree of 
identity and homology is indicated. 
 
Supplemental Figure:  A phylogenetic tree indicating the relationships between all 94 COMMD 
proteins was generated.  First, these sequences were aligned using the ClustalV algorithm, and 
this alignment was then refined using the SAM program.  The resulting refined alignment was 




Proposed name COMMD1 COMMD2 COMMD3 COMMD4 COMMD5 COMMD6 COMMD7 COMMD8 COMMD9 COMMD10
Published name MURR1 Bup HcaRG AK000009
Locus in human genome 2p15 3q25.1 10pter-q22.1 15q23 8q24-qter 13q22 20q11.22 4p12 11p13 5q23.1
Species
Pan troglodytes 98/99 99/99
Sus scrofa 91/95 94/97 86/92
Bos taurus 88/93 89/94
Canis familiaris 88/93 85/92
Mus musculus 86/92 92/97 89/93 90/95 79/88 87/93 88/94 76/86 89/93 89/94
Rattus norvegicus 85/90 92/97 90/93 89/94 80/89 90/95 79/87 93/95 89/93
Gallus gallus 68/81 73/83 54/76 64/75 74/86 64/79 72/82 77/91
Xenopus laevis 61/83 75/85 63/78 65/83 52/75 76/89 57/73 64/82
Silurana tropicalis 60/81 67/83 65/89 52/73 57/73 66/80 75/87
Oryzias latipes 55/76
Oncorhynchus mykiss 75/88 62/81 54/70 61/77 68/81
Danio rerio 46/72 76/88 52/71 66/79 46/70 62/82 48/70 60/77 60/76
Branchiostoma belcheri 61/78
Ciona intestinalis 45/67 33/51 47/65
Apis mellifera 42/64
Anopheles gambiae 30/47
Drosophila melanogaster 30/46 22/40 37/59 24/51 28/53
Caenorhabditis elegans 30/52
Lumbricus rubellus 51/67
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COMMD1 promotes the ubiquitination of NF-jB
subunits through a cullin-containing ubiquitin
ligase
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NF-jB is a pleiotropic transcription factor involved in
multiple processes, including inflammation and oncogen-
esis. We have previously reported that COMMD1 represses
jB-dependent transcription by negatively regulating
NF-jB–chromatin interactions. Recently, ubiquitination of
NF-jB subunits has been similarly implicated in the
control of NF-jB recruitment to chromatin. We report
here that COMMD1 accelerates the ubiquitination and
degradation of NF-jB subunits through its interaction
with a multimeric ubiquitin ligase containing Elongins B
and C, Cul2 and SOCS1 (ECSSOCS1). COMMD1-deficient
cells demonstrate stabilization of RelA, greater nuclear
accumulation of RelA after TNF stimulation, de-repres-
sion of several jB-responsive genes, and enhanced
NF-jB-mediated cellular responses. COMMD1 binds to
Cul2 in a stimulus-dependent manner and serves to facili-
tate substrate binding to the ligase by stabilizing the
interaction between SOCS1 and RelA. Our data uncover
that ubiquitination and degradation of NF-jB subunits
by this COMMD1-containing ubiquitin ligase is a novel
and critical mechanism of regulation of NF-jB-mediated
transcription.
The EMBO Journal (2007) 26, 436–447. doi:10.1038/
sj.emboj.7601489; Published online 21 December 2006
Subject Categories: chromatin & transcription; proteins
Keywords: COMMD1; cullin; NF-kB; transcription;
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Introduction
NF-kB is a dimeric transcription factor that controls expres-
sion of genes involved in multiple processes including im-
munity, apoptosis, and cell cycle progression (Karin and Lin,
2002). In mammals, NF-kB subunits are encoded by five
genes (RELA, RELB, REL, NFKB1, and NFKB2). All subunits
share an B300 amino-acid region of homology termed the
Rel homology domain (RHD) that mediates DNA binding and
dimerization. The NFKB1 and NFKB2 genes encode large
precursor polypeptides known as p105 and p100, which are
cleaved into the mature p50 and p52 subunits, respectively.
NF-kB is ordinarily sequestered in the cytoplasm in a
transcriptionally inactive form as a result of interactions
with IkB proteins or, in the case of RelB, through its dimer-
ization with p105 or p100, which contain IkB-like domains
in their carboxy-termini. In response to a variety of stimuli,
transient nuclear translocation of NF-kB dimers takes place,
a prerequisite for kB-mediated transcription to occur. The
translocation event is triggered by phosphorylation of IkB
proteins by the multimeric IkB kinase, which leads to their
ubiquitination by the SCFb-TrCP ubiquitin ligase (Henkel et al,
1993; Chen et al, 1995; Yaron et al, 1998). Ubiquitinated IkB
is then quickly degraded allowing nuclear translocation of
NF-kB to occur. Once in the nucleus, NF-kB complexes bind
to cognate DNA sequences present in an array of promoters
resulting in gene expression.
In addition to nuclear translocation, transcriptional activa-
tion by NF-kB requires recruitment of co-activators and the
displacement of co-repressor complexes. This is mediated
through an intricate set of nuclear events that involve post-
translational modifications of NF-kB subunits, including
phosphorylation and acetylation (Sakurai et al, 1999; Chen
et al, 2001; Zhong et al, 2002).
In order to achieve controlled expression of its gene
targets, the termination of NF-kB-mediated transcriptional
responses is tightly regulated. Nuclear export of NF-kB com-
plexes is a major step in the regulation of this pathway.
Through a negative feedback loop, NF-kB induces the re-
synthesis of IkB proteins, ultimately driving nuclear export
of NF-kB and termination of transcription (Hoffmann et al,
2002). Despite the important role that IkB proteins play in
regulating the nuclear pool of NF-kB, other factors are likely
involved. For example, NF-kB remains largely excluded from
the nucleus in cells that are profoundly deficient in IkB
proteins, in contrast to the mostly nuclear localization that
results from stimulus-dependent degradation of IkB
(Tergaonkar et al, 2005), suggesting that other pathways are
also involved in the control of nuclear NF-kB levels.
We have previously reported that a factor named MURR1,
now referred to as COMMD1, is a ubiquitously expressed
inhibitor of NF-kB (Ganesh et al, 2003; Burstein et al, 2005).
COMMD1 interferes with HIV-1 replication, a process that is
dependent on kB-mediated transcription (Ganesh et al, 2003).
More recently, we identified that COMMD1 is the prototype of
a family of 10 factors known as COMMD proteins that also
function to repress NF-kB (Burstein et al, 2005). The defining
characteristic of all family members is the presence of an
B70 amino-acid region of high homology in their extreme
carboxy-termini termed the COMM domain, which serves as
an interface for COMMD–COMMD protein interactions
(Burstein et al, 2005). COMMD proteins interact with NF-kB
subunits but, unlike IkB-a, do not control the translocation of
NF-kB from the cytosol to the nucleus (Burstein et al, 2005).
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Rather, COMMD1 is recruited to kB-responsive promoters
and decreases the duration of RelA–chromatin interactions
(Burstein et al, 2005). However, the precise mechanism for
this effect remained elusive.
Recent work has demonstrated that ubiquitination and
proteasomal degradation of nuclear RelA also participate in
the termination of NF-kB–chromatin interactions (Saccani
et al, 2004), prompting us to investigate a potential role for
COMMD1 in RelA ubiquitination. Indeed we demonstrate here
that COMMD1 promotes the ubiquitination and degradation
of NF-kB subunits. COMMD1 deficiency results in stabiliza-
tion of NF-kB and increased nuclear accumulation of RelA
following TNF stimulation. Furthermore, NF-kB activation in
COMMD1-deficient cells results in de-repressed kB-dependent
transcription and enhanced release of chemokines. We show
that endogenous COMMD1 immune complexes contain E3
ubiquitin ligase activity, as well as components of a Cullin-
containing ubiquitin ligase comprised of Elongins B and C,
Cul2 and SOCS1 (also known as ECSSOCS1), which has been
previously implicated in RelA ubiquitination. Immuno-
precipitation of COMMD1 from cells expressing Cul2 or the
ECSSOCS1 complex recovered ubiquitin ligase against RelA
in vitro. Finally, our data indicate that the interaction
of COMMD1 with ECSSOCS1 serves to stabilize SOCS1–RelA
interactions, thereby promoting binding of the substrate to
the enzyme. Overall, these studies define a novel pathway
by which kB-mediated transcription is regulated through
COMMD1-mediated ubiquitination of NF-kB subunits.
Results
COMMD1 promotes the ubiquitination of NF-jB
subunits
We have previously reported that COMMD1 inhibits kB-
mediated transcription by decreasing the duration of RelA–
chromatin interactions (Burstein et al, 2005). Recently,
ubiquitination and proteasomal degradation of DNA-bound
RelA was implicated in the control of RelA–chromatin inter-
actions (Saccani et al, 2004). Therefore, we explored the
possibility that ubiquitination of RelA might be a mechanism
for the inhibitory effects of COMMD1 on kB-mediated
transcription.
To investigate this, we examined the effect of COMMD1
expression on the levels of ubiquitinated NF-kB. First, ubi-
quitination of ectopically expressed, GST-tagged RelA was
evaluated by precipitating RelA and immunoblotting the
recovered material for polyubiquitin (Figure 1A). Heavily
ubiquitinated RelA was recovered after proteasomal blockade
only in cells coexpressing COMMD1. Utilizing a similar
approach, we next examined the effect of COMMD1 expres-
sion on the ubiquitination of endogenous RelA (Figure 1B). In
this case, endogenous RelA was immunoprecipitated and the
recovered material immunoblotted for polyubiquitin. Again,
expression of COMMD1 resulted in increased recovery of
ubiquitinated RelA. To corroborate that the ubiquitinated
material recovered in Figure 1A and B was RelA itself, a
complementary approach was utilized. Here ubiquitinated
proteins were recovered by precipitating ubiquitin (ectopi-
cally expressed as a fusion protein containing the His6 affinity
tag, His6-Ubi) and detecting the presence of RelA in this
fraction by immunoblotting. As shown in Figure 1C, precipi-
tation of cell lysates with Niþ -NTA agarose beads resulted in
the recovery of polyubiquitinated proteins only when the
cells were transfected to express His6-Ubi (and not from
vector-transfected cells). Slight and nonspecific binding of
RelA to the beads was detected, but modified RelA consisting
of material of increasing molecular weight was only recov-
ered from cells expressing His6-Ubi, indicating that this
material is ubiquitinated RelA (Figure 1C, upper panel). As
in Figure 1A and B, increased expression of COMMD1 accele-
rated RelA ubiquitination (Figure 1C, left panel), whereas
decreased expression of endogenous COMMD1 after RNA
interference (RNAi) diminished the amount of ubiquitinated
RelA (Figure 1C, right panel). Importantly, these changes
in the recovery of ubiquitinated RelA were not the result
of uneven expression of RelA or uneven precipitation of
polyubiquitinated proteins across the samples.
COMMD1 is a member of a larger protein family, which
also shares the ability to bind to and inhibit NF-kB activity;
therefore, we investigated the possibility of a similar effect
by other COMMD family members. Decreased expression of
COMMD6, 9, and 10 also resulted in decreased recovery of
ubiquitinated RelA (Supplementary Figure S1). Finally, using
a similar approach, we observed that COMMD1 expression
accelerated the ubiquitination of two other NF-kB subunits,
RelB and p52 (Figure 1D). Altogether, these results indicate
that COMMD1 promotes the ubiquitination of NF-kB.
COMMD1 affects the stability of RelA
If COMMD1-mediated ubiquitination of NF-kB subunits re-
sults in their degradation, we reasoned that COMMD1 should
alter the half-life and possibly the steady-state levels of NF-kB
subunits in cells. We examined this possibility in U2OS cells
with stable RNAi of COMMD1, resulting in nearly undetect-
able COMMD1 protein expression (Figure 2A) and 94%
suppression of the COMMD1 transcript (Figure 2B). In these
cells, basal levels of RelA protein were increased (Figure 2A)
and were not accompanied by changes in RELA mRNA
expression, suggesting a post-transcriptional effect of
COMMD1 on RelA (Figure 2B). In addition, similar increases
in the steady-state protein levels of RelB, p105, and p100
were observed (Figure 2A) in the absence of transcriptional
upregulation of their respective genes (data not shown).
This suggested an effect of COMMD1 on the protein
stability of RelA, and therefore the half-life of the protein
was examined. After metabolic labeling with 35S-labeled
methionine and cysteine, cell lysates were prepared at differ-
ent time points and endogenous RelA was immuno-
precipitated, resolved by SDS–PAGE, and then detected by
autoradiography. Consistent with the previous results, the
half-life of RelA was prolonged in COMMD1-deficient cells
(Figure 2C). Altogether, this indicated that COMMD1 desta-
bilizes RelA by promoting its ubiquitination and targeting
the protein for proteasomal degradation.
COMMD1 controls endogenous jB-mediated
transcription and cellular responses
The predicted functional effect of the stabilization of RelA
that we observed in COMMD1-deficient cells would be an
increase in kB-dependent transcription. Therefore, we exam-
ined the inducible mRNA expression of NF-kB-responsive
genes following TNF stimulation. Treatment with TNF
resulted in time-dependent increases in mRNA expression of
known NF-kB target genes such as ICAM1, BIRC3 (encoding
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c-IAP2), CXCL1, and CCL2 (Figure 2D). In each case,
COMMD1-deficient cells demonstrated increased transcrip-
tion of these genes, consistent with the notion that endogen-
ous levels of COMMD1 serve to restrict kB-mediated
transcription. Interestingly, the transcriptional effects
observed varied in each case (Figure 2D), and for other
NF-kB-regulated genes such as IL8 or TNF, the effects were
minimal (Supplementary Figure S2). These data indicate that
endogenous levels of COMMD1 serve to repress transcription
of a specific subset of NF-kB-inducible genes.
NF-kB-mediated transcription plays a critical role in a
number of cellular events, particularly the expression of
mediators of the inflammatory response in vivo, including
the production of several chemokines. Given the increased
rates of NF-kB-mediated transcription observed in COMMD1-
deficient cells (Figure 2D), we anticipated that these
cells might produce larger amounts of chemokines. To test
this possibility, we examined the ability of conditioned
media to induce chemotaxis of freshly isolated peripheral
mononuclear cells across a membrane barrier. As shown
in Figure 2E, conditioned media from COMMD1-deficient
cells induced a higher rate of chemotaxis than the control
cell line, particularly after TNF stimulation. As predicted,
this increased chemotaxis rate correlated with increased
secretion of NF-kB-inducible chemokines into the media
such as CCL2 (Figure 2F), a chemokine whose mRNA
expression was also upregulated in these cells (Figure 2D,
fourth panel).
COMMD1 deficiency alters the kinetics of nuclear
accumulation of RelA
The data thus far indicated that COMMD1 promotes the
ubiquitination of RelA and affects kB-mediated transcription
and cellular responses, such as the production of chemo-
kines. Given our prior observations that COMMD1 negatively
regulates RelA–chromatin interactions (Burstein et al, 2005),
we reasoned that one potential outcome of COMMD1 defi-
ciency would be decreased RelA ubiquitination leading
to enhanced accumulation of nuclear RelA. To study this
latter possibility, nuclear extracts of control and COMMD1-
deficient cells were prepared at various time points following
pulsed TNF stimulation. As shown in Figure 3A, COMMD1
Figure 1 COMMD1 promotes the ubiquitination of NF-kB subunits. (A) Ubiquitination of RelA. HEK 293 cells were transfected with COMMD1
or a vector control, along with GST-RelA. Cells were treated with Lactacystin (10mM) for 3 h before lysis with Triton X-100 buffer. RelA was
precipitated (PD) using glutathione (GSH) beads and the recovered material was immunoblotted for ubiquitin (Ubi). (B) Ubiquitination of
endogenous RelA. Cells were transfected with COMMD1 (or vector control) as in (A), and endogenous RelA was immunoprecipitated from cell
lysates prepared with Triton X-100 buffer. The recovered material was immunoblotted for ubiquitin. (C) Effects of overexpression and
underexpression of COMMD1 on RelA ubiquitination. HEK 293 cells were transfected with His6-ubiquitin (His6-Ubi) or a vector control, along
with HA-RelA. These cells were co-transfected with a vector control or COMMD1 (left panel), or with control or COMMD1-specific siRNA (right
panel). Ubiquitinated material was precipitated from cell lysates prepared with Triton X-100 buffer, using Ni-NTA agarose beads. The recovered
material was immunoblotted for RelA (HA) and ubiquitin. (D) Effects on other NF-kB subunits. HEK 293 cells were transfected as in (C), except
that HA-RelB (left panel) or HA-p52 (right panel) was used.
COMMD1 and NF-jB ubiquitination
GN Maine et al
The EMBO Journal VOL 26 | NO 2 | 2007 &2007 European Molecular Biology Organization438 51
deficiency resulted in greater nuclear accumulation of RelA,
and the differences observed were not accounted for by the
levels of IkB-a as COMMD1-deficient cells had equal or
higher levels of IkB-a at every time point (Figure 3B).
Interestingly, despite the prolongation in the half-life of
RelA (Figure 2C), the increased accumulation of nuclear
RelA in these cells was not a sustained effect and was only
noticeable during the peak times of 20 and 45 min post-
stimulation. This observation correlated with a faster and
higher rate of IkB-a protein resynthesis in COMMD1-deficient
cells (Figure 3B), explained in part by modest increases in
mRNA expression (Supplementary Figure S3). This is con-
sistent with the known negative feedback loop by which
NF-kB activates transcription of NFKBIA (the gene encoding
IkB-a), an event known to promote nuclear export of NF-kB
(Hoffmann et al, 2002).
Figure 2 COMMD1 deficiency stabilizes RelA and de-represses endogenous kB-dependent transcription and cellular events. (A) COMMD1
deficiency results in higher basal levels of RelA. U2OS cells were stably infected with lentiviruses targeting a control gene (shControl) or
COMMD1 (shCOMMD1). Once stable polyclonal cell lines were established, cell lysates were prepared with Triton X-100 buffer for
immunoblotting as indicated. (B) COMMD1 deficiency does not affect mRNA levels of RELA. In the same cells, mRNA was extracted and
the levels of COMMD1 and RELA expression were determined by qRT–PCR and expressed as % compared to the control line. (C) The half-life of
RelA is prolonged in COMMD1-deficient cells. Cells were metabolically labeled with 35S-labeled methionine and cysteine and cell lysates were
prepared at increasing time intervals as indicated. After immunoprecipitation of RelA, the recovered material was resolved by SDS–PAGE and
subjected to autoradiography. (D) COMMD1 deficiency results in enhanced transcription of several kB-responsive genes. COMMD1-deficient
and control cell lines were stimulated with a 10 min pulse of TNF, rinsed in PBS, and placed in normal media. Extraction of mRNA was
performed for qRT–PCR of the indicated gene transcripts. (E) COMMD1-deficient cells produce greater amounts of chemotactic factors.
Conditioned media from untreated or TNF-treated cells (12 h) were utilized. The ability of the media to induce chemotaxis was determined by
monitoring the migration of fluorescently labeled peripheral mononuclear cells across a membrane barrier (and expressed as a rate of
fluorescence change over time). (F) COMMD1-deficient cells secrete greater amounts of CCL2. Levels of CCL2 in the conditioned media
(prepared similarly as in (E)) were determined by ELISA.
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In order to examine the effect of COMMD1 on nuclear RelA
levels in the absence of IkB-mediated nuclear export, we
examined the kinetics of TNF-induced nuclear accumulation
of RelA after blocking new protein synthesis with cyclohex-
imide (CHX). The presence of this inhibitor largely abrogated
IkB-a resynthesis (Figure 3C compared to B). Under these
conditions, nuclear accumulation of RelA following TNF
treatment was more sustained and, importantly, remained
significantly elevated in COMMD1-deficient cells compared to
the control cells (Figure 3C). Altogether, these data indicate
that COMMD1-mediated ubiquitination of RelA affects
its stability in the nuclear compartment, consistent with
the observation that COMMD1 decreases RelA–chromatin
interactions.
COMMD1 associates with an endogenous ubiquitin
ligase
Although COMMD1 can accelerate the ubiquitination of RelA,
it remained to be determined whether this was a direct effect
on ubiquitination, or an indirect effect that subsequently
facilitates the ubiquitination of RelA. Given that COMMD
proteins do not possess any known catalytic activity, we
examined first whether COMMD1 could interact with an
endogenous ubiquitin ligase. To that end, COMMD1 immuno-
precipitates were offered as a potential source for E3 ubiqui-
tin ligase activity to an in vitro ubiquitination reaction
containing recombinant ubiquitin and the E1 and E2
enzymes. At the end of the reaction, the presence of E3
ubiquitin ligase activity was determined by the formation of
Figure 3 COMMD1 deficiency alters the nuclear accumulation of RelA. (A) COMMD1 deficiency results in greater accumulation of nuclear
RelA after TNF treatment. U2OS COMMD1-deficient and control cell lines were stimulated with a 10 min pulse of TNF. At the indicated time
point, cells were harvested and nuclear extracts were prepared for Western blot analysis of RelA in the nuclear fraction (and GCN5 as a loading
control). Densitometry analysis is also presented. (B) Greater nuclear accumulation of RelA is not due to alterations in IkB-a degradation or
resynthesis. U2OS cells were treated in an identical manner as in the experiment performed in (A) and IkB-a degradation was evaluated by
immunoblotting and densitometry. (C) COMMD1 deficiency promotes greater nuclear accumulation of RelA independent of IkB-a levels.
Similar to (A), U2OS cells were stimulated with a 10 min pulse of TNF, and medium containing CHX (30 mM) was then added. Nuclear extracts
were prepared at the indicated time intervals and immunoblotted for RelA. In addition, IkB-a levels were evaluated utilizing the cytosolic
fractions (bottom panel). Representative data and densitometry analysis are presented.
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polyubiquitin chains. As can be appreciated in Figure 4A,
COMMD1 immunoprecipitates catalyzed the formation of
polyubiquitinated material in the presence of ATP. This effect
was far stronger than the contaminating activity that co-
precipitated with the preimmune serum and indicated that
endogenous COMMD1 interacts with a protein complex
possessing E3 ubiquitin ligase activity.
COMMD1 interacts with the ECSSOCS1 complex,
a Cullin-containing ubiquitin ligase
Previous work identified that SOCS1 can induce the ubiqui-
tination and degradation of RelA (Ryo et al, 2003). SOCS1 is
a member of a large family of proteins containing the con-
served carboxy-terminal SOCS box domain. These factors can
form, through their SOCS box, part of multimeric ubiquitin
ligases that contain a Cullin protein. These complexes are
referred to as ECS and contain Elongins B and C, Cullin 2 or 5,
and a SOCS box containing protein (Figure 4B) and are
similar in structure to the better known Cul1-containing
SCF complexes (Willems et al, 2004). An ECS complex
containing SOCS1 (designated as ECSSOCS1) is involved in
the ubiquitination of various targets, including JAK2, IRS1,
and IRS2 (Rui et al, 2002; Ungureanu et al, 2002).
We have previously reported that COMMD1 interacts
with Cul1, a member of the Cullin family that is highly
homologous to Cul2 (Ganesh et al, 2003). Given the finding
that COMMD1 immune complexes contain E3 ubiquitin
ligase activity and that ECSSOCS1 has been implicated in the
Figure 4 COMMD1 interacts with the Cullin-containing ECSSOCS1 complex. (A) COMMD1 immunoprecipitates possess endogenous E3
ubiquitin ligase activity. An in vitro ubiquitination reaction containing recombinant E1, E2, and ubiquitin was supplemented with
immunoprecipitates prepared with COMMD1 antibody or preimmune serum control. The presence of E3 activity was determined by the
formation of polyubiquitin chains, as detected by immunoblotting. (B) Schematic representation of the ECSSOCS1 complex. SOCS1 is the
substrate binding subunit of the complex. An Elongin B and C complex serves as an adaptor linking SOCS1 to Cul2, which in turn interacts with
the RING finger protein Rbx1. (C) Interaction between endogenous COMMD1 and SOCS1. NIH-SR cells were lysed with Triton X-100 buffer and
COMMD1 antibodies or a control preimmune serum was used for immunoprecipitation. The recovered material was immunoblotted for SOCS1.
(D) COMMD1 interacts with several components of ECSSOCS1. HEK 293 cells were transfected with plasmids expressing Elongin C, Cul2, SOCS1,
or COMMD1 in fusion with GST, along with COMMD1-Flag in each case. TNF stimulation consisted of 30 min. After lysis with RIPA buffer, ECS
components (or COMMD1-GST) were precipitated with GSH beads and the recovered material was immunoblotted for COMMD1 (Flag).
(E) COMMD1–Cul2 interactions are inducible upon TNF stimulation. Similar to the experiment shown in (D), cells were transfected to express
GST-Cul2 and COMMD1-Flag. Cells were stimulated with TNF for 10 min and then placed in fresh media. The cells were lysed in RIPA buffer at
the indicated time points and Cul2 was precipitated using GSH beads. The recovered material was immunoblotted for COMMD1 (Flag).
(F) Endogenous COMMD1 and Cul2 interactions. After TNF stimulation, either as a 10 min pulse or a sustained exposure, endogenous
COMMD1 was immunoprecipitated at the indicated time points or the recovered material was immunoblotted for endogenous Cul2.
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ubiquitination of RelA, we investigated the possibility that
COMMD1 could interact with this complex. Immuno-
precipitation of endogenous COMMD1 resulted in the
co-precipitation of endogenous SOCS1, consistent with an
interaction between these two proteins (Figure 4C). Next,
various components of the ECSSOCS1 complex were expressed
in Human embryonic kidney (HEK) 293 cells, precipitated
from cell lysates, and the recovered material was immuno-
blotted for COMMD1. As shown in Figure 4D, Elongin C,
Cul2, and SOCS1 (but not the control GST protein)
co-precipitated with COMMD1. In addition, the interactions
of COMMD1 with Elongin C and Cul2 (but not SOCS1) were
enhanced by TNF stimulation. Interestingly, the ability of
COMMD1 to interact with itself, an event mediated by the
conserved COMM domain (Burstein et al, 2005), was also
enhanced by TNF stimulation (Figure 4D). In reciprocal
experiments, precipitation of COMMD1 resulted in the
recovery of components of the ECS complex (including
Elongin C, Cul2, SOCS1, and Rbx1) and these interactions
were mediated by the COMM domain of COMMD1
(Supplementary Figure S4).
Given the TNF-inducible nature of COMMD1–Cul2 bind-
ing, we investigated next the temporal profile of this inter-
action. Cells expressing Cul2 were stimulated with a pulse
of TNF and lysates were prepared at different time points
following stimulation. Cul2 was immunoprecipitated and the
recovered material was immunoblotted for COMMD1. As
before, TNF treatment induced greater recovery of
COMMD1 over time, with the peak of the effect taking
place 2 h after stimulation (Figure 4E). Similar experiments
were performed by immunoprecipitating endogenous
COMMD1 and detecting the co-precipitation of endogenous
Cul2 after TNF stimulation (Figure 4F). As before, TNF
augmented the interaction between COMMD1 and Cul2,
and this effect peaked at 2 h, irrespective of whether the
stimulation was provided as a pulse or sustained exposure to
TNF. Altogether, these data demonstrated a physical inter-
action between COMMD1 and the ECSSOCS1 complex, which
is inducible upon activation of the NF-kB pathway, and
suggested the possibility that this might be responsible for
COMMD1-directed RelA ubiquitination.
COMMD1-directed ubiquitination is mediated through
ECSSOCS1
Given the interaction of COMMD1 with the ECSSOCS1 com-
plex, previously implicated in RelA ubiquitination, we inves-
tigated if COMMD1 could be operating through this ligase.
To that end, we examined the ability of COMMD1 to induce
RelA ubiquitination after RNAi-mediated suppression of
either Cul2 or SOCS1. COMMD1 expression induced the
accumulation of ubiquitinated RelA in control cells, whereas
this event was prevented in cells deficient in either Cul2
or SOCS1 (Figure 5A). This experiment was consistent with
the notion that expression of the endogenous ECSSOCS1 com-
plex is required for the effects of COMMD1. Next, we
examined the effects of ECSSOCS1 expression on the rates of
RelA ubiquitination. Expression of Cul2 and SOCS1 increased
the recovery of ubiquitinated RelA and this effect was
enhanced by concurrent expression of COMMD1, particularly
in Cul2-expressing cells (Figure 5B), and to a lesser extent
after proteasomal blockade in SOCS1-expressing cells (data
not shown).
The effect that the expression levels of ECSSOCS1 had on the
recovery of ubiquitinated RelA from cells supported the
notion that COMMD1-directed ubiquitination is mediated
through the ECSSOCS1 complex. Therefore, we set out to test
this possibility in an in vitro ubiquitination system. COMMD1
immunoprecipitates were provided as an E3 ubiquitin ligase
to a reaction containing recombinant ubiquitin, the E1 and E2
enzymes, and purified GST-RelA as ubiquitination substrate
for the reaction. We prepared COMMD1 immunoprecipitates
from cells transfected with Cul1, Cul2, Cul5, or the corre-
sponding expression vector as a control. Despite the ability of
COMMD1 to interact with all three Cullins (data not shown),
only COMMD1 immune complexes recovered from cells
expressing Cul2 were capable of catalyzing detectable poly-
ubiquitination of GST-RelA in vitro (Figure 5C). In a similar
approach, COMMD1-containing complexes were recovered
from cells coexpressing several ECSSOCS1 subunits (Elongin
C, Cul2, SOCS1, and Rbx1) or transfected with the corre-
sponding expression vector as a control. Again, the immuno-
precipitation of COMMD1 from ECSSOCS1-expressing cells was
able to recover an activity that ubiquitinates RelA in vitro
(Figure 5D).
COMMD1 and ECSSOCS1 cooperate to inhibit RelA by
promoting its degradation
Our data thus far indicated that the interaction of COMMD1
with the ECSSOCS1 complex is required for COMMD1-
mediated ubiquitination of RelA in cells and in vitro.
Therefore, we reasoned that these factors should have a
synergistic negative impact on NF-kB-mediated transcription.
We examined this possibility by determining the effects
of COMMD1 and ECSSOCS1 components on RelA-mediated
ICAM1 expression (Figure 5E). Cells were transfected with
RelA and, as expected, this induced strong expression of the
endogenous ICAM1 gene (Figure 5E, lane 3). Under the
conditions of this experiment, expression of COMMD1,
Elongin C, or Cul2 by themselves did not have a substantial
inhibitory effect on RelA-mediated transcription of ICAM1
(Figure 5E, lanes 4, 5, and 7). However, when combined with
COMMD1, both Elongin C and Cul2 had significant inhibitory
activity (Figure 5E, lanes 6 and 8). Similarly, SOCS1-mediated
inhibition of ICAM1 expression was further enhanced by
COMMD1 (Figure 5E, lanes 9 and 10).
The inhibition of ICAM1 expression correlated directly
with the ability of COMMD1 and ECSSOCS1 components to
induce reductions in RelA protein levels (Figure 5E, second
and third panels). The decreases in protein levels observed
were not due to changes in mRNA levels of RelA, and did not
occur with a deletion mutant of SOCS1 that cannot interact
with the catalytic components of the ubiquitin ligase (data
not shown), consistent with a post-transcriptional effect that
requires the activity of the ubiquitin ligase. Altogether, the
synergistic effects of COMMD1 and ECSSOCS1 on transcription
and RelA degradation indicate that these factors cooperatively
repress NF-kB.
COMMD1 serves as an adaptor between SOCS1
and Cul2
Next, we sought to understand the role of COMMD1 in the
activity of the ECSSOCS1 ubiquitin ligase. We began by exam-
ining to which component(s) of the complex COMMD1 binds
to directly. To this end, we tested the ability of COMMD1 to
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bind to deletion mutants of Cul2 and SOCS1 that cannot
interact with the rest of the ECSSOCS1 complex (schematic
representation of domains involved is shown in Figure 6E).
As expected, an amino-terminal deletion of Cul2 (Cul2 DN)
could not bind to Elongin C; however, COMMD1 binding to
this mutant was unaffected (Figure 6A, lanes 2 and 3). This
suggested that the carboxy-terminal end of Cul2 is involved
in COMMD1 binding and indeed, a carboxy-terminal deletion
of Cul2 (Cul2 DC) abrogated binding to COMMD1 (Figure 6A,
lane 4). Similar studies performed with SOCS1 indicated that
a deletion of its carboxy-terminal SOCS box (SOCS1 DSB) did
not affect COMMD1 binding although as expected it pre-
vented binding to Elongin C (Figure 6A, lanes 5 and 6). In
fact, the SH2 domain of SOCS1 was necessary and sufficient
for COMMD1 binding (Figure 6A, lanes 7 and 8), even though
this region alone is incapable of binding to the ECS complex.
Altogether, these studies indicated that COMMD1 can bind
independently with two components of the ECSSOCS1, namely
Cul2 and SOCS1, resembling the binding characteristics of the
adaptor Elongin B/C complex (Figures 4B and 6E).
COMMD1 facilitates the binding of SOCS1 to RelA
SOCS1 is the component of the ECSSOCS1 complex that binds
to its substrates, including RelA (Ryo et al, 2003).
Interestingly, COMMD1 associates with both SOCS1 and
RelA, and accelerates the ubiquitination of RelA, prompting
Figure 5 The ECSSOCS1 complex is required for COMMD1-mediated ubiquitination of RelA. (A) COMMD1-mediated ubiquitination of RelA
depends on the endogenous ECSSOCS1 complex. HEK 293 cells were transfected with His6-Ubi and RelA as before (Figure 1C), as well as siRNA
against Cul2, SOCS1, or a control target. Two days later, mRNA expression levels of Cul2 and SOCS1 were determined by qRT–PCR. In addition,
cell lysates were prepared with an 8 M urea buffer and ubiquitinated proteins were precipitated with Ni-NTA beads. The recovered material was
immunoblotted for RelA (HA) and ubiquitin. (B) COMMD1 and ECS components have additive effects on RelA ubiquitination. As before, cells
were transfected with His6-Ubi and RelA, along with SOCS1, Cul2, and COMMD1, as indicated. Lysates prepared with an 8 M urea buffer were
utilized for ubiquitin precipitation; the recovered material was immunoblotted for RelA and ubiquitin. (C, D) In vitro ubiquitination of RelA by
COMMD1 immunoprecipitates. An in vitro ubiquitination reaction containing recombinant E1, E2, ubiquitin, and GST-RelA as substrates was
provided with immunoprecipitates prepared with COMMD1 antibody or preimmune serum as a source for E3 activity. In (C), the
immunoprecipitates were prepared from cells expressing Cul1, Cul2, Cul5, or a vector control. In (D), the immunoprecipitates were prepared
from cells expressing ECSSOCS1 subunits (Elongin C, Cul2, SOCS1, and Rbx1) or a vector control. (E) COMMD1 and ECSSOCS1 cooperatively
inhibit RelA-mediated ICAM1 expression and promote RelA degradation. HEK 293 cells were transfected with RelA, along with Elongin C
(EloC), Cul2, SOCS1, or COMMD1 as indicated. Two days later, ICAM1 mRNA abundance was determined by qRT–PCR and expressed as fold
over the vector control sample. In addition, RelA (HA) and b-actin protein levels were concurrently determined by Western blot.
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us to investigate if COMMD1 facilitates SOCS1–RelA binding.
To this end, we examined the ability of SOCS1 to co-pre-
cipitate with RelA under increasing expression of COMMD1.
As shown in Figure 6B, precipitation of RelA resulted in
co-precipitation of SOCS1, which was enhanced by increased
expression of COMMD1 in a dose-dependent manner.
The ability of COMMD1 to interact with both SOCS1
and RelA and the cooperative effect of COMMD1 on the
Figure 6 COMMD1 interacts with both Cul2 and SOCS1 and facilitates SOCS1–RelA binding. (A) COMMD1 interacts independently with both
SOCS1 and Cul2. Full-length and specific deletion mutants of Cul2 and SOCS1 were expressed in fusion with GST, along with COMMD1-Flag.
Cul2 and SOCS1 were precipitated from cell lysates (RIPA buffer) and the recovered material was immunoblotted as indicated. (B) COMMD1
facilitates SOCS1–RelA interactions. HEK 293 cells were transfected with GST-RelA, SOCS1, and increasing amounts of COMMD1 as indicated.
Two days after transfection, the cells were lysed in RIPA buffer. RelA was precipitated from the lysate and the recovered material was
immunoblotted for SOCS1 (Flag). (C) SOCS1 binds to the amino-terminus of the RHD of RelA. Cells were transfected as in (B), this time
utilizing GST-RelA full-length and deletion constructs encompassing the amino acids indicated in the figure. Two days after transfection, cell
lysates were prepared with RIPA buffer and RelA was precipitated. The recovered material was immunoblotted for SOCS1 (HA) or RelA (GST).
(D) RelA binds to the entire amino-terminus of SOCS1. HEK 293 cells were transfected to express GST-SOCS1 or the deletion mutants indicated,
as well as RelA 1–180. Two days after transfection, the cells were lysed in RIPA buffer. SOCS1 was precipitated from the lysate and the recovered
material was immunoblotted for RelA 1–180 (HA) or SOCS1 (GST). (E) Schematic representation of COMMD1 interactions with the ECSSOCS1
complex. COMMD1 interacts independently with both SOCS1, at the level of its SH2 domain, and Cul2, at the level of its conserved carboxy-
terminus. The interaction between COMMD1 and Cul2 is inducible upon TNF stimulation, and COMMD1 in turn facilitates the binding of RelA
to SOCS1.
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SOCS1–RelA interaction suggested the possibility of a stabi-
lizing protein–protein interaction. Interestingly, SOCS1
co-precipitated with the first 180 amino acids of RelA
(Figure 6C), the same amino-terminal motif of the RHD that
is also involved in COMMD1 binding (Burstein et al, 2005).
Similar to the ability of COMMD1 to enhance SOCS1 binding
to full-length RelA, expression of COMMD1 also augmented
the binding of SOCS1 to this region of RelA (Supplementary
Figure S5).
This raised the possibility that SOCS1 binding to RelA
might be indirect and mediated through COMMD1.
However, unlike SOCS1 binding to COMMD1 that only
required the SH2 domain (Figure 6A), the entire amino-
terminal end of SOCS1 was required for SOCS1–RelA inter-
actions (Figure 6D). These data indicate that COMMD1 does
not mediate but rather enhances binding of SOCS1 with
RelA, altogether suggesting that COMMD1 stabilizes the
SOCS1–RelA interaction by cooperatively binding to the
same amino-terminal motif in RelA (Figure 6E).
Discussion
In this study, we examined the potential mechanism respon-
sible for COMMD1-mediated repression of NF-kB and its
ability to accelerate the dissociation of RelA from chromatin
(Burstein et al, 2005). Interestingly, others had reported that
ubiquitination of RelA also accelerates its release from chro-
matin (Saccani et al, 2004), suggesting that ubiquitination
of RelA might be responsible for the effects of COMMD1.
Indeed, we present evidence that COMMD1 promotes the
ubiquitination of NF-kB subunits and our data also indicate
that this effect is mediated by the interaction of COMMD1
with ECSSOCS1, a Cullin-containing ubiquitin ligase complex
previously implicated in RelA ubiquitination (Ryo et al,
2003). These events are physiologically important because
COMMD1 deficiency results in de-repression of several
endogenous NF-kB-responsive genes and enhanced kB-
mediated cellular responses such as the production of
chemokines. Finally, our studies indicated that the role of
COMMD1 in this process is to induce greater binding of the
substrate, RelA, to the SOCS1 subunit, ultimately promoting
its ubiquitination.
SOCS1 has been previously implicated in the control of
RelA levels and the data presented here indicate that SOCS1
functions in concert with the ECS complex. More importantly,
we present data indicating that the ability of COMMD1 to
ubiquitinate RelA is mediated through ECSSOCS1. COMMD1
interacts with components of the ECS complex, as shown at
the level of endogenous SOCS1 and Cul2 (Figure 4C and F)
and overexpressed ECS components (Figures 4D, E, and 6A
and Supplementary Figure S4). Similarly, COMMD1-mediated
ubiquitination of RelA in cells is hampered by ECS deficiency
(Figure 5A) and accentuated by overexpression of ECS com-
ponents (Figure 5B). Finally, COMMD1 immune complexes
contain ubiquitin ligase activity and can mediate the ubiqui-
tination of RelA in vitro when recovered from cells expressing
Cul2 and not other Cullins, or from cells expressing ECS
components (Figure 5C and D).
SOCS1 expression is under the control of the JAK/STAT
pathway, which stimulates transcription of the SOCS1 gene
(Naka et al, 1997) and promotes the stability of the SOCS1
protein through Pim-mediated phosphorylation (Chen et al,
2002). These effects predict that STATactivation should result
in negative crosstalk with the NF-kB pathway. In this regard,
NF-kB activation results in the expression of various inducers
of the STAT pathway (such as IL-6) that can upregulate
SOCS1 expression (Zhang et al, 1994), possibly providing
an autocrine negative feedback loop. This mechanism could
be important during inflammatory responses in vivo, when
multiple cytokines are coordinately activated. In addition, our
studies demonstrate that the SOCS1–COMMD1 interaction is
mediated by the SH2 domain of SOCS1 (Figure 5A), a region
that preferentially interacts with tyrosine phosphorylated
targets (Ungureanu et al, 2002). This suggests the possibility
that activation of tyrosine kinase(s) that might target
COMMD1 could enhance this interaction and provide addi-
tional crosstalk regulation of the NF-kB pathway.
Our previously reported data suggest that COMMD1-
mediated inhibition of NF-kB occurs in the nucleus, a
compartment where the protein can be readily identified
(Burstein et al, 2005). Although it is largely accepted that
the cytoplasmic pool of SOCS1 is responsible for its ability to
regulate JAK2 kinase activity (Endo et al, 1997), the presence
of a nuclear pool of SOCS1 is also well documented (Vuong
et al, 2004). Indeed, our analysis indicates that the main
components of the ECSSOCS1 complex, including SOCS1,
Elongin C, Cul2, and Rbx1, can be found in nuclear extracts
(Supplementary Figure S6).
Another important observation in our studies is that there
is dissociation between the duration of transcriptional
responses and nuclear RelA accumulation. The mRNA levels
for all kB-responsive genes evaluated here continued to
accumulate at time points when nuclear levels of RelA were
back to baseline (after 45 min; see Figures 2D and 3A). This
suggests that after RelA has been effectively exported into the
cytosol, other mechanisms are likely involved in the late
termination of transcription. In fact, the inducible COMMD1–
Cul2 interaction peaks at 2 h (Figure 4E and F), a time point
when nuclear export of RelA has been completed, suggesting
that the physiologic role of NF-kB ubiquitination is in late
transcriptional termination.
We have previously reported that COMMD1 binds to Cul1
(Ganesh et al, 2003), and more detailed examination indi-
cates that COMMD1 can bind to additional Cullins (GN Maine
and E Burstein, unpublished observations). This suggests the
possibility that COMMD1 might be a component of various
ubiquitin ligases targeting proteins other than NF-kB subunits
and might ultimately explain functions of COMMD1, such as
its role in copper metabolism, that appear unrelated to its
effects on NF-kB (van de Sluis et al, 2002; Burstein et al,
2004).
Altogether, this study demonstrates that COMMD1, acting
via a Cullin-containing ubiquitin ligase, represses kB-
mediated transcription through ubiquitination of NF-kB
subunits. COMMD1-mediated regulation of NF-kB through
ECSSOCS1 is part of a larger paradigm of transcriptional
regulation. Indeed, various Cullin-containing complexes
have been shown to play critical roles in the regulation of
other transcription factors such as c-Myc (von der Lehr et al,
2003) and HIF1a (Pause et al, 1997). Our data uncover that in
addition to the well-known events that control IkB protein
stability, regulation of the stability of the NF-kB subunits by
this COMMD1-containing ubiquitin ligase is a critical event
in the termination of kB-mediated transcription.
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Materials and methods
Plasmids and small interfering RNA
Expression vectors for RelB and p52 were generated by PCR
amplification of the corresponding coding sequences from plasmid
templates kindly provided by Dr Ranjeny Thomas and Dr Colin
Duckett, respectively. Expression vectors for Elongin C, Cul2,
SOCS1, and Rbx1 were generated by PCR amplification using as
templates the following IMAGE cDNA clones: 3923736, 4104375,
5179306/5093311, and 3138751, respectively. Deletion constructs for
Cul2 and SOCS1 were similarly generated with the amino-acid
boundaries of the encoded mutant proteins being Cul2 DN¼ 109–745,
Cul2 DC¼ 1–415, SOCS1 DSB¼ 1–157, SOCS1 DSB-SH2¼1–78,
SOCS1 SH2¼ 78–174. Information about the sequences of small
interfering RNA (siRNA) oligonucleotides utilized (chlorampheni-
col acetyl transferase, COMMD1, SOCS1, and Cul2, obtained from
Invitrogen) are available upon request. For stable RNAi utilizing
lentiviral delivery we introduced a cassette containing the histone 1
promoter and a short hairpin RNA into the FG12 plasmid (kindly
provided by Dr David Baltimore). All other plasmids used have
been described previously (Burstein et al, 2004, 2005).
Cell culture, transfection, and lentiviral production
HEK 293 cells, HEK 293T cells, U2OS cells, and NIH-SR cells were
obtained from ATCC. HEK 293, HEK 293T, and U2OS cells were
cultured in DMEM supplemented with 10% FBS and L-glutamine
(2 mM). NIH-SR cells were cultured in RPMI supplemented with
10% FBS, L-glutamine (2 mM), sodium pyruvate (1 mM), and
glucose (4.5 g/l). A standard calcium phosphate transfection
protocol was used to transfect plasmids and siRNA into HEK 293
cells (Burstein et al, 2004). TNF treatments (1000 U/ml; Roche)
were for variable amounts of time, as indicated in each experiment.
Production of lentiviruses for stable delivery of short hairpin RNA
constructs was performed as previously described utilizing plas-
mids kindly provided by Dr David Baltimore (Lois et al, 2002).
Quantitative RT–PCR
RNA extraction and RT–PCR methods were performed as previously
described (Burstein et al, 2005). Oligonucleotides and probes for
RELA, ICAM1, BIRC3, CXCL1, CCL2, TNF, and IL8 transcripts were
obtained from Applied Biosystems.
Immunoblotting and immunoprecipitation
The compositions of Triton lysis buffer and RIPA buffer have been
previously described (Burstein et al, 2005). In some experiments, an
8 M urea buffer (8 M urea, 50 mM Tris, pH 8.0, 300 mM NaCl, 50 mM
NaPO4, 0.5% NP-40) was used. All buffers were supplemented with
1 mM sodium orthovanadate and protease inhibitors (Roche).
Preparation of cytosolic and nuclear extracts, immunoprecipita-
tions, GSH precipitations, Ni-NTA precipitations, and immunoblot-
ting were performed as described previously (Burstein et al, 2004,
2005). The following antibodies were used: COMMD1 (Burstein
et al, 2005; Abnova), Flag (Sigma), HA (Sigma), ubiquitin
(Stressgen), RelA (Santa Cruz Biotechnology), RelB (Santa Cruz
Biotechnology), p52 (Upstate Biotechnology), Cul2 (Zymed, Up-
state Biotechnology, and Abnova), Elongin C (BioLegend), SOCS1
(Zymed, Abcam, Santa Cruz Biotechnology), Rbx1 (LabVision),
IkB-a (Upstate Biotechnology), GST (Santa Cruz), b-actin (Sigma),
a-tubulin (Molecular Probes), and GCN5 (Santa Cruz).
Metabolic labeling
One day prior, 8105 cells were seeded in a 10cm dish. They were
placed in a cysteine- and methionine-deficient medium (with 10%
dialyzed FBS) for 30 min, and 500mCi of 35S-labeled methionine and
cysteine (GE Healthcare) was added per plate for 1 h. The media
were then replaced with regular growth media supplemented with
excess non-radiolabeled methionine (2 mM) and cysteine (2 mM).
Denatured lysates were prepared by applying 50 mM Tris, 1% SDS,
5 mM DTT, and boiling the samples for 10 min at 951C. The buffer
was then supplemented with Triton X-100 lysis buffer to decrease
the SDS concentration to 0.2%. Samples were pre-cleared with
protein G Sepharose beads for 1 h at 41C and the supernatant
obtained after centrifugation was subjected to RelA immunopreci-
pitation (Santa Cruz Biotechnology, sc-372). The recovered material
at the end of immunoprecipitation was resolved by SDS–PAGE and
RelA was detected by autoradiography.
In vitro chemotaxis assay and chemokine measurement
Conditioned media before and after 12-h TNF stimulation were
used. Peripheral mononuclear cells were freshly isolated after
dextran sedimentation and Ficoll gradient centrifugation, as
previously described (Diamond et al, 1991). The cells were then
fluorescently labeled with Calcein-AM (Sigma) and chemotactic
migration across a membrane and toward conditioned media was
determined utilizing a 96-well FluoroBlock plate pre-coated with
fibronectin, according to the manufacturer’s instructions (BD
Biosciences). The plate was placed at 371C on a fluorometer (ABI
Cytofluor 4000) and cell migration was monitored every 15 min for
a total of 2 h. CCL2 levels in conditioned media were determined by
ELISA according to the manufacturer’s instructions (R&D systems).
In vitro ubiquitination reaction
Each reaction mixture consisted of recombinant ubiquitin (2.5mg/
reaction), E1 (Uba1, 50 ng/reaction), E2 (UbcH5a, 100 ng/reaction),
and ATP regenerating buffer (Boston Biochem), resuspended in
reaction buffer (40 mM HEPES pH 7.9, 60 mM potassium acetate,
2 mM DTT, 5 mM MgCl2, 10% glycerol). The material obtained from
immunoprecipitation of COMMD1 (or control) was added as a
source for E3 ubiquitin ligase activity. Recombinant GST-RelA was
used as the substrate in these reactions and was prepared by
expression in 293 cells and affinity purification using standard
protocols.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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Figure S1: Underexpression of other COMMDs decreases the ubiquitination of RelA.  HEK 
293 cells were transfected with HA-RelA and His6-Ubi, along with siRNA directed against 
COMMD6, 9, 10 or a control.  Ubiquitinated material was precipitated from cell lysates prepared 
with 8M urea buffer using Ni-NTA agarose beads.  The recovered material was immunoblotted 
for RelA (HA) and ubiquitin.  The level of COMMD expression was determined by qRT-PCR 
and is indicated as % relative to the control (bottom).   
 
Figure S2: COMMD1 deficiency does not potentiate transcription of all κB-responsive 
genes.  COMMD1-deficient and control cell lines were stimulated with TNF for 10 minutes, 
rinsed in PBS and placed in normal growth media.  Following the beginning of the TNF 
stimulation pulse, mRNA was harvested at the indicated time points and used for quantitative 
RT-PCR of the IL8 and TNF genes. 
 
Figure S3: COMMD1 deficiency results in a modest up-regulation of NFKBIA gene 
expression.  This experiment was performed as described in Figure S2, but in this case mRNA 
was harvested for qRT-PCR of the NFKBIA gene. 
 
Figure S4: COMMD1 association with ECSSOCS1 is mediated by the conserved carboxy-
terminal COMM domain.  HEK 293 cells were co-transfected with vectors encoding an 
ECSSOCS1 subunit (SOCS1, Cul2, Elongin C or Rbx1), and COMMD1 in fusion with GST (either 
full-length or a truncated form as indicated,).  Two days after transfection, the cells were lysed in 
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RIPA buffer and COMMD1 precipitated using GSH beads.  The recovered material was 
immunoblotted for SOCS1, Cul2, Elongin C, or Rbx1 (Flag).   
 
Figure S5: COMMD1 stabilizes the SOCS1-RelA interaction.  HEK 293 cells were 
transfected with GST-SOCS1, RelA 1-180 (the binding domain within RelA), and increasing 
amounts of COMMD1 as indicated.  Two days after transfection, the cells were lysed in RIPA 
buffer and SOCS1 precipitated using GSH beads.  The recovered material was immunoblotted 
for RelA 1-180 (HA) and the input material was immunoblotted for RelA 1-180, COMMD1 and 
SOCS1.     
 
Figure S6: ECSSOCS1 can be found in the nucleus.  NIH-SR cells were utilized to prepare 
whole cell lysates (WCL) in RIPA buffer, or cytosolic (C) and nuclear (N) extracts.  Equal 
amount of protein was loaded into each lane and western blot analysis was performed for the 
presence of SOCS1, Elongin C, Cul2, Rbx1 or COMMD1.  GCN5 and α-Tubulin were utilized 








COMMD1 (Copper Metabolism MURR1 Domain-
Containing Protein 1) regulates Cullin RING 
ligases by preventing CAND1 (Cullin-





















Mao X, Gluck N, Chen B, Starokadomskyy P, Li H, Maine GN,  
Burstein E. 
Journal of Biological Chemistry, 286: 32355-32365, 
September 16, 2011 
 
Reprinted with permission 
 
COMMD1 (Copper MetabolismMURR1 Domain-containing
Protein 1) Regulates Cullin RING Ligases by Preventing
CAND1 (Cullin-associated Nedd8-dissociated Protein 1)
Binding*□S
Received for publication, June 30, 2011 Published, JBC Papers in Press, July 21, 2011, DOI 10.1074/jbc.M111.278408
XichengMao‡1, Nathan Gluck§¶1, Baozhi Chen‡, Petro Starokadomskyy‡, Haiying Li‡, Gabriel N. Maine‡,
and Ezra Burstein‡§**2
From the Departments of ‡Internal Medicine and **Molecular Biology, University of Texas SouthwesternMedical Center, Dallas,
Texas 75390, the §Department of Internal Medicine, University of MichiganMedical School, Ann Arbor, Michigan 48109, the
¶Department of Biochemistry, School of Medicine, Hebrew University, 91120 Jerusalem, Israel, and the Department of Clinical
Pathology, William Beaumont Hospital, Royal Oak, Michigan 48073
Cullin RING ligases (CRLs), the most prolific class of ubiqui-
tin ligase enzymes, are multimeric complexes that regulate a
wide range of cellular processes. CRL activity is regulated by
CAND1 (Cullin-associated Nedd8-dissociated protein 1), an
inhibitor that promotes the dissociation of substrate receptor
components from the CRL. We demonstrate here that
COMMD1 (copper metabolismMURR1 domain-containing 1),
a factor previously found to promote ubiquitination of various
substrates, regulates CRL activation by antagonizing CAND1
binding. We show that COMMD1 interacts with multiple Cull-
ins, that the COMMD1-Cul2 complex cannot bindCAND1, and
that, conversely, COMMD1 can actively displace CAND1 from
CRLs. These findings highlight a novel mechanism of CRL acti-
vation and suggest that CRL regulation may underlie the pleio-
tropic activities of COMMD1.
Ubiquitin, a highly conserved 76-amino acid polypeptide,
can be conjugated to substrate proteins through an enzymatic
machinery present in all eukaryotic cells (1). Ubiquitination can
lead to a variety of outcomes, but a particularly notable event is
the degradation of the target protein by the proteasome. Ubiq-
uitination of the target protein involves a multistep enzymatic
process that requires a ubiquitin ligase, also referred to as an E3
enzyme (2). It is estimated that there are500–1,000 ubiquitin
ligases (3–5), and among them, a particularly prolific group are
the Cullin RING ligases (CRLs)3 (6). The core CRL complex
contains a Cullin protein (such as Cul1, 2, 3, 4A, 4B, or 5 in
mammals), and a RING box protein (Rbx1 or Rbx2). In addi-
tion, a variety of substrate binding subunits specific to each
Cullin contributes to a large repertoire of complexes, estimated
at300 distinct ligases (7–9). These complexes are designated
by the Cullin and the specific substrate subunit that they con-
tain. For example, the well known ligase complex that targets
IB-, which contains Cul1 and the substrate receptor protein
TrCP, is designated as CRL1-TrCP.
Structurally, the carboxyl-terminal globular domain of the
Cullin protein binds to Rbx1 or Rbx2, whereas the amino-ter-
minal region is a rigid stalk formed by three unique five–helix
bundle structures called Cullin repeats 1, 2, and 3 (10). The
amino-terminal Cullin repeat 1 is responsible for recruiting the
substrate receptor complex (SRC). Displacement of this com-
plex is a major mechanism of inhibition of these ligases and is
mediated by CAND1 (Cullin-associated Nedd8-dissociated), a
large protein that interacts with all three Cullin repeats and the
carboxyl-terminal domain (11–13). Formation of the CRL-
CAND1 complex is in turn regulated by the ubiquitin-like pro-
tein Nedd8, which upon conjugation to the carboxyl-terminal
domain prevents CAND1 binding to the Cullin protein (11, 12).
On the other hand, the assembled Cul1-CAND1 complex can-
not be effectively neddylated because of steric occlusion of the
lysine acceptor site by CAND1. Therefore, the mechanism of
dissociation of the Cul1-CAND1 complex remains poorly
understood, and the existence of cellular factors that control
CRL-CAND1 interactions has been proposed (13).
COMMD (copper metabolism MURR1 domain-containing)
proteins are pleiotropic factors present in a wide range of
eukaryotic organisms (14) and are defined by the presence of
the carboxyl-terminal COMM domain (15, 16). The best stud-
ied of these factors is COMMD1, which participates in copper
metabolism (17), NF-B-mediated transcription (18), adapta-
tion to hypoxia (19), and electrolyte transport (20, 21). A large
deletion in the canineCOMMD1 gene, which abolishes protein
expression, leads to pathologic copper accumulation, cirrhosis,
and liver failure in Bedlington terriers (17). Although humans
with pathologic copper accumulation caused by COMMD1
mutations have not been identified (22, 23), a role for this gene
in modulating the phenotype ofWilson’s disease has been pro-
posed (24). Moreover, COMMD1 has been found to have cop-
per binding activity in vitro (25) and can modulate the matura-
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tion of the copper-containing enzyme SOD1 (26). In addition,
COMMD1 has been found to play a role in tumor invasion
acting as a regulator of both hypoxia-inducible factor (HIF) and
NF-B (27). Decreased expression of COMMD1 in cancer was
found to promote tumor invasion in a variety of settings and
was associated with a negative impact on patient survival.
Although the mechanisms underlying these pleiotropic
activities of COMMD1 remain unclear, this protein has been
shown to be an activating co-factor for a Cul2-containing ligase
that ubiquitinates NF-B/RelA (15, 16). However, a broader
paradigm that explains the pleiotropic activities of COMMD
proteins has not been defined. Here, we report that these fac-
tors bind to multiple CRLs and that the prototype member,
COMMD1, can activate ligase function through displacement
of the CRL inhibitor CAND1.
EXPERIMENTAL PROCEDURES
Plasmids—Expression vectors for Cullin proteins, CAND1,
and Skp1 (all of human origin) were generated by PCR amplifi-
cation of the corresponding coding sequence, which was then
introduced into the pEBB-FLAG and pEBG vectors. For Cul1,
Pallino-FLAG-Cul1 was used as template (kindly provided by
Dr.Michele Pagano). The following IMAGE cDNAclones were
obtained from Open Biosystems and used as templates for
Cul3, Cul4A, Cul4B, Cul5, Cul7, CAND1, and Skp1: 5784147,
3537176, 5269392, 30331132, 5580027, 5265409, and 6672613,
respectively. COMMD-EYFP constructs were generated by
subcloning EYFP into pEBB-FLAG expression vectors previ-
ously described (15). The plasmid pEBB-COMMD1 (M110A/
H134A)-GST was generated by site-directed mutagenesis.
Deletion constructs for Cul2 were generated by PCR using
pEBB-FLAG-Cul2 as template (16), with the amino acid bound-
aries of the encoded mutant proteins being: Cul2 1–415, 109–
415, 109–745, 415–745, 1–150 (R1), 151–270 (R2), 271–386
(R3), and 151–386 (R2-R3). His6-tagged versions of COMMD1
andSkp1were subcloned from the corresponding pEBBvectors
into pET30a using the BamHI andNotI sites. All other plasmids
have been previously described (15, 16, 28, 29).
Cell Culture andTransfection—HEK293 cells andHeLa cells
were obtained from ATCC. U2OS cells with stable shRNA-
mediated repression of COMMD1 have been previously
reported (16). HEK 293 cells stably expressing GST or GST-
Cul2were generated by lentiviral infection and selection as pre-
viously described (16). All of the cell lines were cultured in
DMEM supplemented with 10% FBS and L-glutamine (2 mM).
Biotin (Sigma; 4 M) was added to the medium when fusion
proteinswith the biotinylation target peptidewere expressed. A
standard calcium phosphate transfection protocol was used to
transfect HEK 293 cells (29). HeLa cells were transfected using
FuGENE (Roche Applied Science) according to the manufac-
turer’s instructions.
Confocal and Fluorescence Microscopy—HeLa cells were
plated in chambered coverglass plates and transfected with the
indicated COMMD-EYFP plasmids (0.5 g/well). The cells
were stainedwithHoechst 33342 (8M) for 30min, and images
were obtained with a Zeiss LSM 510 META confocal micro-
scope equipped with a Chameleon XR NIR laser.
Immunoblotting and Protein Precipitation—Cell lysate prep-
aration, immunoprecipitations, GSH precipitations, and
immunoblotting were performed as previously described (15,
28). For the COMMD1-Cul1 interaction, the cells were soni-
cated in detergent-free buffer E (25 mM HEPES, 100 mM NaCl,
1 mM EDTA, 5% glycerol). Interactions with Cul2 and Cul3
were studied using buffer F (PBS, 0.8% Nonidet P-40). Other
lysis buffer conditions are indicated in the figure legends where
appropriate. The precipitation of RelA after denatured lysis of
nuclei, which was used to detect ubiquitinated RelA (see Fig. 6),
has been previously described (30). The following antibodies
were utilized in our studies: CAND1 (Novus,H00055832-MO1;
Santa Cruz, sc-10672), COMMD1 (15), Cul1 (Santa Cruz,
sc-12761), Cul2 (Zymed Laboratories Inc., 51-1800), Cul3
(kindly provided by Dr. Matthias Peter) (31), Elongin C (Bio-
Legend, 613101), FLAG (Sigma, A8592 and F1804), GST (Santa
Cruz, sc-459), HA (Sigma, H6533; Covance, MMS101R), RelA
(Santa Cruz, sc-372), and Rbx1 (LabVision, 127-075-160).
Recombinant Protein Preparation—HA-tagged Skp1 and
COMMD1 proteins were expressed in HEK 293 cells and puri-
fied from cell lysates. After incubation with an anti-HA affinity
matrix (Roche Applied Science), the purified material was
extensively washed four times with RIPA lysis buffer and then
eluted in dissociation buffer (40 mM HEPES, pH 7.9, 60 mM
potassium acetate, 10% glycerol) containing HA peptide as a
competitor (1 mg/ml). Elution was performed three times at
37 °C with agitation. The combined eluate was used for further
experiments. His6-tagged COMMD1 or Skp1 were expressed
and purified from Escherichia coli (BL21 strain, Stratagene)
using the nickel-nitrilotriacetic acid purification system (Invit-
rogen). The final imidazole eluate was loaded onto an Amicon
centrifuge filter (Millipore) to eliminate imidazole, and the
purified proteinwas redissolved in PBS bufferwith 10%glycerol
through sequential filtration and buffer exchange.
Bimolecular Affinity Purification of the Cul2-COMMD1
Complex—HEK 293 cells were transfected with GST or GST-
tagged Cul2 and COMMD1 fused to TB (a biotinylation target
peptide), grown in biotin-supplemented media, and lysed in
Triton buffer 2 days later. The Cul2-COMMD1 complex was
purified through sequential affinity purification using glutathi-
one and streptavidin columns as previously described (29).
In Vitro Ubiquitination Assays—Each reaction mixture con-
sisted of recombinant HA-human ubiquitin (2.5 g), human
His6-E1 (Uba1, 50 ng), various human E2 enzymes as indicated
(UbcH5a, 5b, 5c, 7, and 10, 100 ng; UbcH3, 150 ng), and anATP
regenerating buffer (all obtained from Boston Biochem). These
were mixed in reaction buffer (40 mM HEPES, pH 7.9, 60 mM
potassium acetate, 2 mM DTT, 5 mM MgCl2, 10% glycerol) and
agitated at 30 °C for 60min (16). Polyubiquitin chain formation
was detected by Western blotting with an anti-HA antibody as
described above.
In Vitro Displacement of CAND1—The CAND1 dissociation
reaction was based on the prior report by Zheng et al. (12). For
displacement of endogenous CAND1 (see Fig. 4B), HEK 293
cells were transfectedwithGST-Cul1 orGST-Cul2 and lysed in
a hypotonic buffer (20 mM HEPES, pH 7.2, 5 mM KCl, 1.5 mM
MgCl2, 0.5 mMDTT) using a Dounce apparatus. The lysate was
cleared by centrifugation at 27,000 g (4 °C for 30 min). In the
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case of displacement of overexpressed FLAG-CAND1 (see Fig.
4, C and D), the cells were similarly transfected but lysed in a
Triton X-100-containing buffer (25 mM HEPES, pH 7.9, 100
mM NaCl, 10% glycerol, 1% Triton X-100). All of the buffers
were supplemented with protease inhibitors (Roche Applied
Science) and DTT (10mM). Cul1 or Cul2 complexes were puri-
fied by GSH-Sepharose (GE Healthcare). The GSH beads were
aliquoted and incubated at 30 °C for 30 min with ATP in disso-
ciation buffer (40mMHEPES, pH 7.9, 60mMpotassium acetate,
10% glycerol), with the indicated recombinant proteins (Skp1
or COMMD1). Thereafter, the beads were washed twice with
Triton X-100 lysis buffer (25 mM HEPES, 100 mM NaCl, 1 mM
EDTA, 10% glycerol, 1% Triton X-100). The leftover material
was utilized for Western blot analysis.
RESULTS
COMMD1 Associates with CRL Complexes—Given the
diverse activities of COMMD1 (32), we initially explored the
possibility that this factor might play a broader role in the reg-
ulation of ubiquitination of various targets by CRLs. To this
end, we examined in more detail the interaction between
COMMD1 and other Cullin proteins. We found that endoge-
nous COMMD1 could be co-precipitated with endogenous
Cul1, Cul2, or Cul3 (Fig. 1A). The Cul1-COMMD1 interaction
was best visualized in a detergent-free buffer, whereas the Cul2
and Cul3 interactions were best seen with a glycerol-free buffer
containing low amounts of Nonidet P-40 (see “Experimental
Procedures”). These interactions were also evident using a
buffer containing 1% Triton X-100 (supplemental Fig. S1). Uti-
lizing expression vectors for all five canonical Cullins (Cul1, 2,
3, 4A, 4B, and 5), we could easily recapitulate the interaction
betweenCOMMD1 and all of the Cullin familymembers tested
(Fig. 1B).
Other COMMD Proteins Also Interact with CRLs—Other
COMMD proteins have largely undefined functions at this point.
Using a similar approach, it was found that other COMMDsmay
also interact with CRLs (Fig. 1C). Interestingly, their patterns of
Cullin preference were not identical.
Several COMMDs are known to display differential tissue
expression (15), yet several of them are ubiquitous and form
heterodimers. To try to understand the potential redundancy in
this system, we examined the cellular distribution of COMMD
proteins expressed with a fused EYFP tag (Fig. 1D). Although
some similarities were found for several family members, cer-
tain COMMD proteins displayed specific and unique cellular
distribution. For example, in the case of COMMD2, the pro-
tein was consistently excluded from the nucleus, whereas
COMMD7 demonstrated a unique punctuate pattern.
COMMD1 Associates with Active CRLs in a Copper-inde-
pendent Manner—Consistent with the interaction between
COMMD1 and CRLs, we found that COMMD1 could precipi-
tate ubiquitin ligase activity when extracted from mammalian
cells. COMMD1was expressed and affinity-purified fromHEK
293 cells or E. coli, and the recovered proteins were offered to
an in vitro reaction containing the E1 and E2 (UbcH5a)
enzymes, recombinant ubiquitin, and an ATP regenerating
buffer. Polyubiquitin chain formation in the presence of ATP
was readily detectable when COMMD1 precipitated from
mammalian cells was provided as a source of ubiquitin ligase
activity (Fig. 2A, left panels). However, if COMMD1 was pre-
cipitated and washed in RIPA buffer, this activity was lost, con-
sistent with the fact that COMMD1-CRL interactions are abol-
ished in this buffer (data not shown). On the other hand,
recombinant COMMD1prepared in E. coliwas devoid of ligase
activity, but when the proteinwas incubatedwith amammalian
lysate and then washed, ligase activity was reconstituted (Fig.
2A, right panels). These results suggested that COMMD1 inter-
acts with cellular factors that provide ligase activity.
Next, we observed that the COMM domain of COMMD1,
which is responsible for binding toCul2 (16), was also necessary
and sufficient for recovering ligase activity (Fig. 2B, COMM
Domain or CD lane). Given the conservation of the COMM
domain across all COMMD proteins and our finding of
COMMD-CRL interactions, we speculated that other family
members may be similarly linked to active ubiquitin ligases.
Indeed, when precipitated from mammalian cells, several
COMMDproteins provided a source of ubiquitin ligase activity
in vitro (Fig. 2C). The ligase activity varied as a function of the
E2 offered to each COMMD protein (supplemental Fig. S2),
consistent with their differential binding to Cullin family
members.
Next, we examined whether CRL interactions were respon-
sible for COMMD1-associated ligase activity. To test this pos-
sibility, COMMD1 and Rbx1 (the main RING finger subunit in
CRLs) were co-expressed in HEK 293 cells, and Rbx1 was
immunoprecipitated prior to assessing the E3 activity associ-
ated to COMMD1. Depletion of Rbx1 led to a significant drop
inCOMMD1-associated ubiquitin ligase activity (Fig. 2D), con-
sistent with the notion that ligase activity associated with
COMMD1 is due to its interaction with CRLs.
Finally, a copper binding activity for COMMD1 has been
found in vitro, and residues that coordinate copper have been
similarly mapped (25). We examined whether copper could
modulate COMMD1-CRL interactions. A double mutation in
COMMD1 (M110A/H134A) targeting copper-binding resi-
dues did not affect Cul2 binding or COMMD1-associated E3
activity (Fig. 2E). Similarly, the addition of copper to the growth
medium did not affect these interactions (data not shown),
indicating that CRL binding is copper-independent.
The Cul2-COMMD1 Complex Excludes the CRL Inhibitor
CAND1—Altogether, the data indicated that COMMD1 asso-
ciates with CRLs, a property that seems to be shared by other
COMMDproteins. Nevertheless, the specific function for such
interactions was not immediately apparent. To address the lat-
ter question, we utilized a bi-molecular tandem affinity purifi-
cation scheme (29) to isolate a purified Cul2-COMMD1 com-
plex frommammalian cells (Fig. 3A). Cul2 was purified using a
glutathione-Sepharose column (fraction A); after elution, this
material was offered to a streptavidin-agarose column for puri-
fication of the COMMD1 subfraction (fraction B). As expected,
COMMD1 and Cul2 were readily demonstrated in fraction B
(Fig. 3B), and based on the amounts recovered, this complex
was estimated to represent 2–5% of all cellular Cul2. In addi-
tion, fractions A and B provided ubiquitin ligase activity in vitro
(not shown here), and known components of the active ligase,
such as Elongin C, were also present in both fractions (Fig. 3C).
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Interestingly, the CRL inhibitor CAND1 was readily identified
in fraction A but was absent in Cul2-COMMD1 complexes
(Fig. 3C).
Next, we sought to ascertain whether the lack of CAND1 in
the Cul2-COMMD1 complex was truly due to the purification
of a distinct cellular fraction of Cul2 rather than an artifact of
the purification scheme itself. To address this question, Cul2
was first purified, eluted, and subsequently offered to a second
column for precipitation of either COMMD1 or CAND1.
Although COMMD1 and CAND1 were readily co-precipitated
with Cul2 in the initial fraction, the second purification step of
either COMMD1 or CAND1 resulted in the depletion of the
other protein (Fig. 3D), consistent with the existence of mutu-
ally exclusive pools of COMMD1 and CAND1 when bound
with Cul2 in cells.
COMMD1 Promotes CRL E3 Activity—Given the exclusion
of CAND1 from Cul2-COMMD1 complexes, we reasoned that
COMMD1 might bind to or promote a more active CRL state.
FIGURE 1. COMMD1 and other COMMD proteins associate with CRL complexes. A, endogenous co-immunoprecipitation (IP) of COMMD1 and CRLs.
COMMD1 was immunoprecipitated from HEK 293 cell lysates. The precipitated material was probed for the indicated Cullins. PIS, preimmune serum.
B, COMMD1binds tootherCullin familymembers. COMMD1wasexpressed inHEK293cells togetherwithCullinproteins fused toGST,whichwereprecipitated
as above and immunoblotted for COMMD1. PD, pulldown. C, COMMD proteins interact with Cullins. In each experiment, one FLAG-tagged Cullin was
expressed together with COMMDproteins fused to GST, whichwere subsequently precipitated. The presence of the Cullin in the precipitates was determined
by immunoblottingwith the FLAGantibody.D, cellular distribution of COMMDproteins. The indicatedCOMMDproteins fused to EYFPwere expressed inHeLa
cells. The cells were counterstained with Hoechst and imaged in a confocal microscope. The scale bar corresponds to 10 m.
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To test this notion, Cul2 was co-expressed with COMMD1 and
subsequently precipitated from cell lysates directly or through
COMMD1. The CRL inhibitor CAND1 was included as a neg-
ative control. At the end of the precipitation and after adjusting
for equivalentCul2 recovery, we utilized the isolated complexes
as a source for E3 ligase activity in an in vitro ligase reaction.
These experiments demonstrated that Cul2 associated with
COMMD1 was the most active isolate, whereas the CAND1
fraction was relatively devoid of enzymatic activity (Fig. 3E).
The preferential binding of COMMD1 to a CAND1-free
pool of Cul2 could be responsible for these findings; alterna-
tively, COMMD1 could promote an active conformation for
the complex. Therefore, we explored further whether
COMMD1 could potentiate CRL E3 activity in vitro. GST-Cul1
that was immunoprecipitated frommammalian cells and its E3
activity was examined in vitro as before. In these assays, its
substrate receptor adaptor Skp1 or COMMD1 were added to
the in vitro reaction. As can be seen in Fig. 3F, the addition of
COMMD1 or Skp1 led to enhanced Cul1 E3 activity. This was
not due to additive E3 activity precipitated by COMMD1 or
Skp1, because there was no associated E3 activity bound to
COMMD1 or Skp1 when these preparations were made with
RIPA buffer (Fig. 3F, right half of the gel). Altogether, this indi-
cated that COMMD1 binds to active CRL complexes and can
lead to their activation in vitro. However, cellular deficiency of
COMMD1 did not substantially affect endogenous CRL2 activ-
ity (supplemental Fig. S3), potentially because of redundant
effects by other COMMDs expressed in these cells.
COMMD1 Promotes the Dissociation of CAND1 from CRL
Complexes—Akin to the distinct fractionation between
CAND1 and substrate receptor complexes (11–13), our data
indicated that CAND1 and COMMD1 do not coexist in the
same CRL complexes. To test this notion further, we examined
whether the purified Cul2-COMMD1 complex was capable of
binding CAND1 in vitro. To that end, after purification of frac-
tion B, unbound complexes were offered again to a glutathione-
FIGURE2.COMMD1associateswithactiveCRL complexes ina copper-independentmanner.A, COMMD1precipitates cellular factorswithubiquitin ligase
activity. In vitro ubiquitination reactions were supplemented with precipitated proteins as indicated. Polyubiquitin chain formation was determined by
Western blotting as an indication of ubiquitin ligase activity. COMMD1-GST or GST were expressed in HEK 293 cells (left panels) or prepared recombinantly in
E. coli (right panels). Recombinant proteins either were offered directly (none) or were first mixed with a mammalian lysate and washed prior to the reaction
(lysate). PD, pulldown. B, COMMD1 precipitates ubiquitin ligase activity through the COMM domain. COMMD1 full-length (FL), its amino terminus (NT), or the
COMMdomain (CD) fused to GSTwere precipitated from transfected HEK 293 cells and added to an in vitro ubiquitination reaction as in A. C, COMMDproteins
precipitate ubiquitin ligase activity. COMMD proteins fused to GST were precipitated and added to an in vitro ubiquitination reaction as in A. D, depletion of
Rbx1 reducesCOMMD1-associated ligase activity. COMMD1-GSTwasutilizedas a sourceof ubiquitin ligase activity asbefore. Theproteinwasexpressed inHEK
293 cells and either precipitated directly () or following immunodepletion of FLAG-Rbx1 (). IP, immunoprecipitation. E, copper binding by COMMD1 is not
involved in E3 and Cul2 binding. WT COMMD1 or anM110A/H134Amutant (MUT) unable to bind copper were expressed in HEK 293 cells. After precipitation,
the protein complexes were examined for associated E3 activity as before (upper panel) and for the presence of co-precipitated endogenous Cul2 (middle
panel). Ubi, ubiquitination.
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FIGURE 3. The Cul2-COMMD1 complex excludes the CRL inhibitor CAND1. A, purification strategy used to isolate the Cul2-COMMD1 complex. Cul2 fused
to GST (G) and COMMD1 fused to a biotinylation tag (B) were expressed in HEK 293 cells. Cul2 was purified through a GSH-Sepharose column (fraction A) and
subsequently eluted. COMMD1 was precipitated from the eluted material using streptavidin (SA)-agarose beads (fraction B). Cul2 remaining in the flow-
throughafter the streptavidin-agarose columnwas reprecipitatedwithaGSHcolumn (Re-PD:Cul2 (GSH)) resulting in fractionC.PD, pulldown.B, Cul2-COMMD1
complex purification. Proteins from fractions A and Bwere separated by SDS-PAGE and stainedwith SYPRO Ruby; the identity ofmajor bandswas determined
by paired Western blot analysis (nonspecific bands indicated by open arrowheads). C, the Cul2-COMMD1 complex excludes CAND1. Fractions A and B were
immunoblotted for Cul2, COMMD1, Elongin C, and CAND1. Endogenous Cul2 and GST-Cul2 are noted by arrowheads to the left of the top panel. D, COMMD1
and CAND1 exist in separate Cul2 cellular pools. GST-Cul2, COMMD1 fused to a biotinylation tag, and FLAG-CAND1 were co-expressed in HEK 293 cells. Cul2
was purified through a GSH affinity column (PD: Cul2) and subsequently eluted. COMMD1 or CAND1were then precipitated from the eluate using SA agarose
beads or FLAG antibody, respectively. The resulting fractions were immunoblotted for Cul2, CAND1, or COMMD1. E, Cul2 complexes containing COMMD1 are
active. GST-Cul2 was precipitated from transfected HEK 293 cells utilizing GSH beads (Cul2) or using protein G beads as a control (Control). FLAG-COMMD1 or
FLAG-CAND1 co-expressed with GST-Cul2 were precipitated utilizing the FLAG antibody. After adjusting for equal Cul2 recovery, the resulting material was
added to an in vitroubiquitination reaction as in Fig. 2A and immunoblotted for ubiquitin. F, purified COMMD1potentiates Cul1 E3 activity in vitro. GST-tagged
Cul1 was expressed in HEK 293 cells and purified using GSH affinity matrix. Purified HA-Skp1 or HA-COMMD1 prepared from mammalian lysates was then
added to the recovered Cul1 complex, and this preparation was used as a source for E3 activity as before.
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Sepharose column to isolate Cul2 devoid of COMMD1 (frac-
tion C; Fig. 3C). All of these preparations were mixed with a
fresh lysate containing expressed CAND1, and binding in vitro
was assessed by co-precipitation. This experiment indicated
that total Cul2 complexes or Cul2 complexes devoid of
COMMD1 (fractions A and C) bound CAND1 well, but the
Cul2-COMMD1 complex (fraction B) could not bind CAND1
efficiently (Fig. 4A). This was the case despite similar loading of
Cul2 among these fractions and the additional purification
steps required to isolate fraction C, strongly suggesting that
these resultswere independent of the purification scheme itself.
Next we examined whether COMMD1 could facilitate the
dissociation of CAND1 from CRLs. To test this notion, GST-
taggedCul1 orCul2was precipitated from transfectedHEK293
cells resulting in the co-precipitation of endogenous CAND1.
Next, the precipitatedCul1 orCul2 complexesweremixedwith
purified COMMD1or their respective substrate receptor adap-
tors, Skp1 or Elongin C, respectively. After incubation at 30 °C
and thorough washing, the presence of CAND1 still associated
to either Cul1 or Cul2 was assessed by immunoblotting. As has
been reported before, substrate receptor adaptors were able to
promote the dissociation of CAND1 (12, 33), particularly when
the reaction was supplemented with ATP (Fig. 4B). Impor-
tantly, the same was true of COMMD1, which promoted
CAND1 dissociation from either Cul1 or Cul2 (Fig. 4B). Inter-
estingly, this displacement reaction was abrogated when
COMMD1 had been heat-inactivated (Fig. 4C). In addition,
recombinant COMMD1 made in E. coli was devoid of activity
compared with a mammalian preparation (Fig. 4D). This is in
contrast with Skp1, which, as previously described (12), was
active irrespective of it being prepared from E. coli lysates (data
not shown).
COMMD1 Binds to CRLs in a Manner Distinct from Sub-
strate Receptors—Structural information indicates that Skp1
and CAND1 bind to an overlapping region of Cullin repeat 1
(R1) in Cul1 (13). CAND1 also binds to the carboxyl-terminal
domain of Cul1 over its neddylation site and makes extensive
contacts with R2 and R3 (13, 34) (Fig. 5F). This information
explains why CAND1 does not bind to neddylated Cullins and
why CAND1 and SRC binding are mutually exclusive.
Next, we tried to ascertain whether competitive binding for a
shared domain on Cul2 may be involved in the ability of
COMMD1 to displace CAND1. First, it was noted that neither
the amino terminus nor the carboxyl terminus of Cul2 were
required for COMMD1 binding (Fig. 5A). Instead, amino acids
109–415 were found to be sufficient tomediate the COMMD1
interaction. Utilizing an alignment between Cul2 and Cul1 and
the published crystal structure of Cul1 as a framework (10), we
predicted the boundaries of Cul2 R1, R2, and R3 (Fig. 5F).
COMMD1was found to bind preferentially to R2 and not to R1
(Fig. 5B).
Based on this finding, we predicted that COMMD1-CRL
binding occurs independently of the SRC. To test this notion,
we introduced a previously reported point mutation in R1 of
Cul1 (10), which disrupted Skp1 binding (Fig. 5D). Interest-
ingly, the T47Amutant lost the ability to interact with Skp1 but
bound to CAND1 (Fig. 5C), consistent with the incomplete
overlap between CAND1 and Skp1 binding surfaces (10, 13).
Importantly, this Cul1 mutant retained its ability to interact
with COMMD1 (Fig. 5D), indicating that this interaction is
independent of the SRC.
Consistent with the competitive nature of the COMMD1-
CAND1 interactions with CRLs, we observed that
siRNA-mediated reduction of CAND1 expression increased
the Cul2-COMMD1 endogenous binding (Fig. 5E). On the
other hand, depletion of COMMD1 by siRNA had little effect
on the CAND1-Cul1 interaction (data not shown), which may
be explained by the potential redundancy of the nine other
COMMD family members.
FIGURE 4. COMMD1 promotes the dissociation of CAND1 from CRL com-
plexes. A, COMMD1 prevents CAND1 binding to Cul2. Fractions A, B, and C
were prepared as depicted in Fig. 3A, mixed for 2 h with a fresh HEK 293 cell
lysate expressing FLAG-CAND1, washed, and immunoblotted for CAND1,
Cul2, or COMMD1. B, COMMD1 can displace CAND1 from Cul1 or Cul2 com-
plexes. GST-Cul1 or GST-Cul2 were expressed in HEK 293 cells and purified
through a GSH affinity matrix. This material was then mixed with HA-Skp1 or
HA-COMMD1 purified from mammalian cells. After incubation at 30 °C with
ATP (15 mM), the GSH beads were washed, and the presence of endogenous
CAND1 still bound to Cul1 or Cul2 was determined by immunoblotting. PD,
pulldown.C, the activity of COMMD1 is heat-labile. GST-Cul1 complexeswere
purified as before from cells also co-expressing FLAG-CAND1. After a dis-
placement reaction (performedaspreviously but using7.5mMATP), thepres-
ence of remaining FLAG-CAND1 bound to Cul1 was determined by immuno-
blotting. HI-COMMD1, heat inactivated COMMD1 (95 °C for 10 min).
D, recombinant COMMD1 made in E. coli is devoid of activity. Shown is the
same reaction as in C, but utilizing mammalian HA-COMMD1 or bacterially
madeHis6-COMMD1.Only theATP containing reactions are shown; each sub-
panel was run in the same gel.
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COMMD1 Is Required for the Ubiquitination of Specific Tar-
gets in Vivo—We next set out to address the role of COMMD1
on the ubiquitination of endogenous proteins in vivo. We
examined this question in the context of the NF-B signaling
pathway. As reported previously, we found that COMMD1 is
required for NF-B/RelA ubiquitination (16, 35, 36). Cells with
decreased levels of COMMD1 (Fig. 6A) demonstrated a pro-
found decrease in the ubiquitination of endogenous RelA (Fig.
6B). In addition, the pro-inflammatory cytokine TNF stimu-
lated the binding of COMMD1 to Cul2 (Fig. 6C), consistent
with its role in promoting NF-B/RelA ubiquitination and deg-
radation as amechanism to terminate signaling (16, 35, 36). Inter-
estingly, TNF stimulation had only modest effects on total CRL2
activity (Fig. 6D), suggesting that the TNF induction of
COMMD1/Cul2bindingmore likely activates specificCRL2com-
plexes, such as those targeting RelA and possibly other targets.
DISCUSSION
Altogether, our studies indicate that COMMD1 can modu-
late CRL activity through its ability to displace CAND1. This
FIGURE 5. COMMD1 binds to CRLs in a manner distinct from substrate receptors. A, full-length and specific deletion mutants of Cul2 fused to GST were
expressed in HEK 293 cells and precipitated from cell lysates with glutathione-Sepharose (GSH) beads. The recovered material was immunoblotted for
endogenousCOMMD1, Rbx1, and ElonginC. PD, pulldown. B, COMMD1binds toCullin repeat 2 in Cul2. COMMD1was expressed inHEK 293 cells togetherwith
Cul2deletionmutants fused toGST (R1, R2, or R3, Cullin repeats 1, 2, or 3, respectively),whichwereprecipitated as inA and immunoblotted for COMMD1.C and
D, Cul1 can bind to COMMD1 independently of Skp1. Cul1 WT or a T47A point mutant fused to GST were expressed in HEK 293 cells. Their interactions with
HA-Skp1 or FLAG-CAND1 were tested by co-precipitation (C). The same Cul1 proteins were expressed together with HA-COMMD1 and Cul1-COMMD1
interactionswereexaminedbyco-precipitation (D).E, CAND1deficiencypromotesCOMMD1-Cul2binding.HEK293cellswere transfectedwith siRNAduplexes
targeting CAND1. Endogenous COMMD1 was immunoprecipitated (IP), and its interaction with endogenous Cul2 was evaluated as in Fig. 1A. F, model
depicting the various domains in canonical Cullin proteins, their known interacting partners, and the competitive binding by COMMD1 andCAND1 for R2. The
amino acid boundaries for R1, R2, and R3 in Cul2 are also depicted. N8, NEDD8.
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finding provides a mechanism for the ability of COMMD1 to
promote protein ubiquitination and degradation (16, 36, 37).
The data also suggest that COMMD1 activates specific CRL
complexes involved in the turnover of specific products, such as
RelA. This activation seems to be regulated by the inducible
interaction between COMMD1 and certain CRL complexes
under specific conditions, as in the case of induced COMMD1-
Cul2 interactions after TNF treatment.
In the present model of CRL regulation, CAND1 exerts its
inhibitory function on all Cullins, potentially regulating 300
different ligase complexes by preventing the full assembly of the
active ligase (9). This broad activity would have a myriad of
effects on cellular physiology, and therefore factors that control
CAND1-CRL regulation in a more restricted fashion would
make physiologic sense. Indeed, others have proposed the
existence of such regulation based on the unexplained variable
affinity of CAND1 for different Cullins in different tissues (8).
Based on the data presented, our view is that the COMMD
protein family, with its variable pattern of tissue and cellular
expression and the unique Cullin binding preferences of each
COMMD family member, could provide fine tuning of CRL
activation by countering CAND1 binding.
Given the myriad of activities regulated by the 300 CRL
complexes existent inmammals, it is anticipated that COMMD
proteins would likely affect many physiological processes.
Indeed, consistent with this notion, COMMD1 has been impli-
cated in a variety of seemingly unrelated processes such as
NF-B regulation, sodium and electrolyte transport, hypoxia
responses, and copper excretion. In most instances, the mech-
anism has been linked to protein ubiquitination, in agreement
with the notion that COMMD1 and other COMMD proteins
regulate CRL ubiquitin ligase complexes. Our view is that the
biochemical events dissected in this study provide a mechanis-
tic explanation for the various biological activities identified for
COMMD1.
Similar to what has been reported for substrate receptor
complexes (11, 12, 33), COMMD1 binding to CRLs displaces
CAND1, leading to an enzymatically active complex. Based on
the structure of Cul1, we speculate that this is mediated by
competitive binding for the highly conserved R2 region (Fig.
FIGURE 6. COMMD1 is required for the ubiquitination of specific targets in vivo. A, Western blot demonstrating stable shRNA-mediated repression of
COMMD1 in U2OS cells. B, RelA ubiquitination is greatly impaired in COMMD1-deficient cells. U2OS cells were treated with the proteasome inhibitor MG-132
as indicated, and cell nuclei were isolated and then lysed in a denaturing buffer. RelA was immunoprecipitated from nuclear extracts and immunoblotted for
ubiquitin (top panel) or for RelA itself (middle and bottom panels). The asterisk indicates the high molecular weight smear consistent with ubiquitinated RelA.
C, TNF stimulates COMMD1-Cul2 binding. HEK 293 cellswere treatedwith TNF (1,000 units/ml) for the indicated time intervals, and endogenous COMMD1was
subsequently precipitated from cell lysates as in Fig. 1A. The recovery of endogenous Cul2 was determined by immunoblotting. D, cells stably expressing
GST-Cul2 (see supplemental Fig. S3 for details) were treatedwith TNF (1,000 units/ml) for the indicated time points. Thereafter, GST-Cul2 was immunoprecipi-
tated with a GST antibody. The recovered material was utilized as a source for E3 activity as previously. WB, Western blot; IP, immunoprecipitation; PIS,
preimmune serum; Ubi, ubiquitination.
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5F), which interacts extensively with CAND1 (13). The com-
petitive nature of COMMD1/CAND1 binding to CRLs is
extensively demonstrated using various in vitro systems, and
the relevance of these findings is validated by the increased
binding of COMMD1 to Cul2 in CAND1-deficient cells.
It is important to note that the biochemical events that lead
to CRL-CAND1 dissociation remain quite enigmatic. In the
case of both COMMD1 and the SRC components Skp1 or
Elongin C, the reaction requires ATP supplementation, yet the
basis for this ATP requirement is not evident, because none of
these factors have ATPase or kinase activity. In addition, a
CRL1-CAND1 complex formed by E. coli-expressed recombi-
nant proteins cannot be dissociated by Skp1 or neddylation
co-factors (13), and this reaction only takes place when the
CRL-CAND1 complex is isolated from mammalian cells (12,
33). For all of these reasons, we speculate that additional factors
present in the mammalian preparations are required for
CAND1 dissociation, and these factors may explain the
requirement for ATP in the reaction. Similarly, we found that
COMMD1was active in this reaction onlywhen extracted from
mammalian cells, suggesting either that post-translational
modifications of COMMD1 are necessary or that co-factor(s)
associated with COMMD1 inmammalian cells are required for
this process.
Recent data indicate that the recycling of CRLs between the
CAND1-bound and SRC-bound states facilitates the loading of
rare SRCs that would otherwise be outcompeted bymore abun-
dant co-factors (38). Although the SRC can dissociate the
CRL1-CAND1 complex in vitro, various in vivo experiments
indicate that other factors regulate this interaction. Disrupting
Cul1-SRC complex formation in vivo has limited effects on
CRL1-CAND1 interactions (39). Similarly, inhibiting CRL ned-
dylation in cells did not promote CRL1-CAND1 interactions,
nor did it destabilize CRL1-SRC complexes (40). These obser-
vations support the notion that other factors regulate CRL-
CAND1 interactions in vivo, which is in keeping with the find-
ings of this study.
At the present time, it remains unclear whether COMMD1
acts to synergize the SRC recycling or whether it constitutes a
parallel activation pathway. Until the precise mechanisms of
CAND1 displacement are further elucidated, addressing these
questions will remain problematic with our current systems.
Nevertheless, the fact thatCOMMD1binds toCullins in aman-
ner that is distinct from that used by SRCs suggests that these
two mechanisms of CAND1 displacement may be related but
are still independent from each other.
Acknowledgments—We are grateful to Michele Pagano and Peter
Kaiser for providing plasmids that were useful for these studies. We
also express our thanks to Matthias Peter for kindly providing the
Cul3 antibody utilized in our studies.
REFERENCES
1. Weissman, A. M. (2001) Nat. Rev. Mol. Cell Biol. 2, 169–178
2. Wilkinson, C. R. (2002) Trends Cell Biol. 12, 545–546
3. Joazeiro, C. A., and Weissman, A. M. (2000) Cell 102, 549–552
4. Patterson, C. (2002) Sci. STKE 2002, pe4
5. Coscoy, L., and Ganem, D. (2003) Trends Cell Biol. 13, 7–12
6. Petroski,M. D., andDeshaies, R. J. (2005)Nat. Rev.Mol. Cell. Biol. 6, 9–20
7. Willems, A. R., Schwab, M., and Tyers, M. (2004) Biochim. Biophys. Acta
1695, 133–170
8. Bosu, D. R., and Kipreos, E. T. (2008) Cell Div. 3, 7
9. Duda, D. M., Scott, D. C., Calabrese, M. F., Zimmerman, E. S., Zheng, N.,
and Schulman, B. A. (2011) Curr. Opin. Struct Biol. 21, 257–264
10. Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P.,
Chu, C., Koepp, D.M., Elledge, S. J., Pagano,M., Conaway, R. C., Conaway,
J. W., Harper, J. W., and Pavletich, N. P. (2002) Nature 416, 703–709
11. Liu, J., Furukawa, M., Matsumoto, T., and Xiong, Y. (2002) Mol. Cell 10,
1511–1518
12. Zheng, J., Yang, X., Harrell, J. M., Ryzhikov, S., Shim, E. H., Lykke-Ander-
sen, K.,Wei, N., Sun, H., Kobayashi, R., and Zhang, H. (2002)Mol. Cell 10,
1519–1526
13. Goldenberg, S. J., Cascio, T. C., Shumway, S. D., Garbutt, K. C., Liu, J.,
Xiong, Y., and Zheng, N. (2004) Cell 119, 517–528
14. Maine, G. N., and Burstein, E. (2007) Cell Cycle 6, 672–676
15. Burstein, E., Hoberg, J. E., Wilkinson, A. S., Rumble, J. M., Csomos, R. A.,
Komarck, C.M.,Maine,G.N.,Wilkinson, J. C.,Mayo,M.W., andDuckett,
C. S. (2005) J. Biol. Chem. 280, 22222–22232
16. Maine, G. N., Mao, X., Komarck, C. M., and Burstein, E. (2007) EMBO J.
26, 436–447
17. Klomp, A. E., van de Sluis, B., Klomp, L. W., and Wijmenga, C. (2003)
J. Hepatol. 39, 703–709
18. Ganesh, L., Burstein, E., Guha-Niyogi, A., Louder, M. K., Mascola, J. R.,
Klomp, L.W.,Wijmenga, C., Duckett, C. S., andNabel, G. J. (2003)Nature
426, 853–857
19. van de Sluis, B., Muller, P., Duran, K., Chen, A., Groot, A. J., Klomp, L.W.,
Liu, P. P., and Wijmenga, C. (2007)Mol. Cell. Biol. 27, 4142–4156
20. Biasio, W., Chang, T., McIntosh, C. J., and McDonald, F. J. (2004) J. Biol.
Chem. 279, 5429–5434
21. Dre´villon, L., Tanguy, G., Hinzpeter, A., Arous, N., de Becdelie`vre, A.,
Aissat, A., Tarze, A., Goossens, M., and Fanen, P. (2011) PLoS One 6,
e18334
22. Mu¨ller, T., van de Sluis, B., Zhernakova, A., van Binsbergen, E., Janecke,
A. R., Bavdekar, A., Pandit, A., Weirich-Schwaiger, H., Witt, H., Ell-
emunter, H., Deutsch, J., Denk, H., Mu¨ller,W., Sternlieb, I., Tanner, M. S.,
and Wijmenga, C. (2003) J. Hepatol 38, 164–168
23. Coronado, V.A., Bonneville, J. A., Nazer,H., Roberts, E. A., andCox,D.W.
(2005) Clin. Genet. 68, 548–551
24. Stuehler, B., Reichert, J., Stremmel, W., and Schaefer, M. (2004) J. Mol.
Med. 82, 629–634
25. Narindrasorasak, S., Kulkarni, P., Deschamps, P., She, Y.M., and Sarkar, B.
(2007) Biochemistry 46, 3116–3128
26. Vonk, W. I., Wijmenga, C., Berger, R., van de Sluis, B., and Klomp, L. W.
(2010) J. Biol. Chem. 285, 28991–29000
27. van de Sluis, B., Mao, X., Zhai, Y., Groot, A. J., Vermeulen, J. F., van der
Wall, E., van Diest, P. J., Hofker, M. H., Wijmenga, C., Klomp, L. W., Cho,
K. R., Fearon, E. R., Vooijs, M., and Burstein, E. (2010) J. Clin. Invest. 120,
2119–2130
28. Burstein, E., Ganesh, L., Dick, R. D., van De Sluis, B., Wilkinson, J. C.,
Klomp, L. W., Wijmenga, C., Brewer, G. J., Nabel, G. J., and Duckett, C. S.
(2004) EMBO J. 23, 244–254
29. Maine, G. N., Gluck, N., Zaidi, I. W., and Burstein, E. (2009) Cold Spring
Harb. Protoc. 10.1101/pdb.prot5318
30. Mao, X., Gluck, N., Li, D., Maine, G. N., Li, H., Zaidi, I. W., Repaka, A.,
Mayo, M. W., and Burstein, E. (2009) Genes Dev. 23, 849–861
31. Sumara, I., Quadroni, M., Frei, C., Olma, M. H., Sumara, G., Ricci, R., and
Peter, M. (2007) Dev. Cell 12, 887–900
32. van de Sluis, B., Groot, A. J., Wijmenga, C., Vooijs, M., and Klomp, L. W.
(2007) Cell Cycle 6, 2091–2098
33. Bornstein, G., Ganoth, D., and Hershko, A. (2006) Proc. Natl. Acad. Sci.
U.S.A. 103, 11515–11520
34. Duda, D. M., Borg, L. A., Scott, D. C., Hunt, H. W., Hammel, M., and
Schulman, B. A. (2008) Cell 134, 995–1006
COMMD1 Regulates CAND1 Binding
32364 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 37•SEPTEMBER 16, 2011












35. Li, H., Wittwer, T., Weber, A., Schneider, H., Moreno, R., Maine, G. N.,
Kracht, M., Schmitz, M. L., and Burstein, E. (2011) Oncogene, in press
36. Geng, H., Wittwer, T., Dittrich-Breiholz, O., Kracht, M., and Schmitz,
M. L. (2009) EMBO Rep. 10, 381–386
37. van de Sluis, B., Groot, A. J., Vermeulen, J., van der Wall, E., van Diest,
P. J., Wijmenga, C., Klomp, L. W., and Vooijs, M. (2009) PLoS One 4,
e7332
38. Schmidt, M. W., McQuary, P. R., Wee, S., Hofmann, K., and Wolf, D. A.
(2009)Mol. Cell 35, 586–597
39. Chua, Y. S., Boh, B. K., Ponyeam, W., and Hagen, T. (2011) PLoS One 6,
e16071
40. Lee, J. E., Sweredoski,M. J., Graham, R. L., Kolawa,N. J., Smith,G. T., Hess,
S., and Deshaies, R. J. (2011)Mol. Cell Proteomics 10, DOI 10.1074/mcp.
M110.006460
COMMD1 Regulates CAND1 Binding
SEPTEMBER 16, 2011•VOLUME 286•NUMBER 37 JOURNAL OF BIOLOGICAL CHEMISTRY 32365


















Mao & Gluck, et al.
Fig. S1: COMMD1 interacts with endogenous Cullin proteins.  
Endogenous COMMD1 was immunoprecipitated and the presence of 
endogenous Cul1, Cul2 and Cul3 was determined by immunoblotting.  
In this experiment, a buffer containing 1% Triton X-100 was utilized 
(HEPES 25mM, NaCl 100 mM, EDTA 1 mM, glycerol 20%, Triton X-100 
1%).
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Fig. S2: COMMD proteins precipitate ubiquitin ligase activity. COMMD proteins fused to GST were 
precipitated and added to an in vitro ubiquitination reaction as in Fig 2C.  In these experiments, different 
recombinant E2 enzymes were utilized as noted.
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Fig. S3: Effect of COMMD1 deficiency on CRL2 activity.  (A) HEK293 cells stably 
expressing GST or GST-Cul2 were generated by lentiviral infection and selection.  
These cells were subsequently transfected with siRNA against COMMD1, an 
irrelevant sequence (Control), or Cul2 (as an positive control).  A western blot 
against Cul2 was utilized to determine the expression of Cul2 and GST-Cul2 (upper 
panel).  Similarly, a COMMD1 western blot demonstrates the effect of siRNA. (B)  
Using these cells, GST-Cul2 was precipitated by GSH-agarose beads.  The 
recovered material was provided to an in vitro ubiquitination reaction as a source for 
E3 activity.  Polyubiquitin chain formation was determined by immunoblotting.  




















GCN5 is a required cofactor for a ubiquitin 

























Mao X, Gluck N, Maine GN, Li H, Zaidi IW, Li D, Repaka A, Mayo MW, 
Burstein E. 
Genes & Development, 23: 849-861, January 25, 2009 
 
Reprinted with permission 

GCN5 is a required cofactor for a ubiquitin
ligase that targets NF-kB/RelA
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The transcription factor NF-kB is a critical regulator of inflammatory and cell survival signals. Proteasomal
degradation of NF-kB subunits plays an important role in the termination of NF-kB activity, and at least one of the
identified ubiquitin ligases is a multimeric complex containing Copper Metabolism Murr1 Domain 1 (COMMD1)
and Cul2. We report here that GCN5, a histone acetyltransferase, associates with COMMD1 and other
components of the ligase, promotes RelA ubiquitination, and represses kB-dependent transcription. In this role,
the acetyltransferase activity of GCN5 is not required. Interestingly, GCN5 binds more avidly to RelA after
phosphorylation on Ser 468, an event that is dependent on IKK activity. Consistent with this, we find that both
GCN5 and the IkB Kinase (IKK) complex promote RelA degradation. Collectively, the data indicate that GCN5
participates in the ubiquitination process as an accessory factor for a ubiquitin ligase, where it provides a novel
link between phosphorylation and ubiquitination.
[Keywords: NF-kB; RelA; GCN5; COMMD1; ubiquitin; Cul2]
Supplemental material is available at http://www.genesdev.org.
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NF-kB is a dimeric transcription factor formed by mem-
bers of a highly conserved family of proteins that share an
;300-amino-acid region termed the Rel Homology Do-
main (RHD) (Karin and Lin 2002). The activity of NF-kB is
primarily regulated by cytoplasmic sequestration of the
NF-kB dimer through its interaction with inhibitory IkB
proteins (Baeuerle and Baltimore 1988). Activation of the
multimeric IkB Kinase (IKK) results in the phosphoryla-
tion of IkB, followed by its ubiquitination and degradation
(Henkel et al. 1993; Chen et al. 1995), allowing the
translocation of NF-kB into the nucleus. Nuclear NF-kB
dimers bind to an array of promoters, ultimately resulting
in the induction of genes involved in processes such as
immunity, apoptosis, cell cycle progression, and onco-
genesis (Silverman andManiatis 2001). Termination ofNF-
kBactivity ismediatedbyresynthesisof IkBproteins,which
facilitate nuclear export of NF-kB (Arenzana-Seisdedos
et al. 1997). More recently, additional mechanisms for
transcriptional regulation have been recognized, includ-
ing post-translational modifications of NF-kB subunits
such as phosphorylation (Zhong et al. 1998; Sakurai et al.
1999), acetylation (Chen et al. 2001; Kiernan et al. 2003),
prolyl-isomerization (Ryo et al. 2003), and ubiquitination
(Saccani et al. 2004; Maine et al. 2007; Tanaka et al.
2007).
CopperMetabolismMurr1Domain-containing (COMMD)
proteins are a group of evolutionarily conserved factors
present in a wide range of organisms (Burstein et al.
2005). COMMD1, the prototype member of the family,
binds to a conserved domain present in the RHD of all
NF-kB subunits (Ganesh et al. 2003; Burstein et al. 2005)
and inhibits NF-kB-mediated transcription, leading to
decreased proinflammatory gene expression (Maine et al.
2007) and impaired HIV-1 viral replication (Ganesh et al.
2003).We recently reported thatCOMMD1 inhibitsNF-kB
by promoting the ubiquitination and proteasomal degra-
dation of NF-kB subunits (Maine et al. 2007). COMMD1
interacts with a multimeric ubiquitin ligase that also
containsElonginsBandC,Cul2, andSOCS1 that is capable
of ubiquitinating NF-kB subunits (Ryo et al. 2003; Maine
et al. 2007). Interestingly, another report implicates IKKa-
mediated phosphorylation of RelA to the subsequent
degradation of this NF-kB subunit, although the precise
6Present address: Department of Internal Medicine, University of Texas
Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Room
J5.126, Dallas, TX 75390-9151, USA.
7Corresponding author.
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pathway of degradation has not been elucidated (Lawrence
et al. 2005). In particular, any potential links between
COMMD1-mediated ubiquitination and the phosphoryla-
tion of RelA are not known.
Here we report that GCN5, a histone acetyltransferase
(HAT), is a COMMD1-associated factor. Unlike its well-
known role as a transcriptional activator (Thomas and
Chiang 2006), we find that GCN5 functions as a repressor
of NF-kB by promoting the ubiquitination and degradation
of RelA, an activity consistent with its interaction with
the COMMD1-containing ligase. Interestingly, GCN5 binds
primarily to the C terminus of RelA, and this interaction
is enhanced by IKK-dependent phosphorylation on Ser
468. The ability of GCN5 to bind to phosphorylated RelA
and to the COMMD1 complex provides a link between
IKK-mediated phosphorylation, ubiquitination, and the
termination of kB-mediated transcription.
Results
Identification of GCN5 as a COMMD1-associated
factor
Using tandem affinity purification (TAP), we previously
identified a number of putative COMMD1-associated
factors (Burstein et al. 2005). The HAT GCN5 was tenta-
tively identified among them through aC-terminal peptide
detected by LC/MS-MS (Fig. 1A). This interactionwas first
confirmed through independent coimmunoprecipitation
experiments. Precipitation of GST-tagged COMMD1 from
cell lysates resulted in the coprecipitation of GCN5, and,
furthermore, binding toGCN5wasmapped to the COMM
domain, thehomologydomain that is present inallCOMMD
proteins (Fig.1B). Indeed, anotherCOMMdomain-containing
protein, COMMD10, was also able to interact with GCN5
(Fig. 1C). Furthermore, immunoprecipitation of endogenous
COMMD1 resulted in the coprecipitation of endogenous
GCN5, and the converse precipitation also demonstrated
thepresenceofanendogenousCOMMD1/GCN5complex in
cells (Fig. 1D).
GCN5 inhibits NF-kB-mediated transcription
Given the role of COMMD1 as an NF-kB inhibitor, we
examined whether GCN5 plays a role in the regulation
of this pathway. Transfection of 293 cells with siRNA
against GCN5 led to exaggerated induction of TNFmRNA
in response to TNF stimulation (Fig. 1E); CX3CL1 (frac-
talkine) and TNFAIP3 (A20) were similarly up-regulated
(Supplemental Fig. S1A,B). Conversely, expression of GCN5
by plasmid transfection inhibited the induction of the
TNF gene (Fig. 1F). Moreover, concurrent expression of an
siRNA-resistant mutant of GCN5 abrogated the effect of
the siRNA oligonucleotide on the expression of TNFAIP3
(Supplemental Fig. S1E). Altogether, these data supported
the conclusion that these are specific effects of the siRNA
oligonucleotide targeting GCN5. Similar experiments
were performed in U2OS cells after lentiviral delivery
of a shRNA targeting GCN5 and, once again, GCN5-
deficient cells demonstrated exaggerated expression of
NF-kB-regulated genes after TNF stimulation, such as
ICAM1 (Fig. 1G) as well as IL8 and TNF (Supplemental
Fig. S1C,D). These data indicated that endogenous GCN5
inhibits several TNF-inducible genes in more than
one cell line. To address whether the repressive effect of
GCN5 is mediated through NF-kB itself, TNF gene
expression was examined after depletion of RelA, a key
NF-kB subunit. The efficiency of the RNAi was demon-
strated by Western blotting (Supplemental Fig. S2). As
predicted, stimulated TNF expression was dampened by
RelA deficiency (Fig. 1H, open bars). Interestingly, the
exaggerated expression of TNF in GCN5-deficient cells
was lost upon concurrent deficiency in RelA (Fig. 1H,
black bars), supporting the notion that GCN5 acts on
RelA to suppress the TNF gene.
GCN5 interacts with RelA and promotes its
ubiquitination
Given the known interaction between COMMD1 and
RelA, we investigated whether GCN5 similarly interacts
with RelA. Immunoprecipitation of endogenous GCN5
resulted in the recovery of RelA from whole-cell lysate
(WCL) or nuclear extracts, and, in both instances, TNF
stimulation resulted in greater coprecipitation (Fig. 2A).
Next, we resorted to a sequential affinity purification
scheme to examine whether purified GCN5/COMMD1
complexes could interact with endogenous RelA. As
expected, GCN5 bound both COMMD1 and RelA (Fig.
2B, PD: GCN5), and importantly, the purified GCN5/
COMMD1 complex also contained endogenous RelA
(Fig. 2B, Re-PD: COMMD1).
The interaction between GCN5 and COMMD1 and
their shared ability to bind to and inhibit NF-kB suggested
that these two proteins might work through a common
mechanism. Hence, we examined if, similar to COMMD1,
GCN5 could promote RelA ubiquitination in the nu-
cleus. Nuclear extracts were prepared and endogenous
RelA was precipitated after denaturing the lysate by
adding SDS and boiling, and the recovered material was
immunoblotted for polyubiquitin. Expression of GCN5
in 293 cells resulted in greater amounts of ubiquitinated
RelA (Fig. 2C, right), while the level of ubiquitinated
RelA was decreased in U2OS cells deficient in GCN5
(Fig. 2C, left). This finding was confirmed by another
approach, where cells were transfected with His6-tagged
Ubiquitin and ubiquitinated RelA was detected after
precipitating ubiquitinated proteins with nickel agarose
beads. As shown in Supplemental Figure S3A, decreased
GCN5 expression also led to decreased recovery of ubiq-
uitinated RelA by this approach. Moreover, GCN5 de-
ficiency impaired the ability of COMMD1 to promote
RelA ubiquitination (Supplemental Fig. S3B), suggesting
that GCN5 is a required cofactor for COMMD1-mediated
ubiquitination, an effect that is congruent with its interac-
tion with COMMD1.
GCN5 controls nuclear RelA stability and its
interaction with promoter sites
Previous studies indicate that RelA ubiquitination is
necessary for the proper termination of RelA–promoter
Mao et al.
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interactions (Saccani et al. 2004). Consistent with this,
COMMD1 deficiency is associated with prolonged RelA
binding to promoter sites (Burstein et al. 2005) and leads
to blunted disappearance of RelA from the nucleus
(Maine et al. 2007). Therefore, we examined whether
GCN5 deficiency would similarly result in both of these
events. First, nuclear levels of RelA in GCN5-deficient
U2OS cells were compared with the corresponding con-
trol. IkB resynthesis and nuclear export, a negative feed-
back loop in the NF-kB pathway, was inhibited by
cycloheximide (CHX). As shown in Figure 2D, GCN5
deficiency led to greater RelA nuclear levels, particularly
at late time points after TNF stimulation. Next, we
examined RelA recruitment to the ICAM1 and IL8
promoters by chromatin immunoprecipitation (ChIP)
and found that in both instances, GCN5 deficiency led
to prolonged promoter occupancy by RelA (Fig. 2E). In
addition, these experiments demonstrated that GCN5
was inducibly recruited to these promoter sites. Alto-
gether, the data indicated that akin to COMMD1, GCN5
participates in controlling the levels of nuclear and
chromatin-associated RelA.
The HAT activity of GCN5 is dispensable for its role in
RelA degradation
RelA can be acetylated by p300 (Chen et al. 2001, 2002),
and the GCN5 homolog PCAF has also been reported
to acetylate RelA (Kiernan et al. 2003). Therefore, we
evaluated whether GCN5-promoted RelA ubiquitination
could be linked to RelA acetylation. While p300 promoted
significant accumulation of acetylated RelA, neither
GCN5 nor PCAF had an appreciable effect (Supplemental
Fig. S4). Nevertheless, the HAT activity of GCN5 could
Figure 1. GCN5 binds to COMMD1 and
inhibits NF-kB-mediated transcription. (A)
Identification of GCN5 as a COMMD1-
associated factor. Schematic representation
of GCN5 with the boundaries of its HAT
domain and Bromo domain (BD). The
C-terminal peptide of GCN5 (amino acids
817–828) identified by LC/MS-MS is shown.
The HAT activity and Bromo domain func-
tion are dependent on residues E575 and
Y814, respectively. (B) COMMD1 binds
GCN5 through its COMM domain. GCN5
was coexpressed with full-length COMMD1
(FL), its N terminus (N), or its COMM
domain (CD) fused with GST. Subse-
quently, COMMD1 was precipitated and
the recovered material was immunoblotted
for GCN5. (C) GCN5 interacts with other
COMMD proteins. HEK293 cells were
cotransfected with GCN5 and the indi-
cated COMMD proteins fused to GST,
which were subsequently precipitated from
cell lysates using GSH Sepharose beads.
The presence of coprecipitated GCN5 was
determined by immunoblotting. (D) Co-
precipitation of endogenous GCN5 and
COMMD1. Cell extracts were subjected
to immnoprecipitation for COMMD1 (top
panel) or GCN5 (bottom panel). Immu-
noblotting for GCN5 and COMMD1 was
performed as indicated (ns, nonspecific
band; input is 0.5% of the IP material).
(E–G) GCN5 represses NF-kB-dependent
gene expression. HEK293 cells were tran-
siently transfected with siRNA against
GCN5 (E) or a GCN5 expression vector.
U2OS cells were stably transduced with
a lentivirus expressing shRNA against
GCN5 (F). After TNF stimulation, the in-
dicated transcript levels were measured by
qRT–PCR. (H) The effect of GCN5 is de-
pendent on RelA. HEK293 cells were tran-
siently transfected with siRNA against
GCN5, and additionally, cells received control siRNA transfection (open bars) or siRNA transfection against RelA (black bars). The
effect on TNF transcript levels was assessed by qRT–PCR.
GCN5 and RelA ubiquitination
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bemore broadly involved in RelA ubiquitination, perhaps
acting on a different substrate. To test this notion, we
introduced an E575Q mutation in GCN5 to inactivate its
HAT domain (Tanner et al. 1999) or a Y814A point
mutation that disrupts acetylated-lysine recognition by
its Bromo domain (Hudson et al. 2000). Interestingly,
neither point mutation significantly impaired GCN5-
mediated RelA ubiquitination (Fig. 2F). Indeed, the
HAT-deficient point mutant E575Q promoted the degra-
dation of RelA to a similar extent as wild-type GCN5 (Fig.
2G) and it inhibited RelA-mediated activation of an NF-
kB-responsive reporter plasmid, whereas it did not affect
the activity of a Smad-responsive promoter (Fig. 2H).
Altogether these results indicated that GCN5-promoted
RelA ubiquitination is separable from its known HAT
activity or the function of its Bromo domain, establishing
this effect as a separable novel property of GCN5.
GCN5 interacts with the COMMD1-containing ligase
COMMD1 promotes RelA ubiquitination through its
interaction with a Cul2-containing ubiquitin ligase
(Maine et al. 2007), suggesting that GCN5 could also
interact with this complex. To investigate this possibility,
GCN5 expressed in mammalian cells was precipitated
from cell lysates and offered to an in vitro reaction
Figure 2. GCN5 interacts with RelA and
promotes its ubiquitination. (A) Copreci-
pitation of endogenous RelA and GCN5.
WCLs or nuclear extracts were prepared
from unstimulated and TNF-stimulated
HEK293 cells. GCN5 was immunoprecipi-
tated, and the recovered material was
immunoblotted for RelA (input is 0.8%
of the IP material). (B) The GCN5/
COMMD1 complex interacts with endog-
enous RelA. GCN5 fused with GST and
COMMD1 fused to a biotinylation tag
were expressed in cells. GCN5 was puri-
fied through a GSH affinity column (PD:
GCN5); GCN5 was eluted from the col-
umn and COMMD1 was precipitated from
this fraction using streptavidin-agarose
beads (Re-PD: COMMD1). Western blots
for endogenous RelA, GCN5, and COMMD1
are presented. (C) GCN5 promotes the
ubiquitination of endogenous RelA. Nu-
clear extracts from U2OS GCN5-deficient
cells (left panels) or HEK293 cells trans-
fected with GCN5 (right panels) were pre-
pared. A denatured immunoprecipitation
for RelA was subsequently performed and
the presence of ubiquitinated RelA was
determined by immunoblotting for ubiq-
uitin. The deficiency and overexpression
of GCN5 were determined by Western
blotting for GCN5. (D) GCN5 deficiency
increases nuclear RelA level. The GCN5-
deficient U2OS cell line or the correspond-
ing control line were treated with TNF for
10 min, followed by cycloheximide (CHX).
At the indicated time points, cells were
harvested and nuclear extracts were pre-
pared and immunobloted for RelA and
RNA Pol II (as a loading control). (Bottom panel) IkB-a levels in cytosolic extracts were determined by Western blotting to monitor
the effect of TNF and CHX. (E) GCN5 deficiency prolongs RelA binding to NF-kB-responsive promoters. The same GCN5-deficient
and control U2OS cell lines were treated with TNF as before. At the indicated time points, cells were lysed and used for ChIP.
Occupancy of RelA, GCN5, and RNA Pol II on the ICAM1 and IL8 gene promoters was analyzed. (F) GCN5 promotes RelA
ubiquitination despite inactivating mutations in its HATor Bromo domains. GCN5 wild-type, E575Q (HAT-deficient), or Y814A (Bromo
domain-deficient) were cotransfected with HA-RelA and His6-tagged ubiquitin, and the levels of ubiquitinated RelAwere determined as
before. (G) GCN5 promotes the degradation of RelA independently of its HAT activity. HEK293 cells were transfected with RelA along
with GCN5 wild-type or E575Q mutant, in combination with COMMD1 or Cul2 as indicated. Cells were lysed and the expression of
RelA was determined by Western blot. (H) The HAT activity of GCN5 is dispensable for repression of kB-dependent transcription. The
effects of GCN5 E575Q on an NF-kB-responsive reporter (3kB-luc) or a Smad-responsive reporter (SBE-JONK) were examined by
luciferase assay.
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containing the E1 and E2 (UbcH5a) enzymes, recombi-
nant ubiquitin, and an ATP regenerating buffer. Ubiquitin
ligase activity, evident by polyubiquitin chain formation
in vitro, was readily recovered. In contrast, recombinant
GCN5 prepared in Escherichia coliwas devoid of activity
(Fig. 3A). However, when recombinant GCN5 was mixed
with cellular lysates and subsequently extensively
washed, ubiquitin ligase activity was reconstituted, sug-
gesting that that the activity detected was secondary to
the association of GCN5 with other cellular factors.
Interestingly, its interaction with the substrate, RelA,
was not responsible for precipitating this activity, as this
was evident when using lysates from rela-deficient fibro-
blasts (Supplemental Fig. S5).
We were particularly interested in knowing whether
GCN5 could interact with Cul2 complexes, given the role
of Cul2 as the main scaffold subunit of the COMMD1-
containing ligase that targets RelA. To address this
question, Cul2 complexes were purified from cells, and
expected partner proteins such as COMMD1 and Elongin
C were identified in this material (Fig. 3B). Importantly,
GCN5 was also copurified, while TAF6, a component of
GCN5-containing coactivator complexes such as TFTC
and STAGA, was absent. Additionally, the converse pre-
cipitation of GST–GCN5 from cell lysates also copreci-
pitated endogenous Cul2 (Fig. 3C) and this was not
affected by TNF stimulation (Supplemental Fig. S6).
Interestingly, the recovered Cul2 was predominantly
the active neddylated form, which is enriched in the cell
nucleus, where GCN5 resides (Maine et al. 2007).
Collectively, these data supported the notion that
GCN5 does not have intrinsic ligase activity, but inter-
acts with an active Cul2/COMMD1 ubiquitin ligase.
However, it was recently reported that PCAF, a close
homolog of GCN5, possesses intrinsic ubiquitin ligase
activity in its N terminus, a region that is conserved
between the two proteins (Linares et al. 2007). Therefore,
we examined which region in GCN5 is responsible for its
interaction with ubiquitin ligase components. The C
terminus of GCN5 (HAT/Bromo, amino acids 491–837)
was found to mediate its interactions with COMMD1
and Cul2 (Fig. 3D), and, in contrast to PCAF, this domain,
and not the N terminus, was able to provide ligase
activity in vitro (Fig. 3E).
RelA phosphorylation enhances its binding to GCN5
While we had determined that GCN5 promotes RelA
ubiquitination, a unique role for GCN5 in this process
was not yet apparent. To address this question, we
examined in more detail the GCN5–RelA interaction,
and the mechanism behind its TNF-inducible nature (Fig.
2A,B). First, cells transfected with GCN5 were treated
with various IKK-activating stimuli, namely TNF, IL1-b,
or Flagellin, and the formation of the GCN5–RelA
complex was assessed by coprecipitation of endogenous
RelA. All of these forms of cell stimulation resulted in
increased recovery of RelA (Fig. 4A). This suggested that
the inducible formation of the GCN5–RelA complex
could be a downstream consequence of IKK activation,
such as the translocation of RelA into the nucleus, where
GCN5 resides. Therefore, we first examined whether the
effect of TNF could be recapitulated under in vitro
conditions, where the cellular redistribution of RelA
would not be a factor. Cell lysates were prepared after
TNF stimulation and offered to bacterially made
recombinant GCN5–GST for in vitro binding. After pre-
cipitation of GCN5, endogenous RelA could be easily
recovered, and, importantly, TNF stimulation prior to
lysis enhanced the ability of GCN5 to bind to RelA (Fig.
4B). Since the interaction in this experiment occurred
post-lysis, the effect of TNF could not be explained by
cellular redistribution of RelA.
Another consequence of IKK activation is IkB degrada-
tion, and, therefore, we speculated that perhaps IkBmight
regulate GCN5–RelA complex formation. To examine
this notion, cells were transfected with IkB-a super-
dominant (SD), a stable mutant that lacks the IKK phos-
phorylation sites. As shown in Figure 4C, the interaction
between GCN5 and RelA was not impaired by IkB-a SD
expression and, in fact, this protein was incorporated into
the GCN5–RelA complex, indicating that IkB proteins do
not impair the GCN5–RelA interaction.
Finally, we examined whether phosphorylation of RelA
itself might be responsible for its increased binding to
GCN5. To this end we repeated the in vitro binding
experiment after treating cells with Calyculin A, a phos-
phatase inhibitor that causes dramatic accumulation of
phosphorylated RelA (Supplemental Fig. S7). Exposure to
this agent prior to cell lysis resulted in very dramatic
enhancement of RelA–GCN5 binding in vitro (Fig. 4D).
Importantly, treatment of cellular lysates with recombi-
nant l-protein phoshatase (l-PPase) prior to incubation
with GCN5 reversed the binding of RelA to GCN5 to the
unstimulated level (Fig. 4E).
RelA phosphorylation is linked to its ubiquitination
and degradation
Since RelA phosphorylation enhances its binding to
GCN5, phosphorylation would be expected to trigger
RelA ubiquitination. Indeed, prior reports indicate that
LPS and other TLR ligands that promote IKK activation
and RelA phosphorylation also accelerate its ubiquitina-
tion (Tanaka et al. 2007). We examined this notion by
determining the effect of Calyculin A on the ubiquitina-
tion of RelA in vivo, and found that this agent promoted
significant accumulation of ubiquitinated RelA (Fig. 4F).
In addition, phosphorylated RelA accumulated more
dramatically when a proteasomal inhibitor was also used
(Fig. 4G), consistent with the notion that phosphorylated
RelA is unstable and undergoes ubiquitination and pro-
teasomal degradation. Finally, we examined the effect of
Calyculin A on the ubiquitination of RelA in vitro. To
this end, GCN5 was expressed and subsequently pre-
cipitated from cell lysates and offered as a source for
ligase activity in vitro. Coprecipitation of endogenous
RelA was observed when this material was immunoblot-
ted for RelA. Interestingly, high molecular weight mate-
rial accumulated after the ubiquitination reaction in the
GCN5 and RelA ubiquitination
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presence of ATP (Fig. 4H). This was particularly evident
when the cells had been treated with Calyculin A prior to
lysis, with the caveat that this treatment also increased
the amount of RelA that coprecipitates with GCN5.
Altogether, the data indicated that GCN5-associated
ligase activity can ubiquitinate RelA, particularly when
it is phosphorylated. This is consistent with the observed
propensity of phosphorylated RelA to bind to GCN5 and
to be ubiquitinated and degraded in cells.
RelA S468 phosphorylation promotes GCN5 binding
We next turned our attention to the mechanism respon-
sible for RelA–GCN5 complex formation by examining
the domain in RelA responsible for GCN5 binding. In
vitro translated radiolabeled GCN5 bound avidly to the
transactivation domain of RelA (TAD, spanning amino
acids 305–551) (Fig. 5A), in contrast to COMMD1, which
binds to the N-terminal end of the RHD (Burstein et al.
2005; Maine et al. 2007). Similar results were observed
when precipitating RelA truncationmutants expressed in
human embryonic kidney (HEK) 293 cells (Supplemental
Fig. S8A). In addition, binding between GCN5 and the
TAD of RelA was similarly inducible by RelA phosphor-
ylation and reversible by dephosphorylation with l-PPase
(Fig. 5B), indicating that the phosphorylation site(s) re-
sponsible for inducible binding might be contained
within the TAD of RelA.
Further in vitro binding experiments indicated that the
last 21 amino acids that constitute the first transactiva-
tion domain (TA1) within the TAD (Schmitz and Baeuerle
1991) are critical for GCN5 binding (Fig. 5C, RelA 1–530),
Figure 3. GCN5 interacts with the COMMD1-containing ligase. (A) GCN5 precipitates ubiquitin ligase activity. GCN5–GST or GST
precipitated from transfected HEK293 cells, or recombinant (r) GST, or GCN5–GST prepared in E. coli were added to an in vitro
ubiquitination reaction. In addition, rGST or rGCN5–GSTwere mixed with an HEK293 cell lysate, incubated at 4°C for 2 h, and then
extensively washed prior to being used as a source for ubiquitin ligase activity. Formation of polyubiquitin chains in the reaction was
determined by SDS-PAGE and immunoblotting for ubiquitin. (B) GCN5 was copurified as a Cul2-associated factor. Lysates were
prepared from HEK293 cells overexpressing a GST-Cul2 fusion protein (Input) and were applied to a GSH-Sepharose affinity column,
from which Cul2-containing complexes were subsequently eluted and concentrated by filtration (Eluate). The input, the flow-through
material not bound to the column (FT), and eluate were subjected to immunoblotting for Cul2, COMMD1, Elongin C (EloC), GCN5,
and TAF6. Silver stain of the eluate is shown in the right panel with the bands corresponding to Cul2, and the immunoblotted subunits
noted by small arrows. Nonspecific bands are indicated by an asterisk (*). (C) GCN5 binds to Cul2, the main scaffold protein of the
COMMD1-containing ligase. HEK293 cells were transfected with GST or GST–GCN5, which were precipitated from cell lysates. The
presence of coprecipitated endogenous Cul2 was determined by Western blot. The position of the 97-kDa molecular weight marker is
indicated. (D) The C terminus of GCN5 binds to COMMD1 and Cul2. Cells were transfected with GCN5 full-length (FL) fused to GST
or the indicated truncation mutants along with Flag-Cul2 or COMMD1-Flag. GCN5 was precipitated by GSH Sepharose beads, and the
presence of Cul2 or COMMD1 in the precipitated material was determined by Western blot analysis. (E) The C terminus of GCN5
containing the HAT and Bromo domains precipitates E3 ligase activity. GCN5 full-length (FL) fused to GST or truncation mutants
spanning its N terminus (N-term, amino acids 1–491) or C terminus (HAT/Bromo, amino acids 492–837) were expressed in mammalian
cells. These proteins were precipitated from cell lysates, added to in vitro ubiquitination reactions, and polyubiquitin chain formation
was determined as before.
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and similar results were obtained in coprecipitation
experiments using mammalian cell lysates (Supplemen-
tal Fig. S8B). Additionally, a recombinant peptide pre-
pared in E. coli and spanning most of the TA1 region
(amino acids 531–547) was capable of completely disrupt-
ing the RelA–GCN5 complex (Fig. 5D), consistent with
the notion that TA1 is a major interface for RelA–GCN5
binding. Interestingly, TA1 contains Ser 536, a major
phosphorylation site in RelA that has been implicated
previously in the stability of this protein (Lawrence et al.
2005). Therefore, we initially speculated that perhaps Ser
536 might be responsible for phosphorylation-dependent
binding between RelA and GCN5. Indeed, loss of the last
21 amino acids of RelA abrogated all inducible binding
between RelA–TAD and GCN5 (Fig. 5E, D21). However,
point mutations of any of the six serines located in this
region, including Ser 536, did not have a substantial effect
on binding (data not shown). Surprisingly, even a com-
bined mutation of all six serines in TA1 did not abrogate
the inducible binding between RelA–TAD and GCN5
(Fig. 5E, 6S/A), suggesting that the phosphorylation site
might be located elsewhere in theTAD. Indeed, examination
Figure 4. RelA phosphorylation enhances
GCN5-RelA interactions. (A) Various IKK-
activating stimuli promote GCN5–RelA
binding. HEK293 cells were transfected
with GCN5–GST or GST and subsequently
treated with TNF, IL-1b, or Flagellin prior
to lysis and GSH precipitation. The pres-
ence of coprecipitated endogenous RelA
was determined by immunoblotting. (B)
TNF treatment prior to lysis promotes
RelA–GCN5 binding in vitro. HEK293 cells
were treated with TNF or Calyculin A, and
the obtained lysates were mixed with bac-
terially made rGST or rGCN5–GST, fol-
lowed by precipitation. The presence of
endogenous RelA in the recovered material
was determined by immunoblotting. (C)
IkB does not impair the GCN5–RelA in-
teraction. HEK293 cells were transfected
with IkB-a superdominant (SD), and the
ability of recombinant GCN5 to precipitate
endogenous RelA post-lysis was examined
as in B. (D) The phosphatase inhibitor
Calyculin A promotes RelA–GCN5 bind-
ing in vitro. HEK293 cells were treated
with Calyculin A and the obtained lysates
were mixed with rGST or rGCN5–GST,
followed by precipitation. The presence of
endogenous RelA in the recovered material
was determined by immunoblotting. (E)
Dephosphorylation of RelA abrogates its
induced binding to GCN5. HEK293 cells
were treated with Calyculin A and sub-
sequently lysed in a buffer without phos-
phatase inhibitors. The lysate was
incubated with l-protein phosphatase (l-
PPase) as indicated, and in vitro binding of
RelA to recombinant GCN5 was performed
as in D. The recovered material was immu-
noblotted to detect the coprecipitation of
endogenous RelA and phosphorylated
RelA. (F) Phosphorylation promotes RelA
ubiquitination. Wild-type MEFs were trea-
ted with MG-132 (30 min) and Calyculin A
as indicated. RelA was subsequently
immunoprecipitated from cell lysates and the presence of ubiquitinated RelA was determined by immunoblotting for ubiquitin. (G)
Phosphorylated RelA is labile and is stabilized by proteasomal blockade. Wild-type MEFs were treated with Calyculin A and MG-132 as
indicated. Phosphorylated RelA levels were determined by Western blot using two phospho-specific antibodies. (H) GCN5-associated
ligase activity ubiquitinates RelA in vitro. HEK293 cells transfected with GCN5–GSTor GSTwere treated without or with Calyculin A
as shown. Material precipitated by GSH beads was applied to an in vitro ubquitination reaction as in Figure 3A. Coprecipitated RelA
and its ubiquitination were shown by immunoblotting.
GCN5 and RelA ubiquitination
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of other serine phosphorylation sites within RelA in-
dicated that mutation of Ser 468 abrogated the inducible
binding between RelA and GCN5 in response to either
Calyculin A or TNF treatments (Fig. 5F). Collectively,
these data suggested that the last 21 amino acids of RelA
provide the main domain for GCN5 binding, and that
upon phosphorylation of RelA at Ser 468, additional
conformational changes take place that increase its
binding to GCN5.
IKK is required for RelA–GCN5 complex formation
Previous reports indicate that IKKb or IKKe can phos-
phorylate RelA on Ser 468 (Schwabe and Sakurai 2005;
Mattioli et al. 2006), while other studies have linked
IKKa-mediated phosphorylation of RelA to its proteaso-
mal degradation (Lawrence et al. 2005). Hence, we exam-
ined the possible participation of the IKK complex as the
kinase for RelA that promotes GCN5 binding. To address
this question, we used Ikk-deficient mouse embryo fibro-
blasts (MEFs) to examine the binding between RelA and
GNC5 in vitro (Fig. 6A). TNF treatment prior to lysis
induced RelA–GCN5 binding when lysates were prepared
from wild-type fibroblasts, while loss of Ikka or Ikkb
completely abrogated the effect of TNF. These data in-
dicated that an intact Ikk complex is required for inducing
the binding between RelA and GCN5, likely because of
the role of this kinase complex in Ser 468 phosphorylation.
IKK and GCN5 are required for inducible RelA
degradation
If the IKK complex promotes RelA–GCN5 binding, one
predicted outcome would be that IKK activation should
Figure 5. The GCN5–RelA interaction
requires the C terminus of RelA and is
enhanced by phosphorylation at Ser 468.
(A) GCN5 interacts with the transactiva-
tion domain of RelA. Recombinant RelA
fragments fused to GST were purified from
E. coli and their ability to precipitate radio-
labeled in vitro translated GCN5 was ex-
amined by autoradiography. Coomasie staining
demonstrates the amount of recombinant
protein used. (B) The TAD of RelA is re-
sponsible for phosphorylation-inducible
binding. The same experiment as in B
was performed, but this time using lysates
from cells transfected with RelA–TAD
(306–551). (Bottom panel) In addition, l-
PPase treatment of the lysate was also
performed prior to binding. (C) GCN5
interacts with TA1, encompassed by the
last 21 amino acids of RelA. The indicated
recombinant RelA fragments fused to GST
were purified from HEK293 cells, and their
ability to precipitate radiolabeled in vitro
translated GCN5 was examined by autora-
diography. Coomasie staining demonstrates
the amount of recombinant protein used.
(D) A peptide from TA1 is capable of dis-
rupting GCN5–RelA binding in vitro.
Recombinant RelA fragments fused to
GST were purified from E. coli, and their
ability to precipitate radiolabeled in vitro
translated GCN5 was examined as in A. In
addition, peptides spanning the indicated
amino acid residues in RelA were added to
the in vitro binding reaction as potential
competitive inhibitors. (E) The phosphory-
lation residue that mediates RelA–GCN5
inducible binding is not contained in the
last 21 amino acids of RelA. The same
experiment as in Figure 4E, but this time
using two mutations in the TAD: deletion
of the last 21 amino acids (306–530), D21;
or mutation of the last six serines in RelA (S535, 536, 543, 547, 550, 551A), 6S/A. (F) Ser 468 phosphorylation is required for RelA–
GCN5-inducible binding. The same experiment as in B and E, but using either Calyculin A treatment (left) of TNF stimulation (right).
Wild-type RelA or a point mutant at Ser 468 are compared.
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destabilize RelA. Using IL1-b as a means of activating the
kinase, we found that this led to decreased stability of
RelA in wild-type fibroblasts compared with unstimu-
lated cells (Fig. 6B). In addition, and consistent with the
role of IKK in RelA phosphorylation, the protein was
stabilized in Ikk-deficient fibroblasts treated with IL1-b
(Fig. 6C). Similar to MEFs, cytokine stimulation resulted
in a shorter half-life of RelA in 293 cells (data not shown),
and most importantly, GCN5 deficiency greatly stabi-
lized RelA in this context (Fig. 6D), akin to the effect of
Figure 6. IKK and GCN5 promote RelA degradation. (A) IKK is required for TNF-induced RelA–GCN5 binding. Wild-type (WT),
Ikka /, or Ikkb / MEFs were stimulated with TNF and subsequently lysed. This material was applied to rGCN5–GST for in vitro
binding as before. The coprecipitation of endogenous RelA was determined by immunoblotting. (B) IL1-b stimulation decreases RelA
stability. Cycloheximide (CHX) was used to determine the stability of RelA in wild-type MEFs that were untreated or stimulated with
IL1-b. RelA levels were determined by immunoblotting and densitometry analysis. (C) Ikk deficiency stabilizes RelA in IL1-b treated
cells. Similar to B, but the effects of IL1-b treatment were compared between wild type, Ikka /, or Ikkb / MEFs. (D) GCN5 defi-
ciency prevents IL1-b-promoted degradation. HEK293 cells were transfected with the indicated siRNA and subsequently treated with
IL1-b. The stability of RelA after cycloheximide (CHX) treatment was examined by immunoblotting and densitometry analysis. (E)
GCN5 deficiency stabilizes RelA in U2OS cells. GCN5-deficient U2OS cells and the corresponding control cells were metabolically
labeled by 35S-methionine and 35S-cysteine. At the indicated time points after labeling, cells were lysed for a denatured immunopre-
cipitation for RelA. The recovered material was examined by autoradiography after SDS-PAGE separation. (F) RelA 1–530 and RelA
S468A are more stable than full-length (FL) RelA. The indicated human RelA constructs were introduced into rela-deficient MEFs
through lentiviral infection and selection. Protein stability was examined as before.
GCN5 and RelA ubiquitination
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IKK deficiency. The stabilization of RelA was similarly
observed in pulse-chase metabolic labeling studies exam-
ining GCN5-deficient U2OS cells (Fig. 6E). Finally, the
stability of mutations in RelA that affect its binding to
GCN5, namely a truncation of its TA1 (RelA 1–530) or
loss of Ser 468 (S468A), was examined after stably
reintroducing these proteins into rela-deficient MEFs.
As shown in Figure 6F, these mutants were stabilized
compared with the wild-type protein. Altogether, these
findings are consistent with the role of IKK-mediated
phosphorylation in promoting the RelA–GCN5 interac-
tion, which in turn leads to RelA ubiquitination.
Discussion
An important phase in the regulation of kB-dependent
transcription is the termination of NF-kB activity, which
has been largely ascribed to NF-kB-mediated resynthesis
of IkB proteins (Hoffmann et al. 2002). Recently, ubiquiti-
nation of NF-kB has been found to be an additional
mechanism by which transcriptionally active NF-kB is
suppressed (Saccani et al. 2004). One of the ligases re-
sponsible for this effect contains COMMD1 in associa-
tion with a multimeric complex that contains Cul2 (Ryo
et al. 2003; Maine et al. 2007), while others have identi-
fied PDLIM2 in a similar role (Tanaka et al. 2007).
Additionally, phosphorylation of RelA by IKKa has been
reported to destabilize the protein, and similar to ubiq-
uitination, this controls the chromatinassociationofRelA
(Lawrence et al. 2005). However, since Cul2-containing
complexes are not known to engage phospho-serine sub-
strates (Petroski and Deshaies 2005), a link between IKK-
mediated phosphorylation of RelA and its ubiquitination
by this ligase was not evident prior to this study.
This report indicates that GCN5, a HAT best known as
an activator of transcription, functions in an unexpected
manner in the NF-kB pathway, where it represses tran-
scription by providing a critical link between serine
phosphorylation of RelA and its ubiquitination. Various
data presented here support a model where GCN5 pro-
motes RelA ubiquitination by interacting directly with
both the ubiquitin ligase and RelA in a manner akin to
a substrate adaptor protein. Similarly, we conclude that in
addition to the well-known core components associated
with Cul2 (Ganoth et al. 2001), the ligase uses accessory
factors such as COMMD1 and GCN5. Interestingly, the
HAT activity of GCN5 is dispensable in this setting, as
the point mutant GCN5 E575Q retains the ability to
promote RelA ubiquitination and repress NF-kB-depen-
dent transcription. Additionally, the sequential purifica-
tion of the GCN5/COMMD1 complex suggests that only
a small fraction of GCN5 interacts with COMMD1,
leading us to speculate that most cellular GCN5 is
probably engaged in its well-recognized role in coactiva-
tor complexes.
The most interesting property of GCN5 in this path-
way is its ability to interact with RelA, preferentially
after IKK activation. Our data indicate that phosphoryla-
tion of RelA itself is responsible for promoting GCN5–
RelA binding, as the increased binding between these
proteins can be reversed in vitro by treating the lysates
with l-PPase. This finding is corroborated by mutational
analysis, which indicates that phosphorylation of RelA
at Ser 468 is required for its inducible binding with
GCN5. Interestingly, this phosphorylation event has been
reported to have an inhibitory effect on transcription
(Buss et al. 2004; Schwabe and Sakurai 2005; Mattioli
et al. 2006), and, indeed, RelA S468A promotes greater
expression of NF-kB target genes such Il6 and Tnf
(Supplemental Fig. S9). This finding is consistent with
our observation that phosphorylation of Ser 468 facili-
tates RelA binding to GCN5, a preamble to the ubiquiti-
nation and degradation of the protein. In addition, the
data also demonstrate that TA1, encompassed in the last
21 amino acids, is critically required for basal GCN5
binding.We speculate that upon Ser 468 phosphorylation,
a conformational change in RelA likely takes place that
possibly cooperates with TA1 to promote the GCN5–
RelA interaction. Given that the structure of the TAD of
RelA has not been solved, the nature of such conforma-
tional change remains unclear. Finally, the data presented
here is consistent with prior reports that place these
events in the nucleus, particularly on gene promoter
sites. Indeed, GCN5, as well as COMMD1, are inducibly
recruited to NF-kB-responsive promoters, and their de-
ficiency results in prolonged occupancy of the promoter
by RelA, an event that presumably explains the increased
transcriptional response.
The participation of GCN5 in the ubiquitination path-
way is consistent with genetic evidence that GCN5 has
HAT-independent functions. Deficiency of Gcn5 in mice
prevents the formation of somites, a neural tube or
a notochord, while a HAT-inactivating mutation in the
Gcn5 gene results in a milder phenotype (Bu et al. 2007).
Finally, our study provides a mechanism to link IKK
activation, RelA phosphorylation, and the degradation of
DNA-bound, transcriptionally active RelA. In this model,
activation of the IKK complex not only initiates NF-kB-
mediated transcription, but sets in motion a process that
ultimately inhibits active NF-kB through the targeting of
RelA for GCN5 binding and ubiquitination.
Materials and methods
Plasmids and siRNA
The plasmids pEBB, pEBG, pEBB-COMMD1-Flag, pEBB-
COMMD1-GST FL, N-term (amino acids 1–118), COMM do-
main (amino acids 119–190), pEBB-Flag-Cul2, pEBG-Cul2 FL
pEBG-RelA FL and its truncations 1–305, 1–180, 306–551,
pEBB-HA-RelA, pEBB-T7-IkB-a SD, pCW7-His6-Myc-Ubiquitin,
3kB-luc, 2kB-luc, and SBE-JONK have been described previously
(Hay et al. 2001; Burstein et al. 2004, 2005; Lewis et al. 2004;
Maine et al. 2007). The full-length coding sequence for human
GCN5 was obtained from an EST clone (IMAGE clone 5575574)
to generate pEBB-GCN5 (untagged). Using this EST clone as
template, PCR was used to generate the following plasmids:
pcDNA3.1-GCN5, pEBB-Flag-GCN5, pET21b-GCN5–GST,
pEBB-GCN5–GSTand pEBG-GCN5 FL. Similarly, PCR was used
to generate pEBG-GCN5 N-term (amino acids 1–491), pEBG-
GCN5 HAT/Bromo domain (amino acids 492–837), pEBG RelA
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1–530, pEBB HA- RelA 1–530, pEBG RelA 1–450. pcDNA-Flag-
p300 was a gift from Dr. Colin Duckett. Expression vectors for
point mutants of GCN5 and RelA (pEBB-Flag GCN5 E575Q,
Y814A, GCN5 RNAi-resistant, pEBG-RelA S536A, pEBB HA-
RelA TAD S468A, pEBB HA-RelA 6S/A) were created by site
directed mutagenesis (Stratagene). The constructs pGEX RelA
RHD (1–303) and pGEX RelA TAD (354–551) were used for
recombinant protein preparation in E. coli as described pre-
viously (Ramsey et al. 2008). The plasmid pEBB-TB was gener-
ated by amplifying the coding sequence for TEV cleavage site and
Biotinylation signal from pFA6a HTB kanMX6 as template,
kindly provided by Dr. Kaiser (Tagwerker et al. 2006). The
COMMD1 coding sequence was subcloned into this plasmid to
generate pEBB-COMMD1-TB. Synthetic siRNA oligonucleotides
against Chloramphenicol acetyl transferase (a control target),
human GCN5 and human RelA were used, and detailed in-
formation about targeting sequences are available upon request.
The plasmids pHCMV-VSV-G, pMDLg/pRRE, pRSV Rev, and
FG12 (Lois et al. 2002) were used for the generation of recombi-
nant lentiviruses (kindly provided by Dr. David Baltimore). For
stable RNAi using lentiviral delivery, we introduced a cassette
containing the Histone 1 promoter and a shRNA from pSUPER
into the XbaI and XhoI sites of FG12.
Cell culture, transfection, and luciferase assays
HEK293 cells, HEK 293T cells, and U2OS cells were obtained
from American Type Culture Collection and cultured in DMEM
supplemented with 10% FBS and L-glutamine (2mM). Ikka/,
Ikkb /, and wild-type MEFs were kindly provided by Dr. Inder
Verma (Li et al. 1999a, b). All transient transfection experiments
were performed in HEK293 cells using a standard calcium
phosphate transfection protocol to transfect plasmids and siRNA
(Burstein et al. 2004). In certain experiments, the following
agents were applied at the indicated final concentration to the
growth media: TNF (Roche, 1000 U/mL), IL-1b (Roche, 10 ng/
mL), Flagellin (Inotek, 50 mg/mL), Calyculin A (Cell Signaling, 50
nM), Cycloheximide (BioVision, 60 mg/mL), andMG-132 (Boston
Biochem, 40 mM). Luciferase assays were performed as described
previously (Burstein et al. 2005).
TAP screening
The TAP screening performed here has been reported previously
(Burstein et al. 2005). Briefly, 293 cells seeded in 15-cm plates
were transiently transfected with pEBB-COMMD1-TAP (15 mg of
plasmid per plate). Cell lysates were subsequently prepared and
applied to a chromatography column containing IgG sepharose
beads (GE Healthcare). After a 2-h incubation at 4°C, the column
was drained and washed prior to addition of TEV protease. The
eluted material was applied to a chromatography column con-
taining calmodulin 4B beads Healthcare) and incubated for 1 h at
4°C. The column was then drained and washed prior to addition
of calmodulin elution buffer containing EGTA. The final eluate
collected was mixed with cold 10% Trichloroacetic acid in
acetone; after overnight incubation at –20°C, precipitated pro-
teinswere collected bycentrifugation, rinsed in100%acetone, and
allowed to air dry. These samples were then submitted to the
ProteomicsCenter at theUniversity ofVictoria for further process-
ing, including tryptic digestion, HPLC separation, and tandem
mass spectrometry (MS/MS) to determine peptide sequences.
Quantitative RT–PCR (qRT–PCR)
Total RNA was extracted from cells using the RNeasy kit
(Qiagen) according to the manufacturer’s instructions. An RT
reaction with 500 ng of total RNA in 25 mL was performed using
random hexamers and TaqMan Reverse Transcription Reagents
(Applied Biosystems). This was followed by quantitative PCR
performed in the 7500 Real-Time PCR system (Applied Biosy-
tems). Oligonucleotides and internal probes for NFKBIA,
ICAM1, TNF, and IL8 transcripts were obtained from Applied
Biosystems, and a TaqMan PCR Master Mix with GAPDH
mRNA quantitation was duplexed in the same well as an
internal control. To quantify CX3CL1 mRNA, specific primers
spanning over an intron were designed (sequences available upon
request). These were combined with SYBERGreen PCR Master
Mix for mRNA quantitation and parallel reactions with primers
targeting GAPDH were performed as a control for mRNA
abundance.
Immunoblotting, immunoprecipitation, and ChIP
WCLs were prepared by adding Triton lysis buffer (25 mM
HEPES, 100 mM NaCl, 10 mM DTT, 1 mM EDTA, 10%
Glycerol, 1% Triton X-100), RIPA buffer (PBS, 1% NP-40, 0.5%
Deoxycholate, 0.1% SDS, 10 mM DTT), or an 8-M urea buffer (8
M urea, 50 mM Tris at pH 8.0, 300 mM NaCl, 50 mM NaPO4,
0.5% NP-40) supplemented with 1 mM sodium orthovanadate
and protease inhibitors (Roche) as indicated in each experiment.
Preparation of cytosolic and nuclear extracts was performed as
described previously (Burstein et al. 2005). Immunoprecipita-
tions, GSH precipitations, Ni-NTA precipitations, and immuno-
blotting were performed as previously described (Burstein et al.
2004, 2005). Densitometry analysis consisted in measurements
of integrated density using the Scion Image software. For
denatured immunoprecipitation, cells were harvested and lysed
initially in Triton X-100 Buffer (75 mL). The lysate was then
mixed with an equal volume of TSD buffer (50mMTris at pH7.5,
2% SDS, 5 mMDTT) and sonicated for 10 sec. Subsequently, the
lysate was heated for 5 min at 80°C and Triton X-100 buffer was
then added to a final volume of 1500 mL (or a final concentration
of 0.1% SDS) prior to conventional immunoprecipitation. For in
vitro binding assays, E. coli-expressed GST fusion proteins were
loaded onto glutathinone sepharose beads (Burstein et al. 2005)
and 2–5 mg of recombinant protein was mixed with mammalian
cell lysates to coprecipitate its binding partner. The following
antibodies were used in our studies: acetylated lysine (Cell
Signaling, 9441), b-Actin (Sigma, A5441), COMMD1 (Burstein
et al. 2005), Cul2 (Zymed, 51-1800), Elongin C (BioLegend,
613101), Flag (Sigma, A8592), GST (Santa Cruz Biotechnologies,
sc-459), GCN5 (Santa Cruz Biotechnologies, sc-20698, sc-6306),
HA (CoVance, MMS101R), IkB-a (Upstate Biotechnologies, 06-
494), IKKa (Cell Signaling, 2682), IKKb (Cell Signaling, 2684),
Rbx1 (LabVision, 127-075-160), RelA (Santa Cruz Biotechnolo-
gies, sc-372 and sc-8008), RelA phospho-S-536 (Cell Signaling,
3031), RelA phospho-S-468 (Cell Signaling, 3039), ubiquitin
(Stressgen, SPA-205), PCAF (Santa Cruz Biotechnologies, sc-
13124). The TAF6 antibody was a kind gift from Dr. Robert
Roeder. ChIP was performed as described previously (Burstein
et al. 2005). Details regarding primer sequences are available
upon request.
In vitro binding experiments
GST fusion proteins bound to GSH sepharose were incubated at
room temperature with BSA (1 mg/mL) in 200 mL of Z-buffer (25
mM HEPES at pH 7.5, 12.5 mMMgCl2, 150 mM KCl, 0.1% NP-
40, 20% glycerol). After 15 min, in vitro translated proteins were
added and incubated for another 45 min at room temperature.
Peptides used for competition experiments were prepared as
previously as GST-PTD fusion proteins, followed by thrombin
GCN5 and RelA ubiquitination
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cleavage as described by the manufacturer (GE Healthcare). The
prepared peptides were applied to in vitro binding reactions at
a final concentration of 50 mM. The beads were then washed four
times with 1 mL NETN buffer (100 mM NaCl, 1 mM EDTA,
0.5% NP-40, 20 mM Tris-Hcl at pH 8.0). Bound proteins were
resolved by SDS-PAGE and subjected to autoradiography. Protein
dephosphorylation was performed by incubating cell lysates
with l-PPase (New England Biolabs) for 30 min at 30°C after
addition of the recommended reaction buffer and Mn.
In vitro ubiquitination assays
Each reaction mixture consisted of recombinant ubiquitin (2.5
mg), E1 (Uba1, 50 ng), E2 (UbcH5a, 100 ng), and ATP regenerating
buffer (all obtained from Boston Biochem). These were mixed in
reaction buffer (40 mM HEPES at pH 7.9, 60 mM potassium
acetate, 2 mM DTT, 5 mM MgCl2, 10% glycerol) and incubated
for 90 min at 30°C (Maine et al. 2007).
Metabolic labeling
This was performed as described previously (Maine et al. 2007).
Briefly, cells were seeded 24 h prior to the experiment and then
placed for 30 min in a cysteine and methionine-deficient me-
dium. At the end of this period, 35S-radiolabeled methionine and
cysteine was added to the medium for 1 h and then replaced with
regular growth medium supplemented with excess nonradiola-
beled methionine (2 mM) and cysteine (2 mM). WCLs were then
prepared at the indicated time points and the samples were
subjected to denatured immunoprecipitation of RelA (Santa
Cruz Biotechnologies, sc-372). The recovered material at the
end of the immunoprecipitation was resolved by SDS-PAGE and
RelA was detected by autoradiography.
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Figure S1.  (A-D)  GCN5 expression was decreased by transient transfection of small interfereing
RNA in HEK293 cells (A,B) or by the small hairpin RNA expression delivered by a lentivirus vector 
in U2OS cells (C,D).  Expression of the indicated NF-κB responsive genes after TNF stimulation 
were assayed by quantitative real-time RT-PCR.  (E) GCN5 siRNA was performed as before, and in 
addition, GCN5 was re-expressed  during siRNA by introducing silent point mutations over the 
siRNA targeting sequence. TNFAIP3 transcript levels after TNF stimulation were measured by 


































Figure S2.  The effect of siRNA against RelA and GCN5 in the experiment  shown on Figure 1H 





















































Figure S3. (A) GCN5 promotes RelA ubiquitination.  HEK293 cells were transfected with HA-
RelA and His6-tagged ubiquitin, along with siRNA against GCN5.  Ubiquitinated proteins were 
precipitated from denatured lysates by nickel beads and the presence of ubiquitinated RelA was 
determined by immunobloting.  (B) GCN5 deficiency impairs COMMD1 promoted RelA 
ubiquitination.  HEK293 cells were transfected with HA-RelA and His6-tagged ubiquitin, as well as 
COMMD1 as indicated. Endogenous GCN5 levels were suppressed by transfection of siRNA.  
Ubiquitinated proteins were precipitated from denatured lysates by nickel beads and the presence of 


























Figure S4. GCN5 does not acetylate RelA.  HEK293 cells were transfected with RelA fused to 
GST along with Flag-p300, PCAF or GCN5.  RelA was precipitated by GSH sepharose beads and 
subjected to immnoblotting for acetyled lysine (top panel) and RelA (middle panel).  Expression of 
the transfected acetyltransferases were determined by western blot analysis in the input lysate






Figure S5. GCN5 precipitated ligase activity does not depend on RelA expression. 
Recombinant GCN5 protein (or GST control) was mixed with cellular lysates, 
thoroughly washed and subsequently offered as a source for ligase activity in an in 
vitro ubiquitination reaction.   In this case, the lysates utilized were from rela deficient 
mouse embryo fibroblasts reconstituted with wild type human RelA or transfected
with an empty vector control. E3 ligase activity precipitated by recombinant GCN5 






































Figure S6.  The Cul2-GCN5 interaction is not affected by TNF. HEK293 cells transfected with 
GCN5 fused to GST were treated with TNF for variable amounts of time as indicated. 
Subsequently, lysates were prepared from the cells and utilized for GSH precipitation. The 






Figure S7. Calyculin A promotes RelA phosphorylation. HEK293 cells were treated with 
Calyculin A or TNF for 30 min as indicated.  Total levels of levels of phosphorylated RelA and 






































Figure S8. GCN5 interact primarily with the TAD of RelA (306-551). (A) HEK293 cells were 
co-transfected with GCN5 and RelA full-length (FL), or truncation mutants spanning the indicated 
amino acids, fused to GST.   Subsequently, GST proteins were precipitated from cell lysates and 
the recovered material was immunoblotted for GCN5. (B) Similar to (A), the indicated RelA
truncations were transfected, and subsequently precipitated from cell lysates.  Co-precipitation of 





































Figure S9. Wild type RelA or RelA S468A were introduced into rela deficient mouse embryo 
fibroblasts by lentivirus mediated transduction.  Expression of the Tnf and Il6 genes was 
determined by quantitative real-time RT-PCR at the indicated time points following 
stimulation with TNF for 10 min.  No difference of RelA level was observed between these 
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The transcription factor NF-kB is a master regulator of inflammation.  Its activity is 
controlled by various mechanisms, including the degradation of chromatin-bound NF-kB 
subunits.  This latter event requires a protein termed COMMD1, which is involved in NF-kB 
ubiquitination.  However, the physiologic importance of COMMD1 in the control of 
inflammation has not been previously studied.  Using tissue-specific deletion of Commd1 in 
mice, we report that deficiency of this gene in myeloid cells leads to greater activation of NF-
kB and exaggerated inflammatory responses.  Moreover, in models of chronic colitis these 
animals demonstrate a greater propensity for cancer progression.  The importance of these 
events in human disease is highlighted by the fact that inflammatory conditions such as 
inflammatory bowel disease can lead to COMMD1 suppression, a process that we found can 






The transcription factor NF-kB controls many aspects of both innate and adaptive immunity1.  
NF-kB is comprised of homo- and heterodimers of Rel family proteins, which in mammals 
are encoded by 5 genes: RELA (encoding RelA, also known as p65), REL (encoding c-Rel), 
RELB (encoding RelB), NFKB1 (encoding p50 and its precursor polypeptide p105) and 
NFKB2 (encoding p52 and its precursor p100).  The so-called ‘canonical pathway’ is 
mediated primarily by RelA or c-Rel containing dimers that are kept in the cytosol through 
interactions with the inhibitory IkB proteins (primarily ‘classical’ IkB proteins, namely IkB-
a, -b and -e).  Activation of canonical NF-kB promotes pro-inflammatory innate immune 
responses and requires the degradation of IkB, an event triggered by a critical kinase complex 
known as IKK2.  This kinase in turn, sits at the crossroads of numerous signaling pathways, 
and can lead to NF-kB activation in a variety of settings. 
 Following its activation a number of mechanisms restore homeostasis and terminate 
canonical NF-kB activity.  NF-kB is known to induce negative feedback loops, such as the 
induction of IkB gene expression3, 4, or the induction of proteins that inhibit IKK activity5-7, 
such as A20 or CYLD.  In addition, it has been recognized that ubiquitination and 
proteasomal degradation of RelA is critical to terminate transcription of a variety of genes8-14.  
One ligase responsible for these effects contains the scaffold protein Cul2, in association with 
the co-factor COMMD110, 13, or in other settings SOCS112, 15 (or potentially both).  In 
addition, another report has also implicated the RING containing protein PDLIM2 as a ligase 
for RelA11. 
 COMMD1 is the founding member of a conserved family of factors whose function is 
largely unexplored at this point16-18.  Most of what is known about COMMD proteins is 
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restricted to COMMD1, which has been implicated in a variety of cellular processes, 
including NF-kB regulation13, 19 as well as copper transport20, electrolyte balance21, and 
hypoxia responses22.  In most instances, these effects have been ascribed to increased 
ubiquitination and/or degradation of a cellular factor, a mechanism that is in agreement with 
the ability of this protein to activate ubiquitin ligases containing Cullin proteins23.   
While the effects of COMMD1 on RelA ubiquitination have been well characterized, it 
remains unclear whether this factor plays a physiologically important in the control of 
inflammation.  Testing this hypothesis has been complicated by the embryonic lethality that 
results from complete Commd1 deficiency in mice24.  With the recent development of a 
conditional Commd1 allele25, tissue specific deletion became an attractive option to test the 
contribution of Commd1 to inflammation.  Here we report that myeloid deficiency of 
Commd1 leads to more severe inflammation in a variety of models including sepsis, acute 
colitis and chronic colitis, and is accompanied by exaggerated NF-kB activation.  Moreover, 
we find that COMMD1 is repressed in the setting of inflammation through a mechanism that 
involves IFN-g production.  These events are observed in various conditions, including 




Commd1 deficient fibroblasts demonstrate decreased RelA ubiquitination   
In order to study the contribution of Commd1 to the control of inflammation in vivo, 
we generated Commd1 deficient mice using a recently described Commd1 conditional allele25  
(Figure S1A). Using these ‘floxed’ mice, we generated murine embryonic fibroblasts (MEFs) 
which were infected with an adenovirus expressing Cre (or a LacZ as a negative control).  The 
isogenic lines derived demonstrated gene deletion (Figure S1B) and complete loss of 
Commd1 protein expression (Figure 1A).  In these cells, Commd1 deficiency led to decreased 
ubiquitination of nuclear RelA (Figure 1B) and exaggerated expression of pro-inflammatory 
NF-kB target genes such as Il6 and Tnf (Figure 1C) in agreement with previously published 
data10, 13.   
Generation of myeloid-specific Commd1 deficient mice 
Commd1 ‘floxed’ mice were crossed with LysM-Cre ‘knockin’ mice, which express 
Cre in the myeloid lineage26, a critical arm of the innate immune system.  LysM-Cre led to the 
expected loss of Commd1 expression in macrophage populations derived from bone marrow 
cells or splenocytes of Commd1 floxed mice but not wild-type controls (Figure 1D).  These 
myeloid specific Commd1 deficient mice (Mye-K/O) did not demonstrate any overt 
phenotype at baseline, except for a small increase in leukocyte counts in blood, still within the 
normal range for mice (Figure 1E, left panel), which was not due to significant alterations in 
any particular leukocyte lineage (Figure 1E, right panel).  In addition, B lymphocytes (B220+) 
and T lymphocyte populations (CD3+ and CD4/CD8 subpopulations) were not significantly 
different (Figure 1F, left) in the spleen or mesenteric lymph nodes (MLN).  Similarly, 
myeloid populations, including granulocytes (Ly6G+), monocytes and macrophages (CD11b+, 
Ly6C+), macrophages (F4/80+), and dendritic cells (CD11c+, both high and intermediate) were 
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not significantly different in frequency between these two mouse strains (Figure 1F, right, and 
Figure S2). 
Myeloid deficiency of Commd1 sensitizes mice to sepsis 
 Next, we compared the sepsis response of Mye-K/O mice and littermate WT controls 
(floxed mice lacking the LysM-Cre gene).  Animals were challenged with LPS, and in a 
blinded manner, morbidity and mortality (or need for euthanasia) were assessed in the ensuing 
30 hours.  Mye-K/O mice demonstrated increased mortality after LPS administration (Figure 
2A), as well as greater morbidity (Figure 2B).  Tissue injury, manifested by enzyme release, 
was also more pronounced in Mye-K/O mice (Figure 2C).  Similarly, plasma levels of pro-
inflammatory cytokines such as TNF, IL-6 and CCL5, were significantly elevated in Mye-
K/O, while the anti-inflammatory cytokine IL-10 was unchanged (Figure 2D).  At the tissue 
level, expression of pro-inflammatory genes in various organs was more pronounced in Mye-
K/O mice, as exemplified by Tnf (Figure 2E).  Several other pro-inflammatory genes, such as 
Ccl5, Il6, Il1b, Cxcl1, and Saa3, were more robustly induced in Mye-K/O mice (Figure 2F), 
and the same was true of other NF-kB target genes such as Nfkbia and Tnfaip3 (Figure 2G).  
Altogether, these data indicated that Commd1 deficiency in the myeloid lineage leads to more 
profound inflammatory responses in this sepsis model.   
Commd1 deficiency enhances NF-kB dependent gene expression in myeloid cells  
 Given the observed phenotype, we examined the effect of Commd1 on NF-kB 
dependent gene expression in bone marrow derived myeloid (BMDM) cells.  GM-CSF driven 
differentiation, reported to induce primarily immature dendritic cells, led to very significant 
deletion of Commd1.  These cells demonstrated comparable kinetics of IkB-a degradation and 
phosphorylation in response to LPS (Figure 3A), indicating that IKK activation downstream 
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of Tlr4 was not significantly affected.  Similar results were obtained when stimulating these 
cells with TNF (not shown here) and were also confirmed in RAW 264.7 murine 
macrophages with Commd1 deficiency secondary to stable shRNA (Figure S3).  However, 
Commd1 deficiency in BMDM cells led to increased expression of several NF-kB inducible 
genes (Figure 3B, left).  Interestingly, while Commd1 can inhibit hypoxia-dependent gene 
expression during development and in cancer cell lines22, 24, BMDM cells did not demonstrate 
significant differences in hypoxia-induced expression of several genes (Figure 3B, right).  
Similarly, expression of IFN-g inducible genes seemed unaffected in Commd1 deficient 
BMDM cells (Figure S4).  Altogether, these data indicate that Commd1 deficiency leads to 
increased NF-kB dependent gene expression, which in turn probably explains the increased 
inflammatory response seen in mice after LPS exposure.  
Commd1 deficiency leads to more severe mucosal inflammation 
 We decided to extend these observations to other models of inflammation where 
innate immunity plays an important role.  Therefore, we examined mucosal inflammation in 
response to dextran sodium sulfate (DSS), a chemical agent that triggers mucosal 
inflammation that is driven by an innate immune response to luminal bacteria27.  The 
experiments were performed in a blinded fashion and disease severity was determined over a 
10-day period while mice were receiving DSS.   Mye-K/O mice demonstrated a more severe 
disease course (Figure 4A), with excess mortality, more pronounced weight loss, and more 
severe disease activity index.  In agreement with this finding, the colon length in these 
animals, a macroscopic marker of tissue injury, was significantly shorter, and blinded 
histologic evaluation for tissue injury also indicated more severe damage (Figures 4B and 
4C).  Myeloid and lymphoid populations in the MLN (Figure 4D) and the spleen (not shown), 
were not significantly different between the groups.  However, immunohistochemistry for the 
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macrophage marker CD68 demonstrated higher numbers of myeloid cells in the mucosa of 
Mye-K/O mice, consistent with the more severe disease course and greater tissue injury 
(Figure 4E).   
Mye-K/O mice did not display preferential M1 activation 
 Macrophage differentiation can lead to a classically activated phenotype (M1) 
characterized by robust production of pro-inflammatory cytokines and reactive oxygen 
species.  In addition, macrophages can differentiate into various alternatively activated 
phenotypes (M2) that generally promote tissue repair, and in specific contexts, can promote 
tumor growth or participate in anti-parasitic responses28.  Therefore, as a potential explanation 
for the differences in mucosal inflammation, we examined whether Mye-K/O mice displayed 
alterations in the balance of the M1/M2 polarity in vivo.  To that end, the expression of M1 
and M2 markers in the inflamed colonic mucosa DSS-treated mice was examined by qRT-
PCR.  Consistent with the more severe injury noted in Mye-K/O mice, these animals 
displayed increased expression of pro-inflammatory genes, such as Il6, Il1b and Cxcr4 
(Figure 4F).  Next, we observed increased expression of the pan-macrophage marker Emr1 
(also referred to as F4/80), in agreement with the tissue immunohistochemistry demonstrating 
greater numbers of CD68+ cells (Figure 4F).  The M1 differentiation marker Nos2 was also 
significantly elevated in Mye-K/O animals.  On the other hand, M2 differentiation markers 
such as Renlta (also referred to as Fizz1) and Mrc1 (also known as Cd206) were significantly 
elevated as well (Figure 4F).  Altogether, the increase in both M1 and M2 differentiation 
markers suggested that the balance between M1 and M2 differentiation was not dramatically 
perturbed in Mye-K/O mice, but that the increased expression of these genes is likely due to 
the overall increase in macrophages in the mucosa (demonstrated by both F4/80 mRNA 
expression and CD68 staining).    
8
	  11
Loss of Commd1 in myeloid cells promotes tumor development 
 Persistent colitis can promote cancer development in patients with inflammatory 
bowel disease29, which can be modeled in rodents by repeated bouts of DSS-induced colitis30.  
This leads to dysplasia and locally invasive tumors, particularly if the animals are pre-treated 
with low doses of the carcinogen azoxymethane (AOM).   Myeloid activation of NF-kB plays 
a critical role in this model of colitis-associated cancer31 through the expression of a variety of 
factors that work in a paracrine fashion to promote tumor growth32.  Therefore, we examined 
the propensity of Mye-K/O mice to develop colonic dysplasia after a 50 day treatment course 
(Figure 5A and 5B).  Macroscopically, the animals had shorter colons and larger spleens, both 
gross markers of chronic colitis in rodent models (Figure 5C and 5D).  Moreover, blinded 
histologic evaluation of the colonic tissue demonstrated greater chronic inflammatory injury 
(glandular distortion, Figure 5C), as well as greater dysplasia, high grade dysplasia and 
multifocal dysplasia in Mye-K/O mice (Figure 5C and 5E).  Altogether, these results indicate 
that Commd1 not only restricts pro-inflammatory myeloid responses, but also limits the tumor 
promoting capabilities of this cell population.   
Inflammatory disorders are associated with decreased COMMD1 expression 
 To examine the relevance of our findings to the pathogenesis of human disease we 
decided to evaluate COMMD1 gene expression in various inflammatory states.  First, we 
observed that the expression of COMMD1 is decreased in circulating leukocytes from patients 
with inflammatory bowel disease (IBD) when compared to unaffected control individuals, 
both at the mRNA level (Figure 6A) and at the protein level (Figure 6B).  Moreover, 
consistent trends were observed in colonic mucosal samples from patients with IBD (Figure 
S5A) and in ileal mucosal samples from patients with Crohn’s disease (Figure S5B), where 
COMMD1 and other COMMD genes were suppressed in the setting of inflammation.  Other 
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mucosal inflammatory conditions also revealed a similar pattern; for example, inflammation 
in the small intestine in patients with celiac disease also led to decreased COMMD gene 
expression (Figure S5C) where the degree of suppression correlated with histological severity 
according to the Marsh score.  Altogether, these findings indicated that various inflammatory 
disorders in humans are associated with decreased COMMD gene expression.   
Given the heterogeneity of these processes, we reasoned that COMMD gene 
suppression was probably secondary to inflammation itself, rather than an initiating event.  To 
test this possibility, we examined the effect of acute colitis on Commd gene expression in 
normal C57BL6 mice.  Murine colitis induced by DSS led to decreased Commd gene 
expression in the colon (Figure 6C), which correlated with reduced Commd1 and Commd9 
protein levels in the colon at the end of the 10-day course of DSS treatment (Figure 6D).  
These data indicate that inflammation can lead to COMMD gene suppression, a process 
observed in clinical situations. 
Interferon-g   suppresses COMMD gene expression 
  Next, we examined the mechanism by which COMMD gene expression is repressed in 
the setting of inflammation.  Similar to the results observed in patients with inflammatory 
disorders, we found that LPS could induce COMMD gene suppression in whole blood of 
normal individuals (Figure S6).  This was recapitulated in mouse splenocyte cultures (Figure 
6E, left), where the effect was most pronounced for Commd10 and was dependent on Myd88, 
as splenocytes isolated from Myd88-/- mice did not display Commd10 gene suppression 
(Figure 6E, right).  As expected, Myd88-/- splenocytes lacked induction of Il6 and Infg (Figure 
S7).   
Despite its effect on whole blood or splenocytes, LPS and other stimuli such as TNF, 
IL-1b, or TGF-b1 did not cause COMMD gene suppression in a variety of cell lines, including 
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RAW 264.7 macrophages (Figure S8A).  This suggested that perhaps a product produced in 
response to LPS by blood cells or splenocytes could be responsible for COMMD gene 
suppression in an indirect paracrine fashion.  In this regard, careful evaluation of the timing 
required for Commd suppression in splenocytes indicated that Commd1 and Commd10 
suppression is a delayed phenomenon that coincides with the induction of IFN-g in these cells 
(Figure S9).  Notably, LPS stimulation of RAW macrophages did not result in Ifng induction 
(Figure S8B), but direct stimulation of splenocytes or RAW macrophages with IFN-g led to 
repression of Commd genes that was comparable to the effects of LPS (Figure 6F).  
Altogether, these studies suggest that IFN-g production is likely responsible for COMMD 




 In this study we demonstrate that COMMD1 plays an important role in the regulation 
of inflammatory responses in vivo.  Given that diverse functions21, 33-37 and in vivo 
phenotypes20, 22, 24, 25 have been reported for this gene, our studies fill a critical void by 
underscoring that COMMD1 also participates in immune regulation.  The data also support 
the role for COMMD1 as a negative regulator of NF-kB through RelA ubiquitination10, 13, 14, 
17, 19.   The increased propensity to colitis that results from Commd1 deficiency coupled with 
the decreased expression of this gene in IBD patients suggests a potential role for COMMD1 
in the pathogenesis of this disorder.  Although COMMD1 itself has not been implicated in 
IBD pathogenesis so far, its associated co-factor for RelA ubiquitination, Cul2 (encoded by 
the CUL2 gene), has been recently reported as a risk allele in genetic studies38.   
An important question to be resolved is why seemingly diverse cellular functions have 
been assigned to a single protein, and whether such convergence has deeper biological 
meaning.  While the molecular mechanism that links these different activities has not been 
completely unveiled, protein ubiquitination leading to degradation or trafficking along the 
endocytic pathway has been demonstrated in a number of instances23, 34, 36.  With this in mind, 
it is interesting to note that other factors that participate in protein ubiquitination are also at 
the convergence point of seemingly unrelated cellular pathways, as is the case for b-TrCP and 
other ligase cofactors39.  Hence, the convergence of diverse targets and cellular functions on 
COMMD1 might represent part of larger paradigm that still needs to be better understood.  
Our studies also identified that inflammation can lead to suppressed expression of 
COMMD1 and other COMMD genes.  Similar alterations in gene expression were evident 
when examining the primary data from a large study of differentially regulated genes in 
leukocytes of patients with IBD40, where decreases in COMMD3 and COMMD4 were noted.  
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The data indicate that this is likely the consequence rather than the cause of inflammation in 
human disease, because this suppression can be induced by inflammation itself in animal 
studies.  Moreover, the disparate nature of the disorders in which this phenomenon was 
observed suggests that this is not likely to be a primary genetic alteration, but rather a 
consequence of inflammation.  This decrease in COMMD1 expression probably plays a 
physiologic role in the initiation of an appropriate inflammatory response.  Nevertheless, in 
view of the more severe inflammatory responses seen in Commd1 deficient mice, persistent 
COMMD1 suppression might promote more severe inflammatory responses in human disease.   
Moreover, polymorphisms in the COMMD1 gene that could affect its expression in the setting 
of inflammation might play a role in the genetic susceptibility to IBD and other inflammatory 
disorders. 
Our studies demonstrate that COMMD gene suppression can be induced by IFN-g, a 
cytokine that is potently induced in many inflammatory disorders.  Interestingly, decreased 
expression of COMMD1 has also been found in a variety of tumors, where the degree of 
suppression correlates with poor outcomes, including decreased survival22.  Those studies also 
demonstrated that neoplastic and non-neoplastic cells in the tumor display decreased 
COMMD1 expression, suggesting that signals present in the microenvironment are 
responsible.  Therefore inflammation, which is regarded as one of the cardinal characteristics 
of cancer41, could be playing a role in COMMD1 repression in this setting.  Moreover, the 
data here indicate that decreased COMMD1 expression in non-neoplastic cells, specifically in 
myeloid cells, may be similarly important in promoting tumor progression in the setting of 
colitis-associated cancer.  Thus, decreased COMMD1 expression in the setting of cancer can 
have cell-autonomous and non-cell autonomous effects that promote tumor growth and 
progression.  Finally, our work highlights the need to gain a refined understanding of the 
molecular events that control COMMD1 gene expression in the setting of inflammation.  With 
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this knowledge we may begin to envision potential interventions that might restore gene 
expression.  If such an approach were available, it could be of therapeutic potential in chronic  




Mouse strains:  Mice were maintained in ventilated microisolator cages in barrier facilities 
with irradiated standard diet.  All animal procedures were approved by the UT Southwestern 
Medical Center Animal Care and Use Committee.  To generate myeloid specific Commd1 
deficient mice (Mye-K/O), animals carrying the conditional Commd1 allele25 (‘floxed’ 
Commd1 or Commd1F/F) were mated with the LysM-Cre mice26 (obtained from the Jackson 
laboratory, stock no: 004781).  
Cell lines and tissue culture: RAW 264.7 macrophages were obtained from ATCC and 
maintained in high-glucose DMEM containing 10% FCS.  Mouse embryo fibroblasts (MEFs) 
obtained at E13.5 were immortalized by lentiviral delivery of E1A and Ras, as previously 
described42.   These cells were maintained in high-glucose DMEM containing 10% FCS and 
subsequently infected with an adenovirus encoding Cre recombinase or a control virus 
expressing LacZ (Vector Core, University of Michigan Medical Center).  Bone marrow cells 
were harvested from long bones and cultured in RPMI media supplemented with 10% FCS, 
antibiotics (penicillin G 100µg/mL and streptomycin 100µg/mL) and  Fungizone (Fisher), in 
the presence of GM-CSF	  (20ng/ml, Peprotech).  After myeloid differentiation for 10 days, the 
cells were treated with LPS (10ng/mL, Escherichia coli 026:B6, Sigma), mouse IFN-
g (100U/mL, Roche), or TNF (10ng/mL, Invitrogen), as indicated in each experiment.  The 
cells were also cultured under 3% oxygen in HeraCell incubators for specific experiments.  
Mouse splenocytes and thymocytes were placed in RPMI containing 10% FCS prior to 
stimulation with LPS or murine IFN-g. 
Lentiviral mediated shRNA of Commd1:  Recombinant lentiviral particles were prepared as 
previously described43, 44.  The target sequences in the Commd1 mRNA used for RNA 
interference are the following: shRNA Commd1-1: ATGAAGTTAAAGTCAAGCAA, and 
shRNA Commd1-2: GTCTATTGCATCTGCAGACAT.   
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Sepsis model:  LPS (Escherichia coli 055:B5, Sigma) was diluted in water to 0.2mg/mL and 
placed in a water bath sonicator for 15-30 min at room temperature (RT) prior to use (Model 
FS20, Fisher).  After sonication, LPS was filtered (0.2 m pore) and injected intraperitoneally 
(0.1mg/mouse). After injection, the mice were individually housed and monitored for 
morbidity every hour for the first 4-6 hours, then every 2 hours for the next 6 hours, and 
finally every 4-6 hours until the conclusion of the experiment (Table S1).  The investigators 
were blinded to the genotype of individual mice until data analysis.  Mice were monitored 
hourly if they developed moderate distress (morbidity score of 5).   At the end of the 
experiment, or at any point when the animals demonstrated severe morbidity (score of 3 in 
any individual category of the morbidity index), they were euthanized and various organs 
(spleen, kidney and lung) were harvested for RNA extraction as described below.  Blood was 
also collected through orbital puncture, and plasma was separated using EDTA (5mM) and 
stored at -80ºC. 
Acute and chronic DSS-induced colitis:  For the acute colitis model, dextran sulfate sodium 
salt (DSS, Fisher) was administered in the drinking water at a concentration of 3g/dL (3%).  
Freshly prepared DSS drinking solution was replaced every 5 days.  Mice were housed in 
individual cages and evaluated daily for their weight and presence of diarrhea or bleeding to 
calculate a disease activity index (Table S2), which was based on the scoring system reported 
by Cooper and colleagues45.  Evaluation for occult bleeding included Hemoccult® testing 
(Beckman Coulter).  Age- and sex-matched littermates receiving water without DSS served as 
controls.  Treatment was given for up to 10 days and animals demonstrating severe distress 
were euthanized at any point prior to the conclusion of the experiment.  At the end of the 
experiment or at time of euthanasia, the colon was dissected and opened along the mesenteric 
side.  The open colon was transected longitudinally with one half rolled onto itself as a ‘swiss 
roll’ and fixed in 4% PFA (in PBS).  After paraffin embedding and sectioning, the tissue was 
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stained with hematoxylin and eosin (HE).  The second half was used for RNA extraction as 
described below.  For the chronic colitis and cancer model, the animals were given 
azoxymethane (AOM, 10mg/kg) intraperitoneally (Sigma).  After 7 days, DSS was given in 
the drinking water over 5 days at a concentration of 2.5% followed by 10 days of regular 
water.  This was repeated for 3 cycles and at the end of 49 days, the animals were euthanized, 
and the spleen and colon were harvested.  The organ length and weight were determined and 
the colon was opened along the mesenteric side, rolled onto itself as a ‘swiss roll’, and stained 
as before with HE for histology.     
Histology and immunohistochemistry:  A histologic severity index was utilized45 to score the 
HE stained colonic sections from mice with acute DSS colitis (Table S3).  For specimens 
from the chronic colitis and cancer model, the presence of glandular distortion, low-grade or 
high-grade dysplasia, multifocal dysplasia, and invasion was determined by standard 
pathological criteria.  All of this analysis was performed by a gastrointestinal pathologist in a 
blinded fashion.    For CD68 staining, we first generated tissue microarrays.  For the acute 
colitis model, random colonic tissue cores were extracted for each mouse from prior paraffin 
blocks. After constructing the microarrays, 5 m sections were subjected to CD68 staining at a 
1:25 dilution (Clone F8-11, Biolegend) by the immunohistochemistry core laboratory at UT 
Southwestern.  Images were then analyzed using the ImageJ software. 
Protein extraction, immunoblotting and immunoprecipitation: Cell lysate preparation, 
immunoprecipitations and immunoblotting were performed as previously described16, 46.  
Mouse tissues were harvested and snap frozen in liquid nitrogen. After mincing with a razor 
blade, tissue pieces were submerged in lysis buffer (50mM Tris-Hcl pH+ 7.5, 250mM NaCl, 
3mM EDTA, 3mM EGTA, 1% Triton X-100, 0.5% NP40, 10% glycerol, 25mM Na-
pyrophosphate) supplemented with protease inhibitor tablets (Roche).  Thereafter, tissue 
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homogenization in lysis buffer was performed using a 2mL Douncer and a cleared lysate 
(supernatant after 10,000g centrifugation), was used for further analysis. 
RNA extraction and quantitative real-time RT-PCR: RNA was extracted from cells and 
tissues using Trizol (Invitrogen) according to the manufacturer’s instructions. In the case of 
colonic RNA from colitic mice we obtained much better results by first stabilizing the freshly 
isolated tissue in RNAlater (Qiagen), followed by RNA extraction using the RNeasy 
chromatography method (Qiagen), according to the manufacturer’s instructions.  RNA (5µg) 
was used for cDNA synthesis using the Superscript III strand synthesis system (Invitrogen).  
Real-time PCR was performed in an Eppendorf real time PCR system (Eppendorf).  Most 
assays were based on gene specific primers and SYBR Green Mix (Invitrogen), as noted in 
Table S4.  Experiments were performed in triplicate, data were normalized to housekeeping 
genes and the relative abundance of transcripts was calculated by the comparative ΔΔCt 
method.   
Flow cytometry:  Spleen or mesenteric lymph nodes (MLN) were freshly isolated and placed 
on a sterile tissue culture dish containing RPMI.  The tissue was manually ground and 
strained through a 40  m tissue strainer.  After centrifugation (300g for 5 minutes at 4ºC), the 
cell pellet was resuspended in 2mL of ACK buffer (150mM NH4Cl, 10mM KHCO3, 0.1mM 
EDTA, pH+ 7.2) to lyze red blood cells.  After 3 minutes at RT, the ACK lysis was 
neutralized by adding 10mL of FACS media buffer (0.01% Sodium azide, 2.5% FCS in PBS).  
This cell suspension was strained again through the tissue strainer to obtain a single cell 
suspension, which was pelleted by centrifugation.  The splenocytes were resuspended in 2mL 
of FACS media buffer and the cells from the MLN were resuspended in 600 L.  For antibody 
staining, 100 L of each cell suspension was incubated on ice with the following primary 
antibodies: anti-B220-PE (BD Pharmingen), anti-CD3-PE (BD Pharmingen), anti-CD4-perCP 
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(BD Pharmingen), anti-CD8a-APC (BD Pharmingen), anti-Ly6G-APC (eBioscience), anti-
Ly6C- PerCP-Cy5.5 (eBioscience), anti-CD11C-APC (BD Pharmingen), anti-CD11b-PE 
(eBioscience), anti-F4/80-FITC (eBioscience) and corresponding isotype controls.  After 30 
minutes, the cells were pelleted by centrifugation (300g for 5 minutes at 4ºC) and washed 
twice in 500 L of FACS media buffer.  Flow cytometric analysis was performed using 
FACSCalibur (BD Biosciences, Mountain View, CA) and analyzed using FlowJo software. 
Multiplex cytokine measurements.  EDTA-Plasma was separated from blood samples by 
centrifugation and stored at -80°C until analysis.  These samples were then processed for 
cytokine measurements using Milliplex MAP beads (Millipore) for quantitation of IL-10, IL-
6, CCL5 and TNF, according to the manufacturer’s instructions.    
Human studies:	  All procedures involving human subjects were reviewed and approved by the 
respective Institutional Review Boards.  The analysis of COMMD gene expression in the 
setting of sepsis was performed at UT Southwestern, while the examination of COMMD gene 
expression in inflammatory bowel disease was performed at Tel Aviv Sourasky Medical 
Center.  The analysis of COMMD gene expression in celiac disease was performed at UT 
Southwestern Medical Center from samples obtained at UMC Groningen.  Circulating 
leukocytes were isolated from patients with IBD and RNA was isolated using the Trizol 
method as described above.  In the case of intestinal tissue, this was obtained during 
endoscopy which was performed as part of medical care.   
Statistical analysis:  In all graphs, the mean is presented and the error bars correspond to the 
standard error of the mean (SEM).  All statistical comparisons between values in the study 
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Figure 1: Commd1 deficiency impairs RelA ubiquitination.  (A) Commd1 deficiency in 
MEFs after adenoviral delivery of Cre.  MEFs from Commd1 floxed embryos were isolated, 
immortalized and then transiently infected with adenoviral particles expressing Cre 
recombinase or a LacZ control virus.  A western blot for Commd1 is shown here.  (B)  RelA 
ubiquitination in Commd1 deficient MEFs.  After preparation of nuclear extracts, the lysate 
was denatured by boiling and RelA was immunoprecipitated.  The material was 
immunoblotted for ubiquitin to detect ubiquitinated RelA.  (C) Exaggerated gene induction 
after TNF.  MEFs were treated with TNF and expression of Il6 and Tnf was determined by 
qRT-PCR.  (D) Commd1 deficiency in myeloid cells.  Commd1 levels were determined by 
western blot in lymphocyte populations (primary thymocytes and non-adherent splenocytes) 
as well as in bone marrow cells or splenocyte-derived myeloid cells.  Floxed Commd1 mice 
that also carried the LysM-Cre gene demonstrated myeloid specific Commd1 deficiency 
(Mye-K/O).  (E)  Myeloid deficiency of Commd1 induced a minimal elevation of WBC (left), 
with no specific skewing of leukocyte populations (right).  (F)  Spleen and MLN populations 
were not affected in Mye-K/O mice.  Various cell populations were determined using flow 
cytometry for the indicated surface markers. 
Figure 2: Mye-K/O mice have a more severe sepsis response.  (A) and (B)  Mye-K/O mice 
(Commd1 F/F, LysM-Cre) have greater morbidity and mortality compared to wild-type (WT) 
littermate controls (Commd1 F/F) after intraperitoneal LPS administration.  (C) Plasma levels 
of tissue enzymes were elevated in Mye-K/O mice.  (D) Plasma levels of cytokines were 
similarly elevated. (E), (F) and (G) Expression of various NF-kB target genes in tissues was 
determined by qRT-PCR.  In (E), expression of Tnf was determined in 3 different organs.  The 
rest of the analysis was performed in kidney tissue.  
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Figure 3: Commd1 deficiency leads to exaggerated pro-inflammatory gene expression.  
(A) Bone marrow derived myeloid (BMDM) cells did not exhibit alterations of NF-kB 
activation or IkB turnover.  These cells were stimulated with LPS and the kinetics of IkB-a 
phosphorylation and degradation were examined by western blotting.  (B) BMDM cells were 
stimulated with LPS and gene expression was determined by qRT-PCR (left column).  
Similarly, gene induction by hypoxia was also examined (right column). 
Figure 4: Myeloid deficiency of Commd1 predisposes to more severe acute colitis.  (A) 
Worse survival, weight loss and disease activity index (DAI) were noted in Mye-K/O mice 
(Commd1 F/F, LysM-Cre) compared to wild-type littermate controls (Commd1 F/F).  (B) Colon 
length was significantly shorter in Mye-K/O mice after acute colitis.  (C) Worse tissue injury 
was also evident histologically.  Using a severity score, colonic sections were examined in a 
blinded fashion.  (D) Lymphocyte and myeloid populations were not substantially different in 
the MLN of Mye-K/O mice compared to controls.  Flow cytometry was utilized to identify 
the indicated cell populations as before.  (E) Expansion of macrophage populations in the 
colonic mucosa of Mye-K/O mice.  A tissue microarray containing colonic samples from 
experimental animals was constructed, and subsequently stained for CD68 by 
immunohistochemistry.  The number of CD68+ cells present in the mucosa was assessed in a 
blinded fashion in microscopic images and the numbers were normalized to the surface area 
(expressed as microscopic fields).  (F) RNA extracted from colonic tissue was utilized for 
qRT-PCR analysis for the genes indicated. 
Figure 5: Mye-K/O mice show greater progression to colitis-associated dysplasia.  (A) 
Schematic representation of the experimental design.  (B) Weight during the course of the 
experiment is presented.  (C) Greater severity of colitis and dysplasia was noted in Mye-K/O 
mice.  Colon length, spleen weight, and glandular distortion histologically indicated more 
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pronounced chronic inflammation in Mye-K/O mice.  Similarly, blinded evaluation of 
dysplasia also indicated more severe disease in Mye-K/O mice.  (D) and (E) Images of the 
spleen are shown in (D), and representative microphotographs of dysplasia are shown in (E).   
Figure 6: Inflammation and IFN-g  repress COMMD1 expression.  (A) COMMD1 gene 
expression was decreased in circulating leukocytes from patients with IBD (n=13, 10 with 
Crohn’s disease and 3 with ulcerative colitis) compared to normal controls (n=8).  (B) Similar 
reduction in COMMD1 protein levels was noted in western blots from leukocytes of IBD 
patients (n=5, 3 with Crohn’s disease and 2 with ulcerative colitis), compared to healthy 
controls (n=4) (C) and (D) Commd gene expression was similarly decreased in colonic tissue 
after DSS-induced acute colitis as shown in (C), and this was demonstrated at the protein 
level for Commd1 and Commd9 in (D).   (E) LPS induces Commd gene suppression in a 
Myd88 dependent manner.  Freshly isolated splenocytes were treated with LPS for 24 hours 
and the expression of Commd genes was determined by qRT-PCR (left).  A similar 
experiment comparing the effects of LPS on Commd10 expression was performed using WT 
or Myd88-/- splenocytes (right).  (F) IFN-g stimulation of splenocytes or RAW 264.7 
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WT K/O p value
AST (IU/L) 122 161 0.012
ALT (IU/L) 63 74 0.265
CPK (IU/L) 230 370 0.030
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Colon length (cm) 8.7 8.2 0.03
Spleen weight (mg) 111 138 0.008
Glandular distortion (%) 35 90 0.0006
Dysplasia (%) 73 100 0.01
High grade dysplasia (%) 15 42 0.002
Invasion (%) 8 15 0.8
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Figure S1. Generation of Commd1 deficient fibroblasts. (A) Schematic
representation of the position of LoxP sites in the Commd1 gene, and the position of
primers used to detect recombination of this allele. (B) Murine embryonic fibroblasts
from Commd1WT/WT, Commd1WT/F and Commd1F/F mice were infected by an adenovirus
expressing Cre (+) or a LacZ control virus (-). Recombination in the Commd1 gene was
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Figure S2. Immune cell 
populations were not significantly 








104 compared to WT controls. Flow 
cytometry immunophenotypic
analysis of splenocytes was 
performed using markers for 
granulocytes (Ly6G+), macrophages 
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Figure S3. Commd1 deficiency did not significantly affect Tlr4 dependent
activation of the NF-κB pathway. RAW264.7 cells were infected with lentiviral particles
to stably express 2 different shRNA constructs targeting Commd1. These cells were
treated with LPS and cell lysates were subjected to western blot analysis. Comparable
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Figure S4. Commd1 deficiency did not substantially affect interferon inducible
gene expression. Bone-marrow derived myeloid cells were stimulated with IFN-γ and
expression of Oas2 and Stat1 was determined by qRT-PCR. Commd1 deficiency did
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Figure S5. COMMD gene suppression was found in inflammatory diseases of the
gastrointestinal tract. (A) Expression of COMMD genes in endoscopic biopsies of the
colon was determined by qRT-PCR in patients with IBD (n=28, 17 with Crohn’s disease
and 11 with ulcerative colitis) and compared to normal individuals (n=13). (B)
Expression of COMMD genes in endoscopic biopsies of the ileum was determined by
qRT-PCR in patients with Crohn’s disease (n=7) and compared to normal individuals
(n 4) (C) Decreased COMMD gene expression was also noted in small intestinal= .
biopsies from patients with celiac disease compared to controls (pools of 5 patient



























Figure S6. LPS induce COMMD gene suppression. LPS stimulation of blood cells


































Myd88: WT K/O WT K/O
Figure S7. Splenocytes from Myd88-/- mice failed to respond to LPS stimulation. LPS-


















































LPS(h): 0 8 12 24
0.0 0 h 8 h 12 h 24 h
Figure S8. LPS fails to induce Commd gene suppression in the absence of Ifng
induction. (A) Stimulation of RAW264.7 macrophages with LPS, TNF, IL-1β, or TGF-β1
failed to induce suppression of 2 representative Commd genes. (B) These cells do not
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Figure S9.  Ifng induction is temporally correlated with Commd gene suppression 
in splenocytes. LPS-induced Commd1 and Commd10 suppression , along with Ifng
induction, were determined over a time course by qRT-PCR.
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Table S1: Morbidity score for the LPS model of sepsis
APPEARANCE
0 Normal 
1 Lack of grooming
2 Coat rough, possible nasal or ocular discharge




2 Respiratory rate altered, respiratory depth altered, skin tents       




2 Abnormal behavior, less mobile, less alert, inactive when activity expected
3 Paralysis, inability to remain upright, shivering, convulsion
Total score: Sum of (Domain scores) for each domain in the scoring system
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Table S2: Disease activity index in the acute DSS colitis model
WEIGHT
0 Unchanged 
1 Loss of 1-5%
2 Loss of 6-10%
3 Loss of 11-20%
4 Greater than 20% weight loss
STOOL CONSISTENCY
0 Normal 
2 Loose stools (not watery)   
4 Diarrhea (liquid stool)
BLEEDING
0 None 
2 Hemoccult positive stools
3 Visible blood on stool
4 Gross bleeding per rectum
Total score: Sum of (Domain scores) for each domain in the scoring system
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Table S3: Histologic score for the acute DSS colitis model
DOMAIN INVOLVEMENT
A) CRYPT LOSS  
0 Intact 
1 Loss of basal one-third of crypt
2 Loss of basal two-thirds of crypt 
3 Loss of entire crypt
4 Erosion (loss of entire crypt and surface 
epithelium) 
B) CRYPT DISTORTION
1 1-25% of surface
2 26-50% of surface 
3 51-75% of surface
4 76-100% of surface
  
0 None
1 Basal one-third of crypt
2 Basal two-thirds of crypt 
3 Entire crypt








1 Basal one-third of crypt
2 Basal two-thirds of crypt 
3 Entire crypt
4 Entire crypt and surface epithelium
Total score: Sum of (Domain score x involvement score) for each domain in the scoring system
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Mouse genes
Gene target Sense primer Antisense primer Reference
Actb GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT This study
Adm TCCGAAAGAAGTGGAATAAGTGG GTCCCGTAGGGTAGCTGCT PrimerBank ID 6752987b2
Table S4: Primer sequences used in quantitative PCR analysis
  
Ccl5 GTGCCCACGTCAAGGAGTAT CCCACTTCTTCTCTGGGTTG Ramirez-Carrozzi, et al6
Cd40 TCACCATTTTCGGGGTGTTTC CCGCAGGGGGTAACATCTC PrimerBank ID 6755829a1
Chi3l3 ATCTATGCCTTTGCTGGAATGC TGAATGAATATCTGACGGTTCTGAG Zhao, et al7
Commd1 TGGCGAAGATGAGAGGACTT GTGATGCCACCTTGCTTTTT This study
Commd2 Taqman primer and probe set from Applied Biosystems
Commd3 Taqman primer and probe set from Applied Biosystems
Commd4 Taqman primer and probe set from Applied Biosystems
Commd5 Taqman primer and probe set from Applied Biosystems       
Commd6 Taqman primer and probe set from Applied Biosystems
Commd7 Taqman primer and probe set from Applied Biosystems
Commd8 Taqman primer and probe set from Applied Biosystems
Commd9 CCTCCTCTGACAACATCAGC GGAGGGTTTCTCTCCACAC This study
Commd10 TGAGAAGTTCCGCCAGAG TTGCTCACTCCCAGTTGC This study
Cxcl1 TGTCAGTGCCTGCAGACCAT GTGGCTATGACTTCGGTTTGG Ramirez-Carrozzi, et al6
Cxcr4 GACTGGCATAGTCGGCAATG AGAAGGGGAGTGTGATGACAAA PrimerBank ID 16268122b1
Emr1 AAAGACTGGATTCTGGGAAGTTTGG CGAGAGTGTTGTGGCAGGTTG Zhao, et al7  
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA This study
Ifng ACTGGCAAAAGGATGGTGAC TGAGCTCATTGAATGCTTGG Benson et al8
Il1b GCTGAAAGCTCTCCACCTCA AGGCCACAGGTATTTTGTCG Ramirez-Carrozzi, et al6
Il6 TGGATGCTACCAAACTGGAT GGACTCTGGCTTTGTCTTTC Moreno, et al9
Il12b AGCCACTCACATCTGCTGCT AACCGTCCGGAGTAATTTGG Ramirez-Carrozzi, et al6
Mrc1 TTTGGAATCAAGGGCACAGAG TGCTCCACAATCCCGAACC Zhao, et al7
Nfkbia CGCAGACCTGCACACCCCAG GGAGGGCTGTCCGGCCATTG Li, et al10
Nos2 CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG Ramirez-Carrozzi, et al6
Oas2 AAACCTCACACCCAACGAAAA CACCGAGGACACCGCAATC PrimerBank ID 29576888b1
Ptgs2 TGTGACTGTACCCGGACTGG TGCACATTGTAAGTAGGTGGAC PrimerBank ID 18130137b2
Rentla CCTCCACTGTAACGAAGACTCTC GCAAAGCCACAAGCACACC Zhao, et al7
Saa3 CTGTTCAGAAGTTCACGGGAC AGCAGGTCGGAAGTGGTT Moreno, et al9
Slc2a1 GGGCATGTGCTTCCAGTATGT ACGAGGAGCACCGTGAAGAT Mastrogiannaki, et al11
Stat1 TCACAGTGGTTCGAGCTTCAG CGAGACATCATAGGCAGCGTG PrimerBank ID 14326481b1
Tnf CCCCAAAGGGATGAGAAGTT TGGGCTACAGGCTTGTCACT Ramirez-Carrozzi, et al6
Tnfaip3 GGCAGCTGGAATCTCTGAAA CTGCAGGTGTGTCTGCTGAT Ramirez-Carrozzi, et al6
Vegfa CTTGTTCAGAGCGGAGAAAGC ACATCTGCAAGTACGTTCGTT PrimerBank ID 6678563a2
Human genes
Gene target Sense primer Antisense primer Reference
ACTB GCGGGAAATCGTGCGTGACATT GATGGAGTTGAAGGTAGTTTCGTG This study
COMMD1 GCAAATATGGACAGGAATC CAGAATTTGGTTGACTTTGAC Burstein, et al5
COMMD2 CTCAAAGCTCATGATTTC TGTCCAGATAAAGCTGAAG Burstein, et al5
COMMD3 TGACAGAGAGCGAATAGAAC TGCCTATACTTCCCAGTAG Burstein, et al5
COMMD4 CCAAGATGTCCTCTGTGAAG ACATCGCCTGACTCAAAC Burstein, et al5
COMMD5 ATACTGCGGGGCTTTTCC ATTGCTGCTGCTTCCTCTTT This study
COMMD6 CATTCAGGCCAAGTAAAG TAGAAATTCTGAAACTGTGG Burstein, et al5
COMMD7 GGCGCGCAGCAGTTCTCA CGATGCTTCTGAGGGAGCCAAG Burstein, et al5
COMMD8 GTTTGGGAATCAGAAGAATG GCTGAAATATCTCTTCATCAG Burstein, et al5
COMMD9 GTCGATCTGGACTGGAGAG TCTTCTTGGATCTTCATCTGG Burstein, et al5
COMMD10 TCTATGGGTCAAGAAACAG CGGTCTCTAGCTTACAGG Burstein, et al5
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General Discussion	  
Inflammation is a complex multicellular response to tissue injury that is genetically 
programmed and highly regulated (1, 2).  Its importance in physiology and disease 
pathogenesis cannot be overstated.  In fact, a large number of human diseases 
involve an inflammatory process either as the driving force that leads to tissue injury, 
or as a necessary contributor to the disease process.  As such, today it is recognized 
that inflammation plays a critical role in such disorders as the metabolic syndrome 
(3), atherosclerosis (2), and neurodegeneration (4) which have not been traditionally 
viewed as primary inflammatory disorders.  In addition, inflammation is now regarded 
as a cardinal characteristic of cancer, where it can play a critical role in initiating the 
neoplastic process or in promoting tumor growth and metastasis (1, 5, 6). 
Among the various mechanisms that orchestrate the inflammatory response, 
activation of the transcription factor NF-κB is a critically important event (6-8).  This 
transcription factor, initially identified through homology with the viral oncoprotein v-
Rel (encoded by the avian reticuloendotheliosis virus), consists of a family of 
polypeptides that form dimers and bind DNA through a homology domain termed the 
Rel homology domain or RHD (9).  In mammals, 7 polypeptides encoded by 5 genes 
(indicated in brackets) are recognized as the main NF-κB subunits: RelA, also 
referred to as p65 (RELA), c-Rel (REL), RelB (RELB), p50 and its precursor p105 
(NFKB1), and p52 and its precursor p100 (NFKB2).  While multiple heterodimer 
combinations have been described, the Rel proteins are the only ones that contain a 
transactivation domain capable of mediating gene expression.   
The classical or canonical NF-κB pathway is mediated primarily by RelA or c-Rel 
containing dimers, with the RelA/p50 heterodimer being particularly abundant (9).  
Under basal conditions, this pathway is inhibited by the so-called classical Inhibitors 
of kB (IκB-α, -β, and -ε), which bind to NF-κB dimers and prevent DNA binding and 
nuclear accumulation (10).  Canonical NF-κB activation can occur downstream of a 
variety of upstream signaling pathways that converge on the IκB kinase complex 
(IKK), resulting in phosphorylation and degradation of IkB proteins (11-13).  A related 
activation pathway for RelB containing complexes has been elucidated and termed 
the non-canonical NF-κB pathway in which RelB/p100 heterodimers are activated by 
IKKα-mediated phosphorylation of p100 and its proteolytic processing to p52 (14-17).   
Given its central role in NF-κB activation, the intricate signaling pathways and 
biochemical events that control IKK function have received great attention. On the 
other hand, the events responsible for terminating NF-κB dependent transcription 
have not been as extensively studied.  In this regard, it is known that NF-κB activates 
transcription of IkB encoding genes, thus resulting in expression of its own inhibitors 
(9).  Similarly, the IKK inhibitors A20 and CYLD are also encoded by NF-κB 
responsive genes (18, 19).  Therefore, NF-κB dependent transcription sets off a 
negative feedback loop that promotes a return to basal conditions.  In addition to this, 
work over the past decade has uncovered that DNA-bound active NF-κB subunits are 
actively removed by a ubiquitin dependent mechanism (20-25).  The identification of 
the ubiquitin ligase(s) responsible for this step in the pathway and its regulation have 
been the main areas of interest of my laboratory.  The cumulative evidence presented 
in this thesis indicates that COMMD1 is an essential cofactor for the ubiquitin ligase 
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responsible for NF-κB termination, and is physiologically important for inflammation 
and human disease. 
Ubiquitination, CRLs and the NF-κB pathway  
Ubiquitin is a highly conserved 76 amino acid polypeptide that can be conjugated 
to substrate proteins through an enzymatic machinery present in all eukaryotic cells. 
A sequential reaction involving 3 enzymes culminates in the transfer of the ubiquitin 
moiety to the target protein by an E3 enzyme, also referred to as a ubiquitin ligase. 
Through an isopeptide bond, a lysine residue on the target protein is linked to the 
carboxyl-terminal glycine of ubiquitin.  In a similar way, additional ubiquitin residues 
can be added onto ubiquitin itself to form polyubiquitin chains. Polyubiquitin chains 
formed onto Lysine 48 of ubiquitin direct the substrate for degradation by the 
proteasome, a multimeric protease complex (26). However, other lysine linkages 
result in different effects such as signaling activation or transcriptional regulation.  
A particularly prolific group of ubiquitin ligases are multimeric complexes 
containing at their core a protein of the Cullin family and the RING domain containing 
proteins Rbx1 or Rbx2 (27-29).  These complexes are referred to as Cullin RING 
ligases (CRL). A substrate binding complex (SBC) composed of 1 to 3 polypeptides is 
recruited to the amino-terminus of the Cullin protein.  Each of the Cullin proteins 
present in mammals (Cul1, Cul2, Cul3, Cul4A, Cul4B, Cul5, and Cul7) has a specific 
preference for particular SBCs (27).  For example, Cul1 and Cul7 interact with 
complexes containing the adaptor protein Skp1 and any of a multitude of F box 
proteins, while Cul2 and Cul5 interact with complexes containing the Elongin B and C 
polypeptides and any of several factors containing a BC box.   
CRLs regulate multiple transcription factors including NF-κB. In fact, the NF-κB 
pathway is regulated at various levels by ubiquitination steps and in particular, two 
CRLs have been linked to this pathway. A Cul1-containing CRL, the CRL1-bTrCP 
complex is responsible for ubiquitinating phosphorylated IkB proteins (30-34). This 
results in their proteasomal degradation, leading to the nuclear translocation of NF-kB 
complexes. As alluded before, ubiquitination of the NF-κB subunits themselves has 
been recognized as a mechanism of regulation in this pathway, as it is required for 
proper transcriptional termination. Work from our group and other laboratories has 
identified a Cul2-containing CRL as the ubiquitin ligase responsible for NF-κB/RelA 
degradation (21, 23, 24). 
COMMD1 is a required factor for NF-kB ubiquitination and signal termination 
In 2003, we reported that COMMD1, referred to at the time as Murr1, is an inhibitor 
of NF-κB dependent gene expression (35).  These studies were the result of a yeast 
two-hybrid screen for interacting proteins that bind to the anti-apoptotic factor XIAP 
(36).  Later work identified that COMMD1 binds to all NF-κB subunits through a 
conserved motif in the RHD (37).  The effects of COMMD1 on NF-κB activity lead to 
decreased pro-inflammatory gene expression (23, 35, 37) and have been similarly 
implicated in the ability of COMMD1 to inhibit HIV-1 replication (35). 
 We demonstrated that binding of COMMD1 to the NF-κB subunit RelA decreases 
the duration of RelA recruitment to promoter sites.  Interestingly, COMMD1 itself is 
also recruited to promoter sites in an inducible manner alongside with NF-κB (37).  
Based on this observation and reports at the time that ubiquitination controls 
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chromatin occupancy, we investigated whether COMMD1 plays a role in RelA 
ubiquitination.  Through a series of studies, we demonstrated that COMMD1 
promotes the ubiquitination of RelA, decreasing its half-life, particularly in the nuclear 
compartment (23).    
The mechanism by which COMMD1 promotes RelA ubiquitination is through its 
association with a Cul2-containing CRL. Work from Ryo and colleagues had identified 
that SOCS1 promotes the ubiquitination of RelA (21). This factor is devoid of intrinsic 
E3 activity but serves as substrate binding subunit for a Cul2-containing CRL.  
Therefore, we investigated whether COMMD1 might interact with Cul2, as well as the 
other components of the complex.  We found that to be the case, and moreover, 
found that COMMD1-mediated ubiquitination of RelA requires the expression of 
ligase subunits such as Cul2 (23).  Conversely, deficiency of COMMD1 greatly 
impaired the ubiquitination of RelA and promoted NF-κB mediated transcription in 
transformed cell lines, and more recently, in cells derived from Commd1 deficient 
mice (Li et al, submitted).  Interestingly, others have reported that certain viruses of 
the herpes family encode proteins that can associate with a Cul2 or Cul5 complex to 
form an active ligase targeting RelA for ubiquitination (38, 39).  This mechanism 
seems to provide the virus with the means to attenuate NF-kB activation and 
promotes completion of the viral cycle.   
The ability of COMMD1 to inhibit NF-κB mediated transcription has been 
independently replicated by other groups (24, 40, 41).  Moreover, the critical events 
that we described, namely the recruitment of COMMD1 to chromatin, its ability to 
promote RelA ubiquitination and its release from promoter sites have been similarly 
re-demonstrated by other laboratories.  Interestingly, there seems to be a correlation 
between the effects of COMMD1 on gene expression and its ability to be recruited to 
promoter sites, whereby genes that are not affected by COMMD1 levels do not 
demonstrate the presence of this factor in the promoter region, and vice versa (24).  
However, the mechanisms responsible for COMMD1 recruitment to chromatin, 
particularly in a gene selective manner, remain unknown. 
Identification of the COMMD gene family 
The discovery of COMMD1 as a regulator of NF-κB mediated transcription was 
nearly coincidental to the identification of this gene as a regulator of copper 
metabolism in mammals (42-47).  An effort by van de Sluis and colleagues to identify 
the gene responsible for an autosomal recessive form of copper toxicosis in dogs 
culminated in 2002 with the discovery of a large deletion in the MURR1 gene -today 
referred to as COMMD1- as the cause of this syndrome (42).  In parallel to those 
studies, we had already identified a family of 10 homologous factors present in a 
range of organisms from unicellular protozoa to humans (37).  These factors 
otherwise had no known function and were largely known only as ESTs.  In 
consultation HGNC, these genes were named “Copper metabolism MURR1 domain 
containing”, or COMMD, with MURR1 being renamed as COMMD1. 
All members in this family possess a carboxyl-terminal homology domain that is 
unique to this protein family (48).  This region is necessary and often sufficient to 
mediate critical protein-protein interactions.  For example, members of this protein 
family can bind to each other via their COMM domains (37).  The precise 
stoichiometry of these complexes is not known, and although the structure of the 
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amino-terminus of COMMD1 has been solved, the COMM domain has been more 
difficult to investigate due to its tendency to form insoluble aggregates when purified 
at high concentrations (49).   
The precise biological roles of most COMMD proteins remain largely unknown.  
Only five reports regarding COMMDs other than COMMD1 have been published to 
date and concern COMMD5 and COMMD6 function (41, 50-52).  We reported that 
other COMMD proteins share some properties with COMMD1, at least with regards 
to NF-κB regulation (37).  However, despite these similarities, the conservation of all 
10 members of this family along a great evolutionary canvas suggests that individual 
COMMD genes have unique and non-redundant functions. Consistent with this 
notion, Commd1 deficiency in mice is embryonic lethal by ~ E8.5 indicating that its 
deficiency cannot be compensated by other family members (53). Mutant embryos 
display abnormal placental vasculogenesis and inappropriate activation of the HIF 
pathway.  In preliminary studies, we have found that deficiency of Commd9 or 
Commd10 are also lethal during embryogenesis.  In each case, the defect is different 
and does not match the reported phenotype of the Commd1 knockout, highlighting 
their unique developmental functions.   
Post-translational modifications of NF-kB as triggers for the ubiquitination 
pathway 
One critical mechanistic aspect of the ubiquitination of NF-kB is how this process is 
targeted to active NF-κB subunits and how this is triggered at the right stage in the 
transcriptional response.  While the answer to this question is not complete, we and 
others have demonstrated that NF-κB/RelA phosphorylation plays a central role in 
this process.  Specifically, IKK dependent phosphorylation and modification of Serine 
468 are required to trigger RelA ubiquitination (24, 25).  Interestingly, Serine 536 
phosphorylation has been similarly implicated in myeloid cells (54), but whether this 
is linked to COMMD1-depedent ubiquitination remains unclear.   
The link between RelA phosphorylation on Serine 468 and its subsequent 
ubiquitination by a COMMD1-containing ligase was not initially evident.  In this 
regard, a tandem affinity purification scheme identified an interaction between 
COMMD1 and the histone acetylase GCN5.  Interestingly, GCN5 proved to be a 
suppressor of NF-κB dependent gene expression and it is able to promote RelA 
ubiquitination (25).  In this role, its acetylase activity is completely dispensable, but its 
interaction with COMMD1 and the CRL2 ligase seems critical.  One unique feature of 
GCN5 is its preferential binding to phosphorylated RelA, particularly at Serine 468.  
Thus, GCN5 serves a role similar to a substrate adaptor, being able to bind to the 
phosphorylated form of the substrate and thus bringing it into contact with the ligase 
for subsequent ubiquitination.  Altogether, this work highlighted the intricacy of the 
ubiquitination mechanism and demonstrated for the first time an acetylation-
independent role for GCN5.  In addition, more recent work highlights the fact that 
other post-translational modifications of lysine residues, such as acetylation, can 
compete with ubiquitination for the same residues and thus modulate protein stability 
(55).   
Despite these advances, a number of questions still remain.  For example, the 
gene specific nature of the regulation that this pathway offers, suggests that it is 
highly targeted.  We speculate that RelA ubiquitination is selectively induced on 
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specific gene promoters where COMMD1 is recruited.  However, the mechanism that 
mediates this selective recruitment is currently unknown and the post-translational 
modifications at play remain to be discovered.  Similarly, while IKK and Serine 468 
phosphorylation are clearly required for GCN5-RelA interactions in vivo, these are not 
sufficient to induce the above biochemical events in vitro, thus suggesting that 
additional post-translational modification may be at play.  Finally, up to this point all of 
our attention has been focused on RelA, the most abundant NF-κB subunit. 
Nevertheless, there is evidence that the same ligase components can trigger the 
ubiquitination of other NF-κB family members (23), suggesting other potential roles 
for COMMD1 in the regulation of NF-κB function. 
COMMD1 mediated regulation of CRLs 
Our work has also uncovered critical details of the molecular mechanism of action 
of COMMD proteins.  In this regard, the specific role of COMMD1 binding to CRLs 
remained unclear until recently.  Our initial studies suggested that COMMD1 can 
improve SOCS1-RelA interactions, and perhaps facilitate substrate recruitment (23).  
However, this failed to explain the broad interactions of COMMD1 with other Cullin 
family members.  In this regard, our most recent studies implicate COMMD1 and 
other COMMD family members in the activation cycle of CRL complexes (56).  CRL 
complexes undergo a cycle of activation characterized by sequential changes in 
complex composition and post-translational modifications. In its most active form, 
CRLs are bound to the substrate binding complex (SBC) and the Cullin protein is 
modified by neddylation, a post-translational modification with the ubiquitin-like 
modifier Nedd8 which promotes ligase activity (57). In addition, neddylation prevents 
binding of CAND1, a key CRL inhibitor that prevents recruitment of the SBC to the 
CRL (58-60).  The transition from the neddylated active state to the deneddylated and 
CAND1-bound state is mediated by the COP9 signalosome, a large protein complex 
that deneddylates Cullin proteins.   
Upon formation of a CAND1-Cullin complex, its dissociation and the initiation of 
the activation cycle are not well understood.  It is known that this event requires 
energy (ATP) and is promoted by the SBC, but the specific events involved are still 
poorly understood (59, 61).  Our recent work identified that COMMD1 is involved in 
this process (56).  COMMD1 and CAND1 compete for binding to a common and 
conserved domain among Cullin proteins.  Moreover, COMMD1 can displace CAND1 
from CRLs, thus promoting the initiation of the activation cycle.   
This work suggests a model in which COMMDs play a role in the activation of 
possibly hundreds of CRLs and therefore it predicts that these proteins can play vast 
biological roles beyond regulation of the immune response.  Indeed, this notion is in 
agreement with the diverse function already ascribed to COMMD1 (62) and the 
increasing complexity of roles that other COMMD genes likely play based on their 
unique developmental roles.   
Role of COMMD1 in inflammation and tumor progression 
A critically important question is to what extent COMMD1 plays a role in regulating 
inflammation in vivo.  Our studies using tissue-specific Commd1 deletion in mice are 
beginning to address this question.  The evidence indicates that this gene plays a 
critical anti-inflammatory role in the innate immune system.   In particular, we find that 
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deficiency of this factor in myeloid cells leads to a pro-inflammatory phenotype 
characterized by exaggerated cytokine induction in response to bacterial 
dissemination.   
Moreover, these mice also display a propensity to intestinal inflammation and its 
progression to dysplasia and cancer.  In this regard it is striking to note that 
individuals with inflammatory bowel disease (IBD), an idiopathic disorder 
characterized by chronic intestinal inflammation, display reduced COMMD1 
expression in peripheral leukocytes and in the intestinal mucosa.  Thus, IBD is a 
state of partial COMMD1 deficiency and the evidence from the myeloid knockout 
model would argue that this change in turn would foment the inflammatory process.  
Genetic evidence linking COMMD1 to IBD risk is still being explored but the 2p15 
region where COMMD1 resides has already been linked to the risk of IBD (63) and 
also ankylosing spondylitis (64-67), a chronic inflammatory process affecting mostly 
the spine that share genetic determinants with IBD.  In addition, firm data already 
links CUL2 to IBD risk (68), and as mentioned above, this gene encodes the main 
ligase component that works together with COMMD1 to control NF-κB activity.  
Therefore, we believe that these data altogether point to a role of this pathway in 
inflammatory disorders in humans, but additional work to cement its role is still ahead 
of us. 
In addition, the underlying mechanism by which IBD is associated with reduced 
COMMD1 expression remains incompletely understood.  However, the bulk of our 
data indicate that inflammatory mediators acting in the local environment probably 
mediate the changes in gene expression that we have observed.  In particular, our 
data indicate that IFN-γ can suppress COMMD1 expression.  In addition, similar 
changes in COMMD1 expression have been noted in a variety of malignancies, 
where reduced levels of COMMD1 mRNA correlated with a more invasive and 
aggressive tumor phenotype (69).  It is tempting to speculate that inflammation in the 
tumor microenvironment, a cardinal feature of cancer, may lead through a similar 
mechanism to reduced COMMD1 expression.  This is turn would facilitate the 
activation of NF-κB as well as HIF-1, and can have a variety of effects on cancer 
cells that increase their invasive potential (69).  Therefore, understanding the 
mechanisms that control COMMD1 expression and how to manipulate them for 
therapeutic purpose could one day have various beneficial applications. 
Future perspective 
COMMD1 is a multifunctional protein that participates in a variety of cellular 
process, all apparently linked at some level to protein ubiquitination, probably through 
CRL enzymes.  The aggregate of the data presented in this thesis clearly 
demonstrate the role of this gene in controlling inflammatory responses.  In this 
setting, COMMD1 plays an interesting role as a factor that facilitates termination of 
an initiated signal, by promoting the removal of active NF-κB dimers from chromatin.  
Thus, alterations in this mechanism would be expected to lead to a pathologic 
prolongation and accentuation of inflammatory responses, and our data suggests that 
indeed this is the case using animal models.   
Despite the progress that we have made, a number of critical questions remain 
unanswered and should be the focus of additional investigation in years to come.  I 
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will delineate the questions that I view as most pressing for this field in the few lines 
that follow: 
1) How is COMMD1 recruited to chromatin and is this required for its specific effects 
of certain NF-κB target genes?  At the present time, it is clear that the binding to 
chromatin by COMMD1 is induced by NF-kB activating stimuli with similar kinetics to 
that of NF-κB dimer binding.  In addition, we know that its recruitment to gene 
promoters is limited to certain targets and not others, but the basis for such specificity 
is not known.  Moreover, while there is limited data supporting the notion that 
COMMD1 recruitment to chromatin sites is a prerequisite for gene regulation by this 
factor (24), this is far from proven at a genomic scale.   An ongoing project in our lab 
is exploring the possibility that chromatin modification with SUMO marks might be the 
signal that brings COMMD1 to certain promoters.  This hypothesis is based on our 
recent identification of SUMO interacting motif in COMMD1, and we are currently 
examining this hypothesis using a variety of biochemical and genetic approaches.  
2) What mechanisms control COMMD1 expression in the context of inflammation and 
cancer?  I view this as a central question in the horizon, one that may be of 
significant translational potential.  Although there is still a lot to be explored here, we 
are examining transcriptional and post-transcriptional mechanisms that may operate 
downstream of IFN-γ and may control COMMD1 expression.  Validating those 
findings in vivo in the context of inflammatory and cancer models will be an important 
next step as well. 
3) Is there genetic evidence for a role for COMMD1 and its associated factors in 
inflammatory disorders?  As mentioned above, the general locus containing the 
COMMD1 gene is linked to inflammatory disorders, but additional work needs to be 
done to ascertain if COMMD1 itself is responsible for such associations.  Moreover, 
gene variants in CUL2 are linked to IBD risk, but whether they participate in IBD 
pathogenesis though effects on COMMD1 or on an unrelated pathway will need to be 
elucidated.   
4) What is the role of other COMMD family members, if any, in the inflammatory 
response? Despite our identification of this gene family 7 years ago, nearly nothing 
has been published on other family members and little is known about their function.  
Nevertheless, their strong conservation through evolution argues that each one of 
these family members probably plays non-redundant function.  In fact, we have 
generated mouse line deficient in Commd9 or Commd10 and in both instances, these 
genes proved essential for embryonic development.  In addition, recent studies from 
our laboratory have identified that COMMD1 and other COMMD family members bind 
to a common co-factor termed CCDC22 (Gluck et al, submitted).  Mutations in this 
gene have been identified in a large Australian family with X-linked intellectual 
disability (70).  Interestingly, a collaborative effort between our group and the 
geneticists that identified this mutation, indicates that these patients have alterations 
in NF-κB signaling.  In particular, we have identified that CCDC22, acting in concert 
with another COMMD family member - COMMD8 -, is required for the CRL-
dependent degradation of IκB.  Thus, the hypomorphic mutation in this family leads to 
impaired IkB degradation and defective activation of pro-inflammatory gene 
expression, and these findings can be recapitulated by RNAi-mediated silencing of 
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CCDC22.  These findings highlight the potential for additional roles for members of 
this family in the control of inflammatory responses.  
Finally, as these questions are tackled, we hope to gain a more complete 
understanding of how this factor plays a role in inflammation during physiologic 
responses and in disease states.  We hope that such knowledge will provide clues to 
devise potential strategies that might leverage this pathway for therapeutic purposes. 
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Inflammation is a genetically programmed cellular response to injury and pathogen 
invasion.  The NF-κB transcription factor is a central regulator of this response and 
plays a critical role in immunity.  As such, pathways that control its activity are 
intensely studied.  Most of the work in the field has focused on activation steps that 
initiate NF-κB dependent gene expression, primarily by activation of the IKK complex 
downstream of various signal transduction pathways.  Thereafter, homeostatic 
pathways that inactivate NF-κB and restore back the basal state are important to 
avert prolonged NF-κB responses and chronic inflammation.  However, this has 
received less attention in the field.    
Over the past few years it has been appreciated that ubiquitin-mediated degradation 
of active, DNA-bound NF-κB subunits plays an important role in controlling pro-
inflammatory gene expression.  This pathway constitutes a major mechanism to 
restore the basal state in the NF-κB system, but the mechanism responsible for 
mediating and regulating NF-κB ubiquitination was not initially apparent.  The work 
presented here has elucidated that COMMD1 is essential in this process and 
plays a regulatory role in inflammation in vivo. 
1) COMMD1 inhibits NF-κB dependent gene expression.  The gene repertoire under 
the control of COMMD1 includes a substantial number of pro-inflammatory genes.  In 
addition, COMMD1-dependent effects also regulate HIV-1 replication, a process that 
is linked to host cell NF-κB activity given the presence of kB sites in the HIV-1 viral 
genome.  As such, COMMD1 serves as a factor that mediates the resistance of naïve 
CD4+ cells to HIV-1 replication.  
2) The mechanism of COMMD1ʼs inhibitory activity on NF-κB can be ascribed to its 
ability to promote the degradation of nuclear and chromatin bound NF-κB/RelA.  This 
occurs through the binding of COMMD1 to NF-κB itself and to Cul2, a central scaffold 
subunit of a ubiquitin ligase belonging to the Cullin-RING ligase (CRL) family.  These 
events are initiated at the promoter level, where COMMD1 is recruited.  However, the 
mechanism responsible for COMMD1 recruitment to chromatin remains unclear. 
3) COMMD1 in turn is the founding member of a large family of highly conserved 
factors present in a variety of organisms.  Despite their shared carboxyl-terminal 
COMM domain, individual members in this gene family appear to have non-
redundant functions.  However, the spectrum of activities of the various COMMD 
proteins in mammals, including any potential role in regulating NF-κB and the 
inflammatory response, remains an area for future investigation. 
4) The mechanism by which COMMD1 promotes ubiquitination of NF-κB/RelA can be 
traced to its ability to activate the Cul2-containing ligase.  COMMD1 binds to a region 
in Cul2 that is conserved among Cullin family members.  This region in turn is also 
involved in binding an inhibitory factor known as CAND1.  This large protein promotes 
the dissociation of the substrate binding components of the Cullin-RING ligase 
complex and therefore inactivates these complexes.  The overlapping binding of 
COMMD1 and CAND1 on the same domain in Cullin proteins leads to CAND1 
displacement upon COMMD1 binding.  As a result, COMMD1 promotes the assembly 
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of a more active Cul2 containing ligase, and this is likely the mechanism by which it 
promotes NF-κB ubiquitination.   
5) The ubiquitination of NF-κB/RelA is additionally regulated by specific post-
translational modifications that target this protein for degradation in the right physical 
and temporal context.  In particular, the phosphorylation of this protein at residue 
Ser468 seems quite important.  This step occurs downstream of the IKK complex, the 
same kinase responsible for IκB degradation.  As such, IKK activation not only 
promotes pathway activation but sets the stage for subsequent inactivation and a 
return to basal conditions.   
6) The link between RelA phosphorylation and subsequent ubiquitination is provided 
by the chromatin regulator GCN5.  Our studies indicate that the phosphorylated form 
of RelA is recognized by GCN5.  This factor in turn binds to COMMD1 and promotes 
the ubiquitin dependent degradation of RelA.  This effect of GCN5 is independent of 
its histone acetylase activity and is in sharp contrast with its general transcriptional 
promoting activities.   
7) Consistent with its ability to regulate NF-κB activity, COMMD1 plays an anti-
inflammatory role in vivo.  Using a tissue specific knockout mouse model, our studies 
indicate that Commd1 deficiency in myeloid cells renders mice prone to more 
exaggerated inflammatory responses, including in sepsis models. These studies also 
confirm that Commd1 deficiency results in exaggerated expression of NF-κB target 
genes in vivo, through impaired NF-κB/RelA ubiquitination.   
8) Inflammatory states in humans, such as inflammatory bowel disease, are 
associated with reductions in COMMD1 expression.  Importantly, correlative 
experiments using the mouse knockout model indicate that Commd1 deficiency 
worsens the course of colitis and its progression towards cancer in these animals.  
Thus, the observed reduction in COMMD1 expression seen in patients with 
inflammatory bowel disease is most likely maladaptive and could serve to perpetuate 
chronic inflammation. 
9) Finally, our studies indicate that suppressed COMMD1 expression in the setting of 
inflammation can be recapitulated in culture conditions by IFN-γ stimulation, 
suggesting a potential paracrine effect of this cytokine in inflammatory states.  As 
such, these effects of IFN-γ would serve as a novel cross-talk mechanism between 
this cytokine and the NF-κB pathway.  	  
	  1
Nederlandse samenvatting	  
Ontsteking is een belangrijk mechanisme van ons lichaam om het te beschermen tegen 
infecties en beschadiging van weefsels. Deze ontstekingsreactie heeft als doel 
lichaamsvreemde en beschadigde cellen te verwijderen en te herstellen. Daarentegen kan 
ongecontroleerde chronische ontsteking veel schade veroorzaken aan weefsel. Om dit te 
voorkomen is het van belang dat deze ontstekingsreacties op tijd worden stopgezet. De 
transcriptie factor NF-κB heeft in dit proces een cruciale rol, naast zijn functie in de regulatie 
van het immuunsysteem. Vanwege zijn centrale rol is de regulatie van deze transcriptie 
factor zeer intens bestudeerd. De afgelopen jaren is er veel aandacht besteed aan het 
verkrijgen van inzicht rond het aanzetten van ontstekingsreacties via NF-κB maar er is nog 
maar weinig bekend over de cellulaire mechanismen en de factoren die betrokken zijn bij het 
stoppen van ontstekingsreacties. 
 
De laatste jaren is men steeds meer te weten gekomen over de rol van ubiquitine-
gecontroleerde degradatie van DNA-gebonden NF-κB subunits. Uit dit onderzoek is gebleken 
dat ubiquitine-gecontroleerde eiwit afbraak een belangrijke rol speelt in het controleren van 
de expressie van genen tijdens ontstekingsreacties. Het blijkt dat dit mechanisme belangrijk 
is om de activiteit van NF-κB terug te brengen tot een basaal niveau. Echter was het 
mechanisme van deze specifieke regulatie nog vrij onbekend. In dit proefschrift tonen we het 
belang van COMMD1 in dit specifieke proces aan en hebben we de betrokkenheid van 
COMMD1 in de regulatie van ontstekingsreacties in vivo bestudeerd. Hieronder worden de 
belangrijkste bevindingen samengevat die beschreven zijn in dit proefschrift.  
 
1)  Naast de remming van COMMD1 op NF-κB activiteit, blijkt COMMD1 ook een effect te 
hebben op de regulatie van HIV-1 replicatie, een proces dat is gekoppeld aan de activiteit 
van NF-κB in zijn gastheer. Het HIF-1 viraal genoom bevat verschillende κB-sites en via 
deze sites kan COMMD1 optreden als een factor om de resistentie van naïeve CD4+ cellen 
tegen HIV-1 replicatie te beïnvloeden. 
 
2) Het mechanisme waarmee COMMD1 de activiteit van NF-κB remt kan toegeschreven 
worden aan de mogelijkheid om eiwit degradatie van de NF-κB subunit RelA te bevorderen. 
Dit vindt plaats via de binding van COMMD1 aan NF-κB zelf en aan Cul2. Cul2 is een 
familielid van de Cullin-RING ligase (CRL) familie en treedt op als een soort “scaffold subunit” 
binnen dit eiwit-complex. De initiatie van COMMD1-gecontroleerde RelA degradatie vindt 
plaats op promoter sites van verschillende NF-κB target genen. Het mechanisme hoe 
COMMD1 naar deze specifieke promoter sites wordt gerekruteerd is nog onbekend. 
 
3) COMMD1 vormde de basis voor de ontdekking van de hele COMMD eiwit familie. Deze 
familie is zeer sterk geconserveerd tussen verschillende organismen. Ondanks hun 
gemeenschappelijk carboxyl-terminale COMMD domein, blijkt elke individuele familie lid een 
specifieke functie te hebben die niet overgenomen kan worden door een ander lid. De functie 
van de meeste leden, waaronder hun rol in NF-κB regulatie, is nog onduidelijk en moet nog 
verder worden onderzocht. 
 
4) COMMD1 vormt samen met Cullin een ubiquitine-ligase complex om de mate van RelA 
ubiquitinatie te bevorderen. COMMD1 bindt aan een gebied binnen het Cullin eiwit dat zeer 
sterk geconserveerd is binnen de Cullin familie leden. Dit gedeelte van het Cullin eiwit is ook 
betrokken bij de binding aan CAND1. CAND1 remt op zijn buurt de functie van Cullin-
ubiquitine ligase door de binding tussen het substraat (in dit geval RelA) en het Cullin-
ubiquitine ligase te verbreken. COMMD1 expressie voorkomt de CAND1 gecontroleerde 
remming door een competitie aan te gaan met CAND1. Deze gegevens suggereren dat de 
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ubiquitinatie van RelA via COMMD1 wordt bevordert doordat COMMD1 voorkomt dat CAND1 
de activiteit van het Cullin-ubiquitne ligase complex remt.  
 
5) Ubiquitinatie van RelA wordt niet alleen via COMMD1 gereguleerd, maar ook via post-
translationele modificaties. Met name de fosforylatie van RelA op het aminozuurresidu serine 
468 blijkt een belangrijke rol te spelen. Deze post-translationele modificatie wordt 
gereguleerd via het IKK complex. Dit is het complex dat zorgt voor IkB degradatie en 
hiermee NF-κB activeert. Dus, het blijkt nu dat via dit mechanisme IKK niet alleen NF-κB 
activiteit bevordert maar ook NF-κB deactiveert om zo NF-κB terug te brengen naar zijn 
basale activiteit. 
 
6) De histon acetyltransferase GCN5 zorgt voor een link tussen RelA fosforylatie en 
ubiquitinatie. In onze studies tonen we aan dat fosforylatie van RelA wordt herkend door 
GCN5. GCN5 zorgt ervoor dat COMMD1 bindt aan RelA en hiermee de ubiquitinatie 
gecontroleerde RelA degradatie. Dit effect van GCN is onafhankelijk van zijn histon acetylase 
activiteit, en heeft dus niks te maken met zijn functie als transcriptie activator. 
 
7) In lijn met zijn functie als NF-κB remmer blijkt COMMD1 een belangrijk rol te hebben als 
ontstekingsremmer in vivo. Door gebruik te maken van een weefsel specifieke knock-out 
muis tonen we aan dat muizen deficiënt voor Commd1 in myeloide cellen veel gevoeliger zijn 
voor ontstekingsreacties, waaronder sepsis. Deze studies laten ook zien dat Commd1 
deficiëntie een verhoging in de expressie van NF-κB gecontroleerde genen veroorzaakt, 
waarbij de mate van RelA ubiquitinatie verlaagd is. Deze studie bevestigt onze bevindingen 
in cellijnen en laten voor het eerst zien dat  COMMD1 ook in vivo belangrijk is om de mate 
van NF-κB activiteit te controleren. 
 
8) Interessant is dat de mens met chronische ontsteking, zoals patiënten met de ziekte van 
Crohn, geassocieerd wordt met verlaagde COMMD1 expressie. Met onze knock-out muis 
modellen laten we een duidelijk correlatie zien tussen verlaagde Commd1 expressie en 
verhoogde gevoeligheid voor darmontstekingen en geassocieerde darmkanker. Dus onze 
waarneming dat COMMD1 expressie is verlaagd in patiënten met darmontstekingen is 
waarschijnlijk maladaptatie en zorgt voor de continuering van de chronische ontstekingen in 
de darm van deze patiënten. 
 
9) Tot slot, onze studies laten zien dat de reductie in COMMD1 expressie tijdens 
inflammatoire condities kunnen worden herhaald in cellulaire condities waarbij we het IFNg 
route activeren. Hiermee laten we zien dat er een mogelijke link is tussen het paracrine effect 
van deze cytokine en inflammatoire condities. Daarmee, tonen we een mogelijke “cross-talk” 
aan tussen de effecten van IFNγ en NF-κB signalering. 
  
Samenvattend, dit proefschrift beschrijft de eerste bevindingen en het mechanisme waarmee 
COMMD1 de mate van NF-κB activiteit controleert. Daarnaast, door middel van 
muismodellen, bevestigen we de rol van COMMD1 in NF-κB signalering, en dat in de 
afwezigheid van COMMD1 de inflammatoire status in de verschillende  ziektemodellen zeer 
sterk toeneemt en hierdoor het ziekteproces verslechtert.  
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